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The 39 million Americans over the age of 65 accounted for 13% of the United States population 
in 2008. The absolute and relative number of older adults (age ≥65 years) is starting to rise 
rapidly as the baby boomers begin to turn 65. The prevalence of mobility disability in older 
(30%) adults is high and is a large public health concern as disability is associated with lower 
quality of life, higher health care costs, and mortality. There are many reasons for age-related 
disability, however; the role of changes to skeletal muscle remains unclear. Fatigue is also an 
independent risk factor for physical disability and is common among older adults. This 
dissertation aimed to provide novel insight into the association between skeletal muscle 
energetics, changes in regional body composition and physical function and fatigability in older 
adults. First, decreases in visceral and intermuscular adipose tissue as well as an increase in 
muscle density, a marker of intramyocellular fat, following a weight-loss and physical activity 
intervention, were shown to be related to improved physical performance. Next, mitochondrial 
function, measured by phosphocreatine recovery (mM ATP/s)  in the quadriceps following an 
exercise-bout using 
31
P magnetic resonance spectroscopy, was examined in relation to walking
performance (time to walk 400m) and perceived performance fatigability (perceived exertion 
following a 0.67ms treadmill-walk). Mitochondrial function was related to walking performance 
in higher functioning older adults and older adults who were functionally impaired but able to 
ambulate 400m without discomfort. Mitochondrial function was also significantly lower in those 
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 v 
with high compared to low fatigability. This research provides novel evidence that function can 
be improved by targeting specific fat depots and mitochondrial function may impact overall 
function and fatigability. These findings could have large public health implications, as the 
etiology of age-related disability in regard to skeletal muscle is unclear. The prevalence of 
disability among older adults is quite high and is associated with increased health care costs and 
mortality. Clinicians, public health professionals and researchers can use this information to 
design interventions, treatments and future research studies focused on skeletal muscle to 
improve function in older adults. 
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1.0  INTRODUCTION 
The 39 million Americans over the age of 65 accounted for 13% of the United States population 
in 20081. The absolute and relative number of older adults (age ≥65 years) is starting to rise 
rapidly as the baby boomers (born 1946-1964) begin to turn 65. By 2030, one in every five 
Americans (72 million) will be aged 65 and older1. Additionally, the United States Census 
Bureau estimates that the number of US citizens age 85 and older will increase 3-fold from 5.7 
million in 2008, to 19 million by 20501. The “squaring of the age pyramid”, as some have called 
it, is expected to precipitate enormous public health problems that could have devastating effects 
on our country’s healthcare system. The increasing risk for physical disability and declines in 
physical function that coincide with increasing age is one of the primary reasons why our rapidly 
aging population is of great public health concern2-4. It has been estimated that community-
dwelling older adults who are functional disabled or transition to being functionally disabled 
spend $10,000 more on healthcare over a 2-year span compared to those who remain 
functionally independent5. Additionally, it is estimated that physically disability attributable to 
sarcopenia, the loss of muscle mass with age, alone in the United States in 2000 was between 
$11.8 billion and $26.2 billion6. Therefore, it is imperative to understand what the etiology of 
and risk factors for age-related physical disability in order to prevent its onset. 
The neuromuscular system contains most of the necessary machinery for physical 
function. Therefore it is a logical area of study when attempting to understand the etiology of 
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physical disability in older adults. This dissertation will focus on age-related changes to the 
neuromuscular system, specifically changes to skeletal muscle tissue and regional body 
composition depots and their effect on physical function and mobility in older adults. This 
dissertation will also explore the cellular basis for skeletal muscle performance by examining 
mitochondrial function, which is responsible for producing over 90% of the energy needed for 
locomotion7, and how it relates to physical function and mobility.  
Additionally, fatigue in older adults has been shown to be associated with physical 
function and disability, independent of disease status8. Therefore, fatigue is an independent risk 
factor for physical decline and is present in the disablement pathway. Additionally, a large 
proportion of it cannot be attributed to underlying diseases9,10. Fatigue is primarily considered an 
energy disorder, thus it has been hypothesized that age-related decreases in mitochondrial 
function may contribute to higher levels of fatigability in older adults11,12. This dissertation will 
also examine the relationship between in vivo mitochondrial function and fatigability. 
Fatigability is a whole-body measure of fatigue normalized to a set activity of a specific intensity 
and duration and has been hypothesized to provide better insight, compared to global fatigue, 
into the degree an individual is limited functionally due to fatigue12. The term whole-body in this 
context is emphasizing that fatigability as it is used in this dissertation is an overall sensation of 
fatigue at the “whole-body level” as opposed to skeletal muscle fatigability. 
The research described in this dissertation will provide novel insight into the association 
between skeletal muscle energetics, changes in regional body composition and physical function 
and fatigability in old older adults. This dissertation will contribute information that will assist 
public health and medical professions in preventing age-related declines in physical function and 
disability. 
2 
1.1 THE DISABLEMENT PATHWAY: A CONCEPTUAL FRAMEWORK 
It is practical to discuss age-related physical disability in the context of the Disablement Process 
model proposed by Verbrugge and Jette13, who elaborated on a framework developed and 
proposed by Saad Nagi14. The Nagi model was adopted by an Institute of Medicine panel formed 
to reflect on the prevention of disability from a policy perspective15. As a result, it is sometimes 
referred to as the Institute of Medicine scheme.  The Disablement Process model was constructed 
with prevention in mind and in a manner to appease both the research and medical communities. 
This model also recognizes the fact that disability is both a relative sociological concept, as well 
as a medical condition. Briefly, the main pathway consists of four concepts. These concepts are 
pathology, impairments, functional limitations and disability. The work presented in this 
dissertation deals with all four of these domains in a significant capacity.  Therefore, for the 
purpose of the dissertation it is worthwhile to take some time to define these four concepts in the 
manor proposed by Verbrugge and Jette and first proposed by Nagi. 
The first domain and furthest upstream in the pathway is pathology. Pathology refers to 
biochemical and physiologic disorders. Verbrugge and Jette state that these disorders are 
detectable and medically labeled as disease, injury or congenital/developmental conditions. For 
the purposes of this dissertation age-related physiologic and biochemical changes16 that are not 
necessarily diseases, but “normal” aging phenomena belong in this domain of the disablement 
pathway. Verbrugge and Jette do state that these changes may not be directly measurable in usual 
medical care. This applies the two of the main topics of this dissertation; age induced changes in 
skeletal muscle and age-related related changes in mitochondrial function. In the more traditional 
sense Verbrugge and Jette give the examples of osteoarthritis, lung cancer, cataracts and 
Alzheimer’s disease as being pathology. The pathologies that will be discussed in this 
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dissertation are decreasing muscle mass, muscle quality and reduced capacity for mitochondrial 
energy production.    
The second domain is impairment. Impairments are defined as dysfunctions and 
structural abnormalities in specific body systems, such as musculoskeletal or cardiovascular 
impairments. Impairments are caused by pathology and can be thought of as signs or symptoms 
of pathology. Examples of impairments mentioned in this dissertation are decreased muscle 
strength and muscle power, the result of skeletal muscle pathology. Decreased muscle strength 
and muscle power are markers of neuromuscular impairment or dysfunction.   
The third domain is functional limitation and is defined as restrictions in basic or 
fundamental physical or mental actions. These limitations depend largely on the individuals’ 
lifestyle and can include things like walking, lifting objects, climbing stairs, visual acuity and 
hearing. The domains of impairment and functional limitation can also be thought of as 
“preclinical disability”, a concept theorized by Lilienfeld & Lilienfeld17 and elaborated on by 
Fried18. Preclinical disability is characterized by the development of functional limitations that 
have yet to manifest themselves clinically or interfere with a person’s perceived ability to 
function “normally”. It has been shown that persons who have difficulty with certain physical 
tasks (i.e. lifting 10lbs, walking up 10 steps, walking ¼ mile) are at an increased risk for further 
functional decline and disability19,20. In epidemiology we attempt to measure these functional 
impairments with performance measures such as the 6-minute walk test 21, the long distance 
corridor walk22, the Short Physical Performance Battery23, the timed up and go test24 and simply 
gait-speed25,26. Additionally, fatigability will be examined in this dissertation and can be thought 
of as a functional impairment. Fatigability impairs one’s ability to tolerate a certain intensity of 
physical activity or tasks of certain intensities. This may cause one to limit one’s activity level 
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which can then leaded to decreases in fitness and ability level. Fatigue has been shown to be 
related to declining physical function and disability independent of disease status9,10. 
In epidemiologic research you will often see the term mobility disability. This term is 
distinct from instrumental activities of daily living (IADL), activities of daily living (ADL), or 
more simply, physical disability which will be discussed in the next paragraph. Mobility 
disability is a functional limitation and is therefore further up the pathway than physical 
disability. Mobility disability can be measured by both self-report and performance testing. Self-
report mobility disability is usually defined as being unable to or having difficulty walking 
400m-500m (about ¼ mile) and/or climbing 1 flight of stairs22,27-31. This definition varies across 
study and even within different analyses from the same study. For example, the Cardiovascular 
Health Study, EPESE and the Woman’s Health and Aging II studies characterized mobility 
disability as the self-reported inability to walk ½ a mile (8 blocks) and/or climb up and down 1 
flights of stairs32-34 and the InCHIANTI study defines mobility disability as the self-reported 
inability to walk 1km in one analysis35 and ½ a km in another27. There are also performance 
based measures of mobility disability in older adult such as the inability to walk 400m without 
sitting down and/or under 15 minutes 36-39, 4m or 6m usual gait-speed < 1.0m/s40 and fast-paced 
gait-speed <1.2m/s27.  Mobility disability is an important epidemiological outcome for studies 
involving older adults because of its strong relationship with further functional decline, 
disability19,20, cardiovascular disease and mortality22,41. 
When referring to physical disability, researchers are usually referring to impairment in 
the ability of a person to independently perform tasks that fall into one of two categories. The 
first category is called instrumental activities of daily living (IADLs), which include: using the 
telephone, shopping, preparing meals, housekeeping, laundry, transportation (public or personal), 
5 
managing medications and managing finances42. The second category is called activities of daily 
living (ADLs), which include: bathing, dressing, toileting, transfer (getting in and out of 
bed/chair), continence, and feeding43. IADLs are further upstream the disablement pathway than 
ADLs and are meant to capture activities necessary for maintaining independent status in the 
context of one’s cultural setting whereas ADLs are activities that are necessary for survival13. To 
help discern the subtle difference, one can also think of ADLs as self-care tasks and IADLs as 
household management activities.  
As mentioned previously, age-related physical disability is an enormous public health 
issue, an issue that is growing due to the rapid aging of the population. With increased age, 
comes an increased risk for physical disability; with physical disability comes an increased risk 
for further disability, institutionalization and ultimately death2,3,44. The next section will quantify 
this growing public health issue by providing an overview of the epidemiology of disability in 
older adults. 
1.1.1 Epidemiology of Disability in Older Adults 
When attempting to quantify or study disability in older adults, it is very important to pay 
attention to the specific definition of disability, as it varies across population and epidemiological 
studies. For example the National Long term Care Study (NLTCS) defines disability as the 
inability to perform an IADL or ADL task due to health or aging45 whereas  the  Established 
Populations for Epidemiologic Studies of the Elderly (EPESE) project defines disability as self- 
or proxy-report of needing help with or being unable to perform one or more IADL tasks46 and 
NHANES defines disability as having any difficultly performing these tasks. 
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Disability in older adults is an immense public health issue. According to NHANES, 20% 
of those aged 60-69 have ADL disability, 23% have IADL disability, 30% have mobility 
disability and 48% experience functional limitations47. This issue is not unique to the United 
States. According to the INCHIANTI study in Tuscany, Italy 5.5% of those age 65 and older had 
ADL disability and 22.2% had IADL disability48. Additionally, a study by Woo et al. conducted 
in Hong Kong revealed that 23.0, 29.4 and 35.9% of women and 9.5, 13.2 and 20.9% of men age 
65-69,70-74 and 75+ respectively have IADL disability49. These data show that the prevalence of 
physical and mobility disability are quite high. Again, this is alarming because of the aging 
nature of the population and the increased utilization of health care services and health care costs 
associated with being disabled or dependent5.   
It is important to note that women report more IADL or ADL disability than men (47% 
vs. 35%)1. There are a few reasons for why this sex disparity exists. First of all, this disparity 
seems to be real and not an artifact of inherent bias in self-reported disability. It was thought that 
women might be more likely to “admit” to difficulty performing certain tasks than men or men 
might report not doing or being able to do certain household activities such as preparing meals 
because they’ve never performed these tasks. However, previous research shows good agreement 
as well as no sex differences in terms of accuracy when comparing self-reported and observed 
performance on similar tasks50. Previous work suggests that the disparity also does not seem to 
simply be a result of woman developing disability more often than men; but rather a combination 
of the fact that woman tend to live longer with disability than men44,51,52 and the fact that 
diseases precipitating disability in men and woman differ53.  For example, women tend to suffer 
from more comorbidities that are risk factors for physical disability, such as arthritis, 
osteoporosis and obesity, than men and present more physical disability at every level of 
7 
comorbidity when compared to men53. Moreover, men are 50% more likely to experience sudden 
cardiac death, which often occurs without physical disability, than women; this also likely 
contributes to the prevalence discrepancy between men and women54,55.  In the same vein, men 
tend suffer from more life-threatening diseases than women such as heart disease and congestive 
heart failure. Thus, men are more likely to die and women are more likely to live with 
disability44. It has also been suggested that due to inherent genetic differences among sexes, men 
have great physical advantages than women. Therefore, it takes less pathology and impairments 
for woman to cross the threshold for mobility and physical disability. For example, in men, a 
larger proportion of total body mass is muscle or lean mass compared to women53. Interestingly, 
despite the apparent differences between men and women concerning the prevalence of 
disability, studies have shown that there is no difference regarding incident rates of disability 
between the sexes56. It is hypothesized that this is due to women living longer with disability 
than men and the fact that men may experience shorter bouts of disability, which are not 
captured in cross-sectional ascertainment at long intervals in large epidemiologic studies56.  
In addition to the sex disparity in the prevalence of age-related physical disability, racial 
disparities exist as well with non-Hispanic blacks having higher prevalence rates of disability 
compared to whites46,57-59. The incidence of disability between African-Americans and whites is 
also different with African-Americans being 1.61 times more likely to develop disability 
according to a study using data from the Health and Retirement Study60. A study using data from 
the EPESE study showed that African-Americans were 2.3 times more likely to develop physical 
disability over a 7-9 year follow-up period58. These differences are partly attributable to 
differences in socio-economic status and education level, but significant disparities still exist 
when these factors are taken into account58,60. It should also be noted that these discrepancies are 
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greater among women than men46,58. It is thought that in addition to socioeconomic status, the 
reason that African-Americans are at greater risk for disability may originate earlier in life where 
African-Americans are at greater risk for developing certain chronic conditions that are risk 
factors for disability including hypertension, heart disease and diabetes 58,61-64.  
Risk factors for mobility, ADL and IADL disability other than age, race and sex include 
lower levels of physical activity65,66, mobility disability or previous disability19,20,67 
hypertension65,66, obesity65,68-70, fractures32,65, arthritis65, stroke32, prevalent cancer32, number of 
chronic conditions2,32, smoking71, diabetes72-75 and others44,65,76. Deteriorating neuromuscular 
function, in the form of lower muscle and strength, power is well documented to be associated 
with physical disability77-79. Declining muscle function is part of the disablement pathway 
leading to ADL and IADL disability and can be thought of as both a precursor to and risk factors 
for disability. It is a precursor to disability in the sense that deteriorating muscle is present in the 
disablement pathway leading to disability. It can also be thought of as risk factors for disability 
because those with lower muscle performance are at higher risk for developing disability and 
interventions exist to improve muscle function which may also then confer improvements to 
overall physical function and prevent disability.  
It is important to note that the non-neuromuscular risk factors for ADL and IADL 
disability mentioned above can also affect muscle mass and muscle performance, and that not all 
of the changes to the neuromuscular system are due to aging per se. Changes to the 
neuromuscular system with age are due both in part to illness, which can cause weight-loss, 
inactivity and inflammation which in-turn negatively affect muscle mass and performance, and 
intrinsic changes that occur with aging.  
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Muscle performance in the form of strength has been shown in the Health Aging and 
Body Composition Study (Health ABC) to be an independent risk factor for mobility disability30. 
Also in Health ABC, high and low relative knee extensor strength in both men and woman was 
shown to be related to fast-paced gait-speed over 20 meters80. These results have been replicated 
in Invecchiare in Chianti (InCHIANTI) study. In this study, over a 3-year follow-up period, low 
muscle power was associated with a 9- and 3-fold greater risk of developing mobility disability 
in men and women, respectively. In this same study, low knee extensor strength was associated 
with gait-speed declines of 0.24 and 0.06m/s over the 3-year period in men and women 
respectively.  Additionally, hand-grip strength and declining hand-grip strength, as measures of 
muscle performance, have also been shown to be strong predicators of physical disability in 
older adults81,82  
However, the role of changes in the neuromuscular system and their effect on disability 
are still unclear. It was largely believed that the loss of muscle mass was largely responsible for 
declining muscle strength and neuromuscular performance. However, longitudinal evidence 
shows that declining muscle mass only explains about 5% of the variance in declining muscle 
strength83. This dissertation will attempt to fill certain gaps in this knowledge base. The 
neuromuscular system is a logical point of study when attempting to understand the etiology of 
and prevent physical impairments and disability in older adults. The role of the neuromuscular 
system in the disablement pathway is depicted in supplemental Figure 1. Age-related changes in 
the neuromuscular system and proposed mechanisms for their decline are described in the 
subsequent sections. 
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Figure 1. The Role of the Nueromuscular System in the Disablement Pathway 
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1.2 CHANGES TO SKELETAL MUSCLE WITH AGE 
Muscle cross-sectional area (CSA) and muscle mass can be measures in several different ways. 
Before presenting change in muscle mass and CSA, briefly presenting these methods and the 
pros and cons of each is important. Magnetic Resonance Imaging (MRI) and Computed 
Tomography (CT) are considered to be the gold standard method for measuring muscle CSA84. 
They both produce high resolution images which can be used to assess both lean and fat mass 
depots including muscle density which is an indirect marker of intramyocellular adipose tissue85. 
MRI may be more advantages than CT because subjects are not exposed to radiation. However, 
high cost of using these technologies is a barrier to widespread use and in larger studies. Dual 
energy X-ray absorptiometry (DXA) is one of the most widely used methods for measuring 
muscle and fat mass due to its low cost, good accuracy and the fact that it does not require highly 
trained personnel to operate. DXA can also be used to estimate regional body composition as 
well as bone mass. It should be noted that DXA can over estimate lean mass in older adults 
because it does not differentiate between water and bone-free lean mass86. However DXA is a 
valid and reliable tool87. Bioelectrical impedance is also a relatively common, accessible and 
easy  way to measure muscle mass, however it has limited accuracy and validity88,89.  Ultrasound 
is another relatively lost cost method that can be used to measure muscle CSA of individual 
muscle groups90. However, this method requires highly trained technicians and cannot provide 
whole body muscle mass estimates84. Urinary creatinine excretion is used as a measure of total 
muscle mass, because creatinine in the body is restricted almost exclusively to skeletal muscle. 
This method has several limitations including, delay in availability of results, complicated 
procedure, participants must ingest a meat-free diet the day before collection and creatinine 
excretion may vary from day to day84. Peripheral quantitative computerized tomography (pQCT) 
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is becoming a more widely used technique because of its portability. However this method 
provides less accurate estimates of muscle when compared to MRI or CT as it was initially 
developed to measure bone84. This method is attractive though because it is portable, less 
expensive than MRI and CT and can provide reliable cross-sectional area estimates of specific 
fat depots present in skeletal muscle such as intermuscular and subcutaneous adipose tissue as 
well as muscle cross-sectional area and muscle density, which is a surrogate measure of fat 
infiltration into muscle fibers84,91-93. 
Perhaps the most fundamental and well documented structural change in skeletal muscle 
with age is decreasing muscle size or mass. This reduction has been shown both cross-
sectionally, comparing young adults to older adults, and longitudinally using various 
measurement techniques83,94-116. Reductions have been observed in muscle groups of both the 
upper and lower extremities95,105,107,116,117.  Muscles cross-sectional area (CSA), as measured by 
MRI, of the lower extremities has been shown to decrease more than those of the upper body105. 
This suggests that there are non-systemic causes of muscle loss with age. For example, the 
reason for larger decreases in lower compared to upper body muscle mass may be due to age-
related reductions in physical activity levels. Reducing activity levels would affect the lower 
extremity muscle groups more than the upper because ambulation is powered by the lower 
extremities. However, changes across muscle groups are highly correlated, which also implies 
systematic reasons for muscle loss (which will be discussed later), so one muscle group is often 
used to represent changes in muscle mass or CSA of the whole body. This review will mainly 
discuss changes to the lower extremities, in particular the quadriceps, because lower extremity 
muscle performance is more vital to performing IADL and ADL tasks and for mobility. The 
following will present observed changes in muscle mass with age and proposed mechanisms 
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driving the atrophy. There are several other very important qualitative and physiologic changes 
that take place in the aging skeletal neuromuscular system. These changes and their implications 
will also be presented and discussed. 
1.2.1 Cross-sectional Evidence for Age-Related declines in Skeletal Muscle Mass or Area 
A majority of the studies reporting age-related muscle atrophy have been cross-sectional, 
comparing the muscle size or mass of older adults to that of younger adults. These studies are 
shown in Table 1. These studies were conducted using a variety of techniques, including, 
ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), bioelectrical 
impedance, creatine excretion, dual energy X-ray absorptiometry (DXA) and direct measurement 
from post-mortem subjects. Annual declines in muscle CSA, as measured by ultrasound, MRI 
and CT, from cross-sectional studies have been shown to be ~0.5% per year and changes in 
muscle mass on the order of ~0.48% in men and ~0.51% per year mm in woman. These rates are 
rough estimates calculated from cross-sectional studies. Muscle CSA has been shown to peak 
around the age of 25 and decline thereafter, with accelerated declines after age 50106. 
Additionally, it has been shown by full body MRI that muscle CSA of the lower body tend to 
decrease more than in the upper body105. 
Young et al. conducted studies comparing the CSA of the quadriceps in older (age 70-79) 
compared to younger (20-29) men and woman using ultrasound111,112. They showed that 
quadriceps CSA was 33% smaller in older woman and 25% smaller in older men compared to 
their younger counterparts. Borkan et al. conducted a similar study comparing older (mean age 
69.4) to younger (mean age 46.3) men using CT and found similar results104. This study showed 
a 12% reduction in CSA of the quadriceps in older compared to younger men, a similar annual 
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decline as the Young et al. study (Table 1.). These results were confirmed yet again in another 
study of younger and older men using CT117. Although most of the research in this area focuses 
on the lower extremities, it should be noted that reductions in CSA of the triceps and biceps of 
older men compared to younger men have also been reported using CT107.  
The studies described in the previous paragraph all had relatively small sample sizes (n= 
n=24-41), were done mostly in men and were limited to a few muscle groups. The participants in 
the older adult groups also tended to be in their 60s or 70s, thus the oldest and frailest of older 
adults are not represented. Larger cross-sectional studies have been conducted using different 
methods in much larger samples of both men and women. For example, Frontera et al. conducted 
a study of 200 45-78 year old men and woman, using creatinine excretion to measure total 
muscle mass103. This study showed 9.6% and 19.1% lower muscle mass in men and woman aged 
65-78 compared to those aged 45-54. Similar differences have been shown using creatinine 
excretion to measure total muscle mass in studies of 184118 and 959119 younger men and women. 
These studies reported a 23.4% and 22.0% decrease in men and woman between the age of 30 
and 70118 and an average 50 year decrease of 33%119. Baumgartner et al. measured total 
appendicular skeletal muscle mass (ASMM) using DXA in 426 and 382 older men (mean age 
73.3) and woman (mean age 73.7) in the New Mexico Health Survey as well as 107 and 122 
young men (mean age 28.7) and women (mean age 29.7)94. This study showed an ASMM 
difference of 17.6% and 18.1% in older men and woman compared to their younger counterparts. 
A similar study using DXA to measure ASMM showed 14.8% and 10.8% differences in older 
compared to younger men and woman, after adjustment for height, body weight and age95. In 
summary, cross-sectional studies show that muscle mass decreases by about 40% between the 
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ages of 20 and 80 with greater decreases seen in lower extremity groups compared to upper 
extremity. 
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Table 1. Cross-sectional Studies examining Changes in Muscle Mass or Area with Age 
Author YN, ON Technique Measurement Sex 
Young 
Age 
Older 
Age 
Young 
Value 
Old 
Value Difference 
%     
Difference 
% Annual                           
Difference 
Baumgartner94 553, 883 DXA AMM, kg 
m 28.7±5.1 73.6±5.8 27.3 22.5 -4.8 -17.6 -0.39 
f 29.7±5.9 73.7±6.1 17.7 14.5 -3.2 -18.1 -0.41 
Frontera103 24,34 hydrostatic weighting 
whole-body 
muscle mass, kg m 50.5±2.8 68.5±2.8 60.2 55.4 -4.8 -8.0 -0.44 
f 50.2±2.6 69.6±3.8 40.5 36.2 -4.3 -10.6 -0.55 
Borkan104  21,20 
CT 
upper leg CSA, 
cm2 
m     
f 46.3±2.6 69.4±4.1 
147.3 129.1 -18.2 -12.4 -0.53 
CT 
upper arm CSA, 
cm2 54.6 48.2 -6.4 -11.7 -0.51 
total body 
potassium 
lean body mass, 
kg 56.2 49.6 -6.6 -11.7 -0.51 
Jansen105 
66,11 
MRI 
upper body 
SMM m 18-29 70+ 14.3 13.5 -0.8 -5.6 ~-0.10 
lower body 
SMM m 18-29 70+ 18.5 13.8 -4.7 -25.4 ~-0.45 
40,19 
upper body 
SMM f 18-29 70+ 8.7 7.7 -1.0 -11.5 ~-0.21 
lower body 
SMM f 18-29 70+ 12.5 9.7 -2.8 -22.4 ~-0.40 
Lexell106  9,9  Post-mortem 
whole vastus 
lateralis, cm2 m 32.0 73.0 75.0 56.0 -19.0 -25.3 -0.62 
Young111 12,12 Ultrasound quad CSA, cm2 m 20-29 70-79 - - - -25.0 -0.50 
Young112 25,25  Ultrasound quad CSA. cm2 f 20-29 70-79 - - - -33.0 -0.66 
Overrend117 13,12 CT quad CSA. cm2 m 24.5±1.5 70.7 84.7 65.7 -19.0 -22.4 -0.49 
Abbreviations: YN= Number of young participants; ON= number of older adult participants: DXA = Dual X-ray Absorptiometry; AMM= appendicular muscle mass; kg = 
kilogram; CT= computed tomography; CSA = cross-sectional area; m = male; f= female; SMM= skeletal muscle mass; cm= centimeters; quad= quadriceps 
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1.2.2 Longitudinal Evidence for Age-Related Declines in Skeletal Muscle Mass or Area 
Although cross-sectional studies are easier, less expensive and produce data more quickly than 
longitudinal studies, they are subject to inherent biases and can only be used to roughly estimate 
“true” age-related changes in muscle mass. Longitudinal studies show greater declines in muscle 
CSA and muscle mass than were previously estimated cross-sectionally, likely due to the 
inherent selection bias associated with cross-sectional studies. That is, older adults who are 
healthier than the general older adult population may be more likely to volunteer for research 
studies, and therefore may have experienced less muscle atrophy than the average older adult. 
This would lead to an underestimation of muscle loss with age than if the same individuals were 
followed from middle to old age. However, longitudinal prospective cohort studies are not 
immune to a healthy participant bias. Older adults who remain in prospective cohort studies for 
the longest amount of time are also likely to be healthier than those who have either dropped out 
or died. That being said, longitudinal studies, compared to cross-sectional, are significantly better 
equipped to determine actual change over time. Longitudinal studies of muscle mass or muscle 
area across are shown in Table 2. 
The two of the earliest examples of observational prospective studies measuring changes 
in muscle CSA or mass were conducted in a small number of participants who had originally 
took part in an exercise intervention102,120. In these studies, participants were only measured 
twice, once at baseline and once the follow-up visit. In a study by Greig et al., 4 men (aged 79 to 
84) and 10 women (aged 79 to 89) showed an average of 6.4% decrease in the CSA of the 
quadriceps after 8 years120. Muscle CSA was measured by ultrasound at baseline and by CT at 
the 8-year follow-up visit. In a similar study by Fontera et al., 9 men presented 12-year 16.1% 
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and 14.9% decreases in the CSAs of the quadriceps femoris and flexors as measured by CT102. 
Smaller changes in the CSA of the quadriceps were observed in a similar 8-year follow-up study 
by Frontera et al., in which only 12 out of 24 participants had follow-up data. This study 
consisted of a subset of men and woman originally aged 45-70, who were an average of 60.4 
years old after a mean follow-up time of 9.7 ± 1.1 years, total muscle mass measured by 
creatinine excretion, decreased 12.9 ± 15.5% per decade in men and in −5.3 ± 18.2% per decade 
women from CT121.   
The Health Aging and Body Composition Study (HABC) is a large prospective cohort 
study designed to measure changes in body composition using both DXA and CT and how they 
relate to functional measures in older adults. This study enrolled and is following 3,075 men 
(48.4%) and woman (51.6%) of whom 41.6% were black, who were aged 70-79 at baseline99. 
For these reasons, it is arguably the most well equipped study to document longitudinal changes 
in muscle mass and CSA. In a 3-year follow-up study of the Health ABC cohort by Goodpaster 
et al. annual leg mass declines from DXA of 1.01% in white men, 1.32% in black men, 0.86% in 
white women and .93% in black woman were observed83. These were significant gender 
differences within races and significant racial differences within genders. During a 5 year follow-
up period in Health ABC, muscle CSA of the thigh was shown to decrease 0.98%/year in men 
and 0.64%/year in woman122.  Finally, 1178 female and 1129 male Health ABC participants, 
annual percent changes in lower leg lean mass as measured by DXA of 0.71% and 0.85% were 
observed over a 7-year follow-up period123. The differences in the percent changes observed in 
the three Health ABC analyses is likely attributable to a healthy participant effect, as the analyses 
that were conducted over longer periods of time actually show less severe declines in muscle 
mass. It is unlikely that muscle mass decline is attenuated over time in old-age; instead, these 
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differences are likely due to the healthier participants, who presumably lose less muscle mass, 
surviving longer. In summary, these longitudinal data are invaluable and suggest that muscle 
mass declines are greater in men than woman and African Americans compared to whites, 
although the reasons are not clear. As previously mentioned African Americans have been shown 
to have a higher prevalence of chronic diseases, such as diabetes and higher levels of 
inflammation, which may in part explain the racial disparity in muscle loss. They also start with 
higher levels of muscle mass, and those who start with the most muscle mass have been shown to 
lose the most. 
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Table 2. Longitudinal Changes in Muscle Mass or Area in Older Adults 
Study N Technique Measurement Sex BL Age 
FU-
Time 
(Yrs) 
BL 
Value 
FU 
Value Change 
%     
Change 
% 
Annual                           
Change 
Frontera102 7 CT 
Total Thigh Muscle CSA, cm2 
M 65.4±4.2 12.2 
135.7 115.8 -19.8 -12.5 -1.02 
Thigh Extensor CSA, cm2 64.8 54.5 -10.3 -16.1 -1.32 
Thigh Flexors CSA, cm2 34.2 29 -5.2 -14.9 -1.22 
Hughes124 78 Hydro-densitometry Total Body Muscle Mass, kg F 60±7.4 9.4 41.9 41.8 -0.1 -0.24 -0.03 
53 M 61.1±8.1 58.8 57.7 -1.1 -1.87 -0.20 
Goodpaster83 
 
DXA Leg Lean Mass, kg 
BF 73.0±2.8 
3 
7.0 6.8 0.2 -2.78 -0.93 
 WF 73.4±2.8 5.9 5.7 0.2 -2.59 -0.86 
 BM 73.4±2.8 9.3 8.9 0.4 -3.97 -1.32 
 WM 73.7±2.8 8.7 8.4 0.3 -3.03 -1.01 
Delmonico122 865 CT Total Thigh Muscle CSA, cm2 F 73.2±2.9 5 92.9 89.7 -3.20 -3.44 -0.69 
813 M 73.6±2.8 133.2 126.4 -6.80 -5.11 -1.02 
Koster123 1178 DXA Leg Lean Mass, kg F 73.9±2.8 7 12.4 11.8 -0.62 -5.00 -0.71 
1129 M 74.2±2.8 17.2 16.2 -1.02 -5.90 -0.85 
Abbreviations: N= Number participants; BL= baseline; FU= follow-up; Yrs= Years; CT= computed tomography; CSA = cross-sectional area; cm = centimeters; m= male; 
kg= kilograms; f= female; DXA= dual x-ray absorptiometry; bf = black female; wf= white females; bm= black male; wm= white male;
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1.2.3 Physiologic and Structural Mechanisms underlying Changes in Muscle Mass with 
Age 
This section will discuss the underlying age-related physiologic and structural changes in the 
neuromuscular system that have been postulated to cause reductions in muscle mass with age. 
These are, in part, hypothesized to be distinct from the general consensus that age-related 
declines in physical activity levels result in many of the age-related changes in skeletal muscle. It 
is important to note that these physiologic changes, driving the loss of muscle mass, (as well as 
other changes in skeletal muscle that will be discussed later) likely contribute to functional 
declines in skeletal muscle function independent of muscle mass. This is because it has been 
shown that the age-related declines in muscle strength are 2-5 times larger than changes in 
muscle strength83,125. Furthermore, several studies well equipped to do so, including Health 
ABC83,99,122 and the Baltimore Longitudinal Study of Aging (BLSA)116,126 have shown a decrease 
in muscle quality, defined as muscle strength per unit muscle mass with age. This suggests that 
qualitative neuromuscular changes, not just changes in mass, largely affect changes in 
neuromuscular function. This idea will be discussed in more detail throughout the remainder of 
this document. 
Muscle mass and CSA are functions of both the mass or area and number of individual 
muscle fibers. The general consensus in the literature is that the loss of muscle mass with age is a 
combination of both a reduction in muscle fiber size and number. Cross-sectional research using 
both in vivo biopsy techniques and direct measurement in cadavers shows reductions in the 
number of both type I and type II muscle fibers106,109,113. The percent reduction in type I fiber 
number is markedly smaller than the decrease in the number of type II fibers, with some studies 
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even showing increases in type I fiber number102,106,108,109,113,127.  In addition to the preferential 
loss of type II fibers with age, it has been shown that type II fibers also atrophy with age, 
whereas type I fibers seem to preserve their size106,109. However some studies show no reduction 
is type II fiber size102,109. Conversely, a compensatory fiber hypertrophy has also been observed 
in both humans and rats where remaining fibers become enlarged to compensate for the 
reductions in number121,128,129. 
Contradictory findings have also been reported in the literature. Two small longitudinal 
studies in older adults conducted by Frontera et al. showed no reduction in the number of type II 
fibers after 8 years and a surprising increase in the proportion of type II fibers after 12 
years102,121. There have been very few longitudinal studies that examined changes in fiber type 
number and sizes, but they do not seem to corroborate this finding by Frontera et al.128,130. 
Longitudinal research in rats also shows a reduction in the number both type I and type II fibers, 
with greater reductions in type II131,132. Assessing number and size of fiber types is subject to 
large biases. Lexell et al., found that in a ordinary sized biopsy (~600 fibers), containing equal 
proportions of both fiber types, the 95% confidence interval for the estimate of the proportion of 
fiber type can vary by as much as 40-60%113. Additionally, the proportion of type I fiber type 
taken for different areas of the quadriceps can vary from 32 to 65% 113. Anderson et al. have 
shown that aged muscle fibers may express two or three myosin isoforms (how fiber types are 
determined), thus histochemical analysis could misclassify fibers. In summary, the current 
literature seems to suggest losses in muscle mass result mainly from reductions in the number of 
both type I and type II muscle fibers, with reductions in individual muscle fiber size of the latter.  
Reduction in muscle fiber number and size is thought to be due in large part to ongoing 
denervation and renervation process127,133,134. Muscle fibers are functionally grouped together 
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into motor units. They are called motor units, because all of the muscle fibers in a motor unit are 
innervated by a single motor neuron. The hypothesis that there is a progressive age-related 
denervation and renervation process was suggested in response to the observed grouping of type 
I fibers that occur with age106,127,135. It is thought that motor neurons enervating type II fibers 
begin to fail, causing a neighboring motor neuron to expand its territory by renervation the fibers 
that were originally enervated by the failing motor neuron. There is experimental evidence 
supporting this hypothesis. It has been shown that the number of excitable motor units declines 
with age, using the electrophysiological technique136. Furthermore, indirect evidence suggesting 
a greater number of muscle fibers per motor unit has been found using the macro- 
electromyographic (EMG) technique. This technique showed an increase in size of motor units 
of the vastus lateralis, the tibialis anterior, and the biceps brachii137,138. There is also 
controversial evidence showing that the number of muscle satellite or stem cells decreases with 
age139,140. As muscle cells are post mitotic, a decreasing number of these cells would result in a 
limited capacity to regenerate losses in muscle tissue140.  
In addition to being implicated in the etiology of sarcopenia, the loss of muscle mass with 
age, poor peripheral nerve function has also been associated with lower muscle performance and 
physical function in older adults141,142.  In Health ABC, Strotmeyer et al. showed that the  poorest 
motor nerve conduction amplitude quartile (<1.7 mV) was associated with 8% lower quadriceps 
strength compared to the highest quartile, after adjustment for covariates including muscle mass 
and diabetes142. In the InCHIANTI study, individuals with peripheral arterial disease were shown 
to have reduced leg muscle power and muscle CSA and that poor nerve conduction velocity was 
related to slower 400m walk time and lower physical performance score as measured by the 
Short Physical Performance Battery143. 
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Another very important physiologic change in skeletal muscle that occurs with age is 
increasing adiposity. There are two fat depots present in skeletal muscle, intramuscular or 
intramyocellular fat (IMF) – fat infiltration in the muscle fibers themselves and intermuscular fat 
(IMAT) – fat that is visible within the muscle fascia, surrounding skeletal muscles. These fat 
depots have both been shown to increase with age122,144-147. In a longitudinal study in HABC 
participants, Delmonico et al. showed, using CT, that intermuscular fat increased in older adults 
who lost, gained and maintained their overall body weight122. This suggests that increasing 
intermuscular fat is a feature of the aging process independent of overall weight gain. In this 
study 5-year increases in IMAT of 48.5 ± 59.6% and 29.0% ± 43.6 in men and woman 
respectively were observed. Goodpaster et al. observed a one year increase of 3.6% in IMF in the 
education control group of an intervention study148. Interestingly, although IMAT has been 
shown to be linked to obesity, it has been shown in a study of men of both Caucasian and 
African ancestry, that those with African ancestry had higher levels of IMAT in the calf, despite 
having lower levels of total adiposity compared to Caucasians149. Higher levels of 
intramyocellular fat have been linked to worse functional performance in older adults30,144,150. 
IMAT in the calf has been linked with poorer muscle power and physical performance151 . 
However, a larger study by Buford et al. was unable to find and association between IMAT 
levels in the calf or thigh and physical performance145. 
It is important to note that these two fat depots are hypothesized to have two distinct 
etiologies. It has been postulated that intermuscular fat is a result of changes in the differentiation 
of quiescent skeletal muscle satellite or stem cells152, as these cells can either mature into 
myoctyes or adipocytes. There is evidence that the adipocytic phenotype is increased with age153; 
however research in this area is conflicting and this process is still poorly understood. Increasing 
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intramyocellular lipid content with age is thought to be the result of a decreased oxidative 
capacity of muscle with age and increasing insulin resistance154. Fatty acid oxidation includes 
~90% of the energy requirements at rest and the oxidative capacity of skeletal muscle has been 
shown to decrease with age7,155,156. Therefore, it is hypothesized that larger lipid droplets are 
present in aged muscle fibers because they are not being metabolized as efficiently or as readily. 
Furthermore, higher intramyocellular fat content has been associated with insulin resistance in 
humans157-160. Higher IMAT levels have also been linked to diabetes and insulin resistance in 
humans52,146,161. Additionally, higher IMAT levels have also been shown to be associated with 
lower mitochondrial function (r2=0.32, p=0.004) in a study consisting of both older (75.7±1.0 
years) and younger (27.2±1.0) adults162. However, this was an unadjusted correlation, so this 
could be an affect of age, decreased physical activity or another confounding factor and not 
higher IMAT per se.   
In addition to increasing adiposity of skeletal muscle tissue, Obesity in general has been 
shown to exacerbate physical disability in older adults65,68-70,163,164. In addition to the loss of lean 
mass, aging is accompanied by an increase in fat mass100. Specifically, aging is associated with 
increases in central adiposity or visceral adipose tissue (VAT)165,166 , intracellular deposition of 
fat and deposition of fat outside of adipose tissue153,167.  
Despite obesity being related to physical disability in older adults, there is controversy as 
to whether older adults should lose weight and whether overall body weight or particular aspects 
of body composition should be targeted168-170. Observational studies have shown a positive 
association between weight loss in old age and mortality171; whereas  randomized controlled 
trials have shown that weight-loss (WL) in combination with moderate physical activity (PA) 
improves physical function in older adults to a greater degree than physical activity alone49,172, 
26 
weight loss alone49 and normal care173. Additionally, WL in conjunction with PA has been 
shown to improve components of frailty, including physical function, in obese frail older adults 
174.  This may be attributable to the fact that intentional and unintentional weight-loss may target 
fat mass differently. Intentional weight loss combined with a moderate physical activity 
intervention has been shown to decrease fat mass to a greater degree than lean mass48,174-176. 
Intentional weight loss may also target particularly harmful fat depots. Few studies have shown 
specific composition data following intentional weight loss in older adults173,175,177, but the few 
that do seem to support this hypothesis. Furthermore,  Shea et al. have published findings from a 
randomized controlled trial showing that intentional weight loss in old age is not associated with 
increased mortality49. 
1.2.4 Changes in Muscle Performance with Age 
Changes to the neuromuscular system lead to age-related changes in muscle performance in the 
form of decreased muscle strength and power. It is well documented that muscle strength 
decreases with age79,134. This has been shown both cross-sectionally and longitudinally in both 
the upper and lower extremities. Upper extremity muscle strength in older adults is using 
measured in the form of grip strength by a hand held dynamometer. Lower extremity muscle 
strength is usually measured by an isokinetic dynamometer. Lower extremity muscle strength 
can also be measured isometrically, where the participant’s one repetition maximum is 
determined by having them push against increasing resistance until they are no longer able to 
move the load. This review will discuss changes in the lower extremities because lower 
extremity function is more important for mobility and most IADL and ADL tasks.  
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Cross-sectional studies estimate knee extensor strength to be between 20-40% lower in 
those in their 60s and 70s compared to those in their 20s and 30s for both men and 
women111,112,115-117,127,178-185. Additionally, Frontera et al. observed 20.0% and 17.6% lower knee 
extensor strength in men and women age 65-78 respectively compared to men and woman age 
45-54103. Cross-sectional evidence from HABC showed 17.8% and 13.5% lower muscle strength 
in white and black men and 16.9% and 23.1% in white and black woman respectively, age 79 
compared to age 70. There is also some evidence that strength declines at a steeper rate starting 
in the late 8th decade and into the 9th decade of life184. However, there is a lack of data 
concerning  
Fewer longitudinal studies have been done. In a study by Frontera et al. where 9 of 12 
men, age 71.1±5.4 years at baseline, where revaluated 9 years after participating in a resistance 
training intervention. Percent annual declines in knee extensor strength, measured using an 
isokinetic dynamometer at 60°/s, of 2.5%. These are similar estimates to those observed in the 
much larger epidemiologic Health ABC study. In Health ABC, percent annual declines of 4.12% 
and 3.42% in white and black men and 2.65% and 2.97% in white and black women 
respectively. It is important to note that rates of decline different significantly by sex within race 
and race within sex. In summary, longitudinal evidence suggests that the rate of decline may be 
more severe than previously estimated by cross-sectional studies and that men lose a greater 
proportion of strength compared to woman. However, men start with higher levels of strength 
than women, and thus have more to lose. Additionally white men and black woman appear to 
experience more severe declines in strength than their within gender racial counterparts. It should 
be noted that these longitudinal studies examined participants with a much greater minimum 
baseline age than cross-sectionally. Therefore, in the addition to the inherent design biases 
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between longitudinal and cross-sectional studies, the loss of strength with age may be accelerated 
in old age, partly accounting for the differences seen in cross-sectional compared to longitudinal 
studies. It should be noted that the above changes in knee extensor strength were absolute 
measures and not adjusted for lean or body mass. However, several studies well equipped to do 
so, including HABC83,99,122 and the Baltimore Longitudinal Study of Aging116,126 have shown a 
decrease in muscle quality, defined as muscle strength per unit muscle mass with age.  
Muscle power, which is defined as force multiplied by velocity, decreases with age at a 
greater rate than muscle strength77,186 which is thought to be due to the velocity component 
decreases with age along with the strength (force) component187,188. Muscle power can be 
measures several different ways, none of which have been agreed upon as a gold-standard 
method. These methods include: vertical jumping on a force plate, Nottingham power rig (fixed 
load leg extensor power), isokinetic dynamometry and leg extensor power using pneumatic 
resistance machines77,189.  A recent study by Pojednic et al. showed that muscle power in healthy 
middle aged adults (mean age 47.2 ± 4.5 years) was 19.4% and 44.5% higher when compared to 
healthy older adults (mean age 73.6 ± 3.5 years) and mobility-limited older adults (mean age 
77.9 ± 4.3 years) respectively187. It has also been shown by several studies that muscle power is 
more strongly related to certain physical limitations in older adults than muscle strength186,190-192. 
Similarly, the velocity component has been shown to be related to physical impairment in older 
adults independent of the strength component187,193; this may be why power has been shown to 
be a stronger predictor of physical limitations than strength. 
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1.2.5 Interventions Improving Muscle Function 
Many studies have been conducted attempting to increase muscle performance in older adults. 
These studies include pharmacological, nutritional and physical activity interventions. The most 
common form of physical activity intervention for improving muscle strength in older adults is 
resistance training194. It is also important to note that interventions specifically designed to 
improve muscle power, as opposed to strength, have also been conducted. An overview of the 
efficacy and effectiveness of these interventions will be presented in this section. 
Several studies have been designed to assess whether or not nutritional supplementation 
increases the benefits of resistance training on muscle performance in older adults. Protein, 
creatine and vitamin D supplementation are nutritional supplements that have been studied. In 
Health ABC, participants in the highest quintile of energy-adjusted protein intake lost about 40% 
less total and appendicular lean mass when compared to those in the lowest quintile over a 3-year 
follow-up period195. Over the same 3-year follow-up period and after adjustment for potential 
confounders, higher energy-adjusted protein intake was associated with smaller losses in total 
and appendicular lean mass, as measured by DXA195. Therefore, protein deficiency in older age 
may contribute to the loss of muscle mass and performance. 
Several studies have been specifically designed to assess the added benefits of protein 
supplementation to resistance training in older adults196-200. In a study conducted by Meredith et 
al in which 11 older men underwent a 12-week lower extremity resistance training program, 6 of 
these men were given a daily dietary supplement of 560 +/- 16 kcal/day (17% energy from 
protein, 43% from carbohydrate, 40% from fat)201. In this study, the supplement group increases 
their muscle mass to a greater degree than the non-supplement group, but no differences in 
improvements in strength were observed between groups201. Fiatrone et al. published findings in 
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the New England Journal of Medicine from a randomized controlled trial comparing the effects 
nutritional supplementation (360 kcal in a 60% carbohydrate, 23% fat, 17% soy-based protein 
formula and one-third of the recommended daily allowance of essential vitamins and minerals), 
progressive resistance training, both and neither on muscle strength (1 repetition maximum 
(1RM)) in nursing home residents over the age of 70202. In this study, nutritional 
supplementation did not convey significant additional benefits to resistance training in improving 
muscle strength after 10-weeks202.  The same group published findings from a subset of 26 
individuals involved in the previously mentioned clinical trial, who were willing to undergo a 
muscle biopsy203. In these individuals, protein supplementation did significantly augment 
increases in muscle strength following the exercise intervention203. Esmarck et al. conducted a 
randomized controlled trial in 13 men, comparing the effects of protein supplementation 
immediately following, compared to 2 hours following an identical resistance training 
program204. In this study the group that ingested the supplement immediately following training 
improved both their 1RM and  isokinetic strength, whereas the group that ingested the 
supplement 2 hours following training only improved their 1RM strength and to a lesser degree 
than the immediate ingestion group204.  However, Candow et al. observed no effect of protein 
supplementation consumed before or after resistance exercise on muscle performance or size in 
men aged 59-76200. Similarly, no effect of protein supplementation, creatine supplementation or 
a combination of both immediately following resistance training was observed in men aged 
57.0±1.9 years205. The studies by Candow et al. 200 and Carter et al. were conducted in much 
larger (n= 38 and 42) samples than the Esmarck study (n=13). 
In summary, sufficient evidence does not exist suggesting protein supplementation is 
necessary to improve muscle function in older adults198. A comprehensive review of the effects 
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of protein supplementation on muscle composition performance in older adults can be found 
here197. Studies including women as well as older (aged ≥80) and more frail adults appear to be 
lacking. Although protein supplementation does not appear to augment the effects of resistance 
training on muscle performance, in a meta- analysis of trials examining the effects of protein 
supplementation and resistance training on fat-free mass a significant relationship between 
amount of protein supplementation and change in lean mass observed197. In fact, those who 
consumed the average daily dietary recommendation of 0.8g of protein/kg of body weight 
actually would be predicted lose about 0.2 kgs of lean mass over a 12-week period. Protein 
intake of 1.0 g/kg of body weight was associated with no change in lean mass. Thus, although 
protein supplementation does not appear to augment changes in muscle performance induced by 
resistance training, consuming adequate levels of protein seem to be important for preserving 
lean mass in old age.    
Creatine supplementation is another nutritional agent of interest because of its 
involvement in skeletal muscle performance, specifically through increasing energy stores 
(Phosphocreatine (PCR)). Creatine may also aid in reducing the amount of protein breakdown 
and increase protein synthesis in skeletal muscle, as well as reduce oxidative stress206.  Several 
studies have assessed the added benefits of creatine supplementation with resistance training in 
older adults206. In a study conducted by Brose et al. comparing the added benefits of creatine 
supplementation to a 14-week resistance training program, the creatine supplementation group 
showed a greater increase in isometric knee extension strength in men and women compared to 
the placebo group207. Interestingly, isometric dorsiflexion strength was improved in the 
supplement group to a greater degree than the placebo group, but only in men207. A similar study 
in men only conducted by Chursch et al. produced similar results, with significant group by time 
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interactions on knee extensor strength (1RM) and knee extensor power, with the creatine 
supplement group showing greater improvements following 12-weeks of resistance training208.  
In a study consisting of both men and women comparing the added benefits of creatine 
supplementation to 6-months of resistance training, both men and women in the supplement 
group showed greater improvements in both isokinetic knee extensor strength and 1RM 
compared to the placebo group209. In a study consisting of 32 older men and woman (age 67-80) 
comparing the effects of weight training with and without supplementation to control groups 
with and without training, no added benefit was observed in regard to lean mass or 1RM strength 
after 8 weeks210.  In a study comparing creatine supplementation to placebo after 30 days, 
without resistance or exercise training, reported no difference between the two groups in regard 
to both muscle strength and muscle mass211. In two similar studies comparing the effects of 
creatine supplementation to placebo after 5 days, no differences between groups concerning 
elbow extensor strength or isokinetic knee extensor strength was observed212,213. Conversely a 
study in 15 men and woman comparing the effect of creatine supplementation vs. placebo 
showed significant increase in grip strength following 14 days of supplementation214.  
In summary, results are conflicting regarding the added benefits of creatine 
supplementation to resistance training, and creatine supplementation without exercise. In three of 
the four trials comparing creatine supplementation plus resistance training to resistance training 
plus placebo, an added benefit of creatine supplementation was reported. Two of the three trials 
showing an added benefit of creatine supplementation on muscle performance included both men 
and women207,209, while one included men only208. The trial showing no benefit included both 
men and women210.  Therefore, it is unlikely that the conflicting results are attributable to gender 
differences between studies. The trial that showed no benefit lasted 8 weeks, where the minimum 
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length of the three trials showing a benefit was 12-weeks. Perhaps 8-weeks were not long enough 
to see a benefit of creatine supplementation with resistance training compared to placebo with 
resistance training. Importantly, the only trial of the 4 to include functional or physical 
performance measures207, timed chair-stand, timed walk and a timed stair-climb test, showed 
greater improvements for all 3 tests in the creatine supplementation group compared to the 
placebo group. Additionally, it appears as though resistance training is necessary to observe 
benefits of creatine supplementation, as 2 of the 3 trials comparing creatine supplementation to 
placebo without either group participating in an exercise intervention, showed to benefit. In 
summary, there does seem to be some promise to creatine supplementation while participating in 
a resistance training program. Larger double-blind placebo trials are warranted206.  These trials 
should also include a measure of overall physical function, such as the SPPB and/or walking 
performance, such as the 400m walk or timed get-up-and-go test. It is important to determine 
whether or not improvements in muscle performance are also conveying improvements in 
physical function, i.e. gait-speed or SPPB score.  
Vitamin D is another nutrient that has been suggested to possibly improve muscle 
function in older adults. Several studies assessing the benefits of Vitamin D supplementation 
with and without exercise training, have been conducted206,215.  Two randomized controlled trials 
comparing the added benefit of Vitamin D supplementation to resistance training in older adults 
have been conducted. Neither of these trials showed any additional beneficial effect with 
Vitamin D supplementation compared to resistance training alone in regard to muscle 
function216,217. However the trial conducted in Vitamin D deficient individuals showed added 
benefits of Vitamin D, specifically greater improvements in physical function measured by the 
timed up and go test216. It should also be noted that a meta-analysis conducted examining the 
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effect of Vitamin D supplementation on fall risk showed a protective effect of supplementation, 
which may be due to increased muscle performance218. More work examining the effect of 
Vitamin D on muscle performance is needed. However, it has been suggested that Vitamin D 
supplementation should be considered for those with low levels or in populations who are likely 
to have low levels, such as nursing home residents198.  
Testosterone therapy has been hypothesized as a possible mechanism to prevent age-
related declines in muscle performance in men, because testosterone levels have been shown to 
decrease in men age 40 and older. Similar to protein and creatine supplementation, results are 
mixed regarding the effectiveness of testosterone, especially in community-dwelling men198,206. 
A meta-analysis looking at the combined effect size in 11 randomized controlled trials 
comparing the effect of testosterone or dihydrotestosterone (DHT) replacement therapy in 
healthy men aged 65 and older was published by Ottenbacher et al in 2006219. A modest 
improvement in strength in those receiving testosterone compared to placebo was reported in this 
meta-analysis, with those trials implementing injection as opposed to topical or oral 
administration of testosterone showing larger effects219. One study in particular severely drove 
the effect size up as sensitivity analyses showed that excluding this study reduced the mean g-
index from 0.53 to 0.23 (g-index of 0.0 = no effect).  
Selection of participants (healthy men vs. hypogonadal men with low testosterone) is 
likely to affect results. In a more recent clinical trial of 237 men with testosterone levels below 
the 50th percentile of the population screened (13.7 nmol/L), 80 mg of testosterone or placebo 
were administered twice a day for 6 months220. This study reported greater increases in lean mass 
in the testosterone group, but this increases in lean mass did not result in improvements in 
muscle strength220. Conversely, in a randomized controlled trial in 274 frail men comparing the 
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effects of 50 mg per day of testosterone compared to placebo over the course of 6-months, 
greater improvements in muscle mass and strength were recorded in the testosterone group 
compared to the control group221. Testosterone supplementation also conveys certain health 
risks, as testosterone treatment has been reported to be associated with an increase in prostate 
disorders, raised hemocrit levels and adverse cardiovascular events198,206,222.  
In summary, testosterone supplementation is promising, but the long term risks and 
benefits need to be assessed before general use can be recommended. However, those with low 
muscle mass, strength and testosterone levels may benefit from supplementation.  The fact that 
two large trials arrived at conflicting results, with one showing an improvement in strength221 
while the other did not220, may be due to the fact that the latter enrolled frail men, while the 
former did not. It could be that testosterone supplementation is important for subsets of older 
men, especially those who are hypogonadal (have low testosterone), frail or both. Currently, 
there is a large trial being conducted in 800 men, across 12 sites in the United States designed to 
compare the effects of testosterone supplementation to placebo. To be enrolled in the trial men 
had to have low blood testosterone and also have one or more of the following: difficulty 
walking a quarter of a mile, less interest in sex, or less vitality than they used to have. This trial 
is going to examine the effects of testosterone compared to placebo on physical function, sexual 
function, vitality, cognitive function, and low hemoglobin concentration, as well as risk factors 
for cardiovascular and diabetes. The trial will also examine any adverse effects associated with 
testosterone. This trial should provide a wealth of information concerning the risk and benefits of 
testosterone supplementation. Although muscle performance was not directly evaluated, walking 
performance was and improved muscle function is ultimately of little importance unless it also 
coveys improvements in physical performance - e.g. walking.   
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Growth Hormone (GH) supplementation is another means by which muscle strength may 
be improved in older adults. Liu et al. published a review paper titled “Systematic Review: The 
Safety and Efficacy of Growth Hormone in the Healthy Elderly” in 2007223. The review included 
randomized clinical trials designed to assess the effects of GH therapy on body composition, 
exercise capacity, bone density, serum lipid levels and glucose metabolism as well as adverse 
events. The review included only those trials that compared injectable GH with no GH and GH 
plus a lifestyle intervention with a lifestyle intervention alone. The doses ranged from 1.7 µg/kg 
– 45 µg /kg, with a mean and standard deviation of 14.3 ± 14.7. The duration of GH therapy 
ranged from 2-52 weeks w/ a mean of 26.6 weeks w/ SD of 15.6223.  Those receiving GH 
manifested a decrease in fat mass and increase in lean body mass compared to non-GH 
participants. The differences in these body composition measures were not statistically 
significant, but suggested that GH therapy can reduce fat mass and increase lean mass in the 
healthy elderly. Additionally, several trials have failed to show increases in muscle performance 
following GH supplementation, whereas others have found a positive effect198,206. Furthermore, 
significantly higher rates of soft tissue edema, carpel tunnel syndrome, joint pain and 
gynecomastia in GH participants as compared to non-GH participants were reported in the 
review by Lui et al223.  
Angiotensin II-converting enzyme (ACE) inhibitors have also been hypothesized to have 
positive effects on skeletal muscle. In Health ABC use of ACE inhibitors was associated cross-
sectionally with larger lower extremity lean mass224. However, results of clinical trials looking at 
the effect of ACE inhibitors on muscle mass and performance have been conflicting206. In an 
extensive review by Rolland et al. from 2010 discussing pharmacological treatments for 
sarcopenia, 3 trials are discussed; two of which reported null results, while a 3rd reported 
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significantly greater improvements on the 6-minute walk test in the ACE inhibitor group, which 
may indicate increased muscle performance206. However, this could be due to cardiovascular 
affects and not improvements in skeletal muscle per se206. Other pharmacological agents 
discussed in this review include statins, beta-blockers, vasodilators and anti-inflammatory drugs. 
There is insufficient evidence regarding these drugs and their effects on muscle 
performance198,206. Larger, double-blind placebo clinical trials are needed to determine the 
effects of ACE inhibitors and other medications on muscle performance. These trials should also 
examine dose response effects and not just effects in general. Cardiovascular measures such as 
blood-pressure and ankle arm indexes, nerve function, blood lipid panels, metabolic profiles and 
inflammatory marker levels should be collected in these trials to examine underlying factors 
associated with improved muscle performance and medications.  
The most well-documented and perhaps the most effective way to improve muscle 
performance, mainly strength, is resistance training. This is exemplified in an exhaustive 2009 
Cochrane review by Liu and Latham et al. in which 121 randomized controlled trials of 
resistance training in older adults were reviewed194. The authors of this review found a large 
standard mean difference (SMD), or effect size, when comparing resistance training groups to 
control groups. In the 73 trials that were equipped to measure this, the SMD was calculated to be 
0.84 (95% CI 0.67 to 1.00) using a random effects model. This indicates that the average person 
in a resistance training group showed larger improvements in strength than 79% of those in the 
control group. To minimize heterogeneity, the authors only used strength data concerning the 
most common muscle group used, which was the leg extensor, when calculating this SMD. This 
review also noted that high vs. low intensity resistance training resulting in slightly greater 
improvements in strength194. Also, of particular interest, this review found that 10 studies 
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(n=487) compared the effect of resistance to aerobic training on muscle strength and found that 
resistance training improves muscle strength to a greater degree than aerobic training. Also of 
interest, in the Lifestyle Interventions and Independence for Elders pilot (LIFE-P) study, the 
intervention group, which consisted mainly of over ground walking, supplemented with lower 
extremity resistance and balance training, lost knee extensor strength, but to a significantly lesser 
degree than the control group148. This loss in strength did not translate into overall loss of 
physical function or mobility225. Finally, strength training is also recommended to older adults by 
the American College of Sports Medicine226. Data concerning very old (aged ≥80) are lacking, 
however there have been a 2 trials in conducted in populations of older adults in their eighties. 
These studies both show that plasticity of skeletal muscle may diminish significantly in the 9th 
decade of age, with muscle showing a blunted response, compared to younger older adults, to 
training in both studies227,228. More work regarding those in their 9th decade of life and older is 
needed.  
Specific interventions to improve muscle power have also been conducted. These 
interventions focus more on the speed of the exercise rather than the resistance. That is exercises 
are performed with lower resistance with an emphasis on speed229.  Lower resistance exercises 
would induce less stain on muscle and joints may be particularly appropriate for older more frail 
adults. These interventions have been shown to increase both strength and power in older adults. 
A meta-analysis conducted by Tschopp et al. actually reported greater improvements to muscle 
strength and power with power training as opposed to resistance training230, but results in the 
literature are conflicting77,229. It is important to note that with both traditional resistance training 
and power training, both strength and power will increase to some degree, as strength (force) is 
one of the two components of power, the other being velocity. 
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1.2.6 Changes in Muscle and Physical Performance: Its’ not only the Mass 
In Health ABC, Goodpaster et al. showed that change in muscle mass was only able to explain 
~5% of the variability in strength decline83.  A similar finding was presented by Hughes et al. 
where age-associated changes in muscle mass explained  about 5% of the variance in the change 
in knee extensor strength decline124. Furthermore, Fleg et al. has shown, in the BLSA, that 
maximum aerobic capacity (VO2 peak), normalized to fat-free mass, decreases with age at 
similar rates across those who report low, intermediate and high levels of physical activity231. 
That is, although those with high levels of physical activity start and end with higher levels of 
aerobic capacity, the rate of decline in aerobic capacity normalized to lean mass and across 
physical activity group. This suggests that the rate of decline in aerobic capacity cannot be fully 
explained by changes in lean mass and lower levels of physical activity. For these reasons it is 
important to examine other physiologic changes that occur with age. Mitochondrial function and 
biogenesis may be an important contributor to declining muscle and physical function with age. 
This is because the ability of skeletal muscles to extract and use the oxygen to produce energy is 
one of two major components of VO2 peak. Additionally, mitochondria produce ~90% of the 
energy required for movement7; therefore, declines in mitochondrial function may be of major 
importance in explaining the loss of muscle performance and physical function with age. 
1.2.7 Changes in Mitochondrial Energy Production with Age 
The mitochondria as it exists today is thought to be the result of evolution and a symbiotic 
relationship between ancient bacteria and eukaryotes232. Mitochondria allowed for enhanced 
energy production via oxidative phosphorylation in ancient eukaryotic cells. Mitochondria 
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contain their own DNA (mtDNA), which is inherited maternally and includes genes that encode 
for proteins involved in oxidative phosphorylation, the mitochondria’s energy producing process.  
Mitochondria are the primary producers of adenosine triphosphate (ATP) in the human body. In 
fact, mitochondria have been shown to produce about 90% of the energy needed for human 
ambulation7. This dissertation focuses on this energy production and how decreases in 
mitochondrial energy production may affect fatigability and physical function in older adults.  
Skeletal muscle mitochondrial function is extremely complex and regulated at multiple 
biologic levels, including proteins encoded by both nuclear and mtDNA. For example, the 
replication, maintenance, and transcription of mtDNA is controlled by transcription factor A, 
mitochondrial (TFAM) and TFAM is regulated by nuclear transcription factors (NRF1, NRF2), 
which also regulates the expression of nuclear genes encoding mitochondrial proteins233,234.  
(PGC-1α) regulates NRF1 and NRF2 and is a key regulator of energy metabolism235. 
Additionally, alterations to lipid-membrane health and other factors including calcium release 
from the sarcoplasmic reticulum to maintain the energy gradient needed for proper function of 
the respiratory chain and oxidative phosphorylation can affect mitochondrial function236. 
Interestingly, Amara et al. found mild uncoupling in aged skeletal muscle, which did not impact 
ATP production in the tibialis anterior muscle and this uncoupling was hypothesized to be a 
compensatory mechanism protecting against oxidative damage from ROS production237.  
However, larger uncoupling was observed in the first dorsal interosseus muscle, which resulted 
in lower ATP production237. Thus, there are many factors they may affect and lead to 
dysfunctions in ATP production with age. A few of these are discussed in the section after next, 
but an in-depth discussion of the biochemistry and regulatory process and age-related changes to 
these processes is beyond the scope of this epidemiologic dissertation. This dissertation focuses 
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on the culmination of these changes, impaired ATP production, and whether or not decreases in 
mitochondrial ATP production affect physical function in older adults. It should be noted that 
mitochondria may be implicated in declining physical function with age by processes not directly 
related to ATP production, such as apoptosis. Mitochondria play a large role in regulating 
apoptosis and there is some evidence that apoptosis, induced by mitochondrial dysfunction, may 
lead to nuerodegeneration and declines in skeletal muscle mass with age238,239. Reviews of this 
can be found elsewhere238-241.  
Researchers have arrived at conflicting results regarding the independent relationships 
between age and physical activity level with mitochondrial function. Some research has shown 
an independent decline in mitochondrial function with age, while others have argued that these 
declines are simply a function of lower physical activity levels. These studies are described in 
Table 3 and in the following section. 
Several studies using both in vitro and in vivo methods (information regarding 
measurements of mitochondrial function can be found in section 1.2.9), have shown that 
mitochondrial function decreases with, despite older and younger subject having similar physical 
activity levels. Conley et al. showed a significant cross-sectional difference in mitochondrial 
function and mitochondrial volume density in older compared to younger participants using 31P 
MRS156. This difference was said to be independent of activity, as all participants were 
recreationally active, although there were no data presented to support this. Furthermore, Coggan 
et al. showed, using 31P MRS dynamics, in activity matched older and younger adults, that older 
adults had significantly lower mitochondrial function. Short et al. showed a significant 
relationship (r = -0.51, p=0.001) between citrate synthase activity (CS), which is a marker of 
oxidative capacity and mitochondrial content, and age in a study consisting of 86 females and 60 
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males age 18-89. This same study showed a significant correlation (r=-0.55, p<0.001), between 
maximal ATP production, measure with Firefly luciferase, and age. Furthermore, Lanza et al. 
showed that regular endurance training only partly attenuates age induced declines in 
mitochondrial function (CS activity) in a cohort of young trained and untrained compared to 
older trained and untrained adults 242. However, Lanza reported that MAPR was lower in older 
untrained compared to younger untrained individuals, but similar in older trained and younger 
trained participants. This evidence supports the notion that the aging process has detrimental 
effects on oxidative metabolism, independent of physical activity level, but physical activity is 
largely responsible for age-related declines in mitochondrial function.  
Other research has shown that when physical activity level is adjusted for, no 
independent age effect on mitochondrial function exists. Brierly et al. revealed that when 
physical activity was adjusted for, overall in vitro mitochondrial respiratory activity was not 
significantly associated with age 243. This same research group showed similar results in a study 
comparing mitochondrial function in young athletes (22-33 years) with older athletes (61-68 
years) 244. In this study, no difference in CS activity was observed between young and older 
athletes. It should be noted that physical activity was assessed via questionnaire in the two 
previously mentioned studies. Furthermore, no independent age effect on mitochondrial function 
was observed in a study of young and older participants with similar physical activity levels 245. 
In this study by Kent-Braun and Ng, physical activity was measured objectively by 
accelerometry and mitochondrial function of the tibialis anterior was measured by 31P MRS. 
Similar results using 31P MRS and accelerometry have been observed by Lanza et al. 
Interestingly, Larsen et al. showed that mitochondrial function, measured by31P MRS, in the 
vastus lateralis (quad) but not the tibialis anterior was lower in older compared to younger 
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participants matched for physical activity levels246. In fact, this studied showed that 
mitochondrial function in the tibialis anterior was actually higher in older compared to younger 
adults. These and other studies are depicted in Table 3.  
To summarize, cross sectional studies have led investigators to arrive at conflicting 
conclusions. One possible explanation for the conflicting results is that most of these studies 
assessed physical activity levels via questionnaire or self-report, with only a few of the cross-
sectional studies implementing an objective measure of physical activity245. Additionally, the 
studies reporting no age-related changes in mitochondrial function, in participants matched for 
activity or when activity was adjusted for, had small sample sizes ranging from comparing 20 
younger adults to 19 older adults to comparing 9 younger to 12 older adults. These studies may 
not have been adequately powered to detect differences.  Conversely, the study by Conley et al. 
compared 9 younger to 40 older adults and the study by Short et al. contained 146 total 
participants; both of these studies detected age-related differences. Furthermore, studies in the 
oldest of older (aged ≥80) and frail adults are lacking. Studies including older more frail 
individuals may show greater age related declines, however these declines may be attributable to 
inactivity and disuse. Studies including lower function individuals would yield important 
information regarding declines in mitochondrial function. Perhaps a threshold of mitochondrial 
dysfunction exists, where mitochondrial function ceases to decline, while function continues to 
deteriorate. Conversely, mitochondrial function may continue to decline even in the oldest and 
frailest of older adults. Research is needed establishing subsets of older adult in which 
mitochondrial function may be a particularly limiting factor. 
Additionally, studies examining declines in mitochondrial function with age measured 
different muscle groups, either the quad or vastus lateralis or the gastrocnemius or tibialis 
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anterior; and as illustrated by the Larsen study, age-related changes may differ between muscle 
groups. Finally, all these studies were cross-sectional; therefore they are subject to inherent 
biases. For example, healthy older adults are more likely to volunteer for studies, especially 
those involving muscle biopsy or performing an exercise bout in an MR magnet for 31P MRS 
studies. Therefore, the older adults in these studies were healthier and may have experienced less 
mitochondrial dysfunction than the average older adult.  
Despite differences in methodologies, conclusions and the recall bias introduced by 
subjective measures of physical activity, important conclusions can be drawn from these cross-
sectional studies. It appears as though there are age-related declines in mitochondrial function 
and that physical activity is a very strong mediator in the relationship between age and 
mitochondrial function. An extensive review of studies examining the impact of age and physical 
activity of both enzymatic activity and 31P MRS parameters of mitochondrial function has been 
published by Russ and Kent-Braun247. In summarization, it seems as though both conclusions are 
partly right – independent age-related declines in skeletal muscle mitochondria exist and 
engaging in regular physical activity can attenuate these declines.  
Additionally, mitochondrial dysfunction may be a contributor to as well as a consequence 
of age-related declines in physical activity. For example, mitochondrial dysfunction may lead to 
an increase in fatigability or exercise intolerance, which may in turn lead to a decrease in activity 
level in order to keep fatigability at a minimum. There is also evidence that skeletal muscle 
mitochondrial dysfunction activate apoptotic pathways; activation of these pathways may lead to 
nuerodegeneration and could contribute to declines in muscle mass with age240,248. These 
changes may also result in a decrease in physical activity level. Longitudinal studies measuring 
mitochondrial function both in vivo and in isolated mitochondria from muscle biopsy and that 
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include objective measures of free-living physical activity for a period of time (e.g. 7 days) are 
needed to truly established the relationship between age and mitochondrial function and how 
physical activity mediates or affects this relationship. 
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Table 3. Effects of Age and Physical Activity on Mitochondrial Function 
Study Y Age O Age YN/Sex 
O 
N/Sex 
Muscle Mito Parameter PA Measure 
Difference Between  
Y and O Effect of PA 
Short249 18-89 86F 60M VL CS activity MAPR 
Excluded if 
active 
CS - R age = -0.51, 
p=0.001 
MAPR – Rage = -55, 
p<0.001 
Participants matched 
for PA 
Conley156 39±8 69±6 6M 3F 18M22F Quad PCr Recovery (mM ATP/s) 
All 
considered 
recreation-
ally active 
O 47.4% < Y, S Not directly Examined 
Lanza242 18-30 59-76 VL CS activity MAPR Q 
MAPR OT ≈ YT 
MAPR OUT < YUT 
CS OT <YT 
CS OUT <YUT 
Training status 
attenuated age affects 
but effects remained  
 -  - 
Lanza250 22±1 75±5 8M 8M tibialis anterior PCr Recovery (mM ATP/s) AC O ≈ Y PA: O≈Y 
Lanza251 27±1 70±1 10F 10M 8F 10M 
tibialis
anterior PCr Recovery (mM ATP/s) AC O ≈ Y PA: O≈Y 
Brierly243 21-96 51 VL CS activity Q R age = -0.27, p=0.07 attenuates to p=0.17 
Brierly244 22-33 61-68 3F 6M 2F 10M VL CS activity 
All 
considered 
highly 
active-Q 
O ≈  Y, S 
All participants highly 
active-attenuated age 
effect 
Kent-Braun245 34±5 76±5 9F 10M 9F 9M 
tibialis 
anterior t1/2 PCr Recovery AC 
OF 6%<  YF, NS      
OM 10% < YM,NS 
No difference in PA 
between Y and O 
Coggan252 20-29 60-69 10F10M 
10F 
10M gastro CS activity None 
OF 14%< YF, S 
OM 28% < YM, S N/A 
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Coggan253 YU:
25±2 
OU: 
63±3 
YU: 
6M 
OU: 
6M 
gastro Pi/PCr slope Q OU < YU, S OT < YT, S Matched for PA YT: 
27±4 
OT: 
62±2 
YT: 
6M 
OT: 
6M 
Chilibeck254 26±2 70±4 6F 7M 2M 8F gastro IT from Pi/PCr and pH 
All 
considered 
moderately 
active – Q 
IT O < Y, S Participants matched for PA 
Chilibeck255 28±2 67±4 4F 6M 8F 2M gastro Time for PCr recovery 
All 
considered 
moderately 
active – Q 
O ≈ Y Participants matched for PA 
McCully256 28±7 66±6 4M 1F 5M gastro Max PCr recovery rate (mM/kg/min) 
Range of 
Activity 
levels – Q 
O 32.5% < Y, S N/A 
Schunk257 27±4 61±6 4F 6M 11F11M RF t1/2 PCr Recovery 
Survey – all 
not involved 
in formal 
exercise 
O ≈ Y Participants matched for PA 
Young258 20-29 70-83 - - gastro t1/2 PCr Recovery None O ≈ Y N/A 
Larsen246 21-35 65-80 8F 8M 8F 8M TA and VL Max PCr recovery rate (mM/kg/min) AC 
TA O > Y 
VL O < Y 
Participants matched 
for PA 
Abbreviations: y= young; o= old; Mito= mitochondrial; PA= physical activity; f= female; m= male; VL= vastus lateralis; CS= citrate Synthase; Quad= Quadriceps; PCr= 
phosphocreatine; mM= millimolar; ATP= adenosine triphosphate; S= significant; QU= questionnaire; MAPR = Mitochondrial ATP Production Rate; OT= old trained; YT= 
young trained; OUT= old untrained; YUT= young untrained; AC= accelerometry; t1/2= half-time; OF= old female; YF= young female; NS= non-significant; OM= old male; 
YM= young male; gastro= gastrocnemius; Pi= free phosphorous; IT=  intracellular threshold; kg= kilogram; min= minute; RF=rectus femoris; TA= tibialis anterior; 
Table 3 Continued 
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1.2.8 Reasons for Age-Related Declines in Mitochondrial Dysfunction 
There a few theories with supporting empirical evidence for why mitochondria may become 
dysfunctional with age, independent of physical activity level. The main and probably most well-
known theory postulates that accumulated oxidative damage due to prolonged ROS exposure, to 
mitochondrial DNA and RNA results in mtDNA mutations and deletions, which lead to 
dysfunctional mitochondria in aged skeletal muscle. As mitochondria are the primary producers 
of reactive oxygen species (ROS) in humans, mitochondrial DNA are inherently exposed to more 
ROS than nuclear DNA. Further exacerbating the oxidative damage are the facts that 
mitochondrial DNA lack histones which help to protect nuclear DNA from ROS damage and that 
mitochondrial DNA lacks the advanced repair system of nuclear DNA. A vicious cycle of aging 
has been hypothesized involving ROS induced mtDNA mutations and deletions, leading to 
dysfunctional mitochondria that produce more ROS and thus inflicting more damage to mtDNA 
which then leads to further mitochondrial dysfunction and eventually cellular 
apoptosis238,239,241,259. However, data from mouse models has put into question whether or not 
increased ROS production in dysfunctional mitochondria is implicated in or necessary to induce 
more damage leading to cellular apoptosis. More recently it has been hypothesized that general 
electron transport chain (ETC) dysfunction, leading to energy deficient mitochondria, is the 
culprit of mitochondrial dysfunction induced apoptosis. This is discussed in more detail in 
elsewhere241. Regardless, mtDNA damage leading to mutations and deletions in mtDNA, 
initially induced by ROS exposure, seems to be a primary cause in age-related mitochondrial 
dysfunction and decreased energy production.  
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 Mitochondrial membrane uncoupling also seems also increase with age in certain 
muscles237 and it has been shown that permeability of mitochondrial membranes to protons 
increases in aged muscle tissue260. This uncoupling would lead to a decrease in energy and ROS 
production, as the energy gradient needed for proper mitochondrial function would be impaired. 
It has been suggested that this uncoupling may precede significant accumulations of mtDNA 
mutations, and has been suggested to be a compensatory mechanism to reduce ROS production 
and prevent oxidative damage236.  
A more recent theory as to why mitochondrial become dysfunctional with age is called 
“Mitochondrial-Lysosomal Axis Theory of Aging”261. This theory has to do with impaired 
mitophagy (autophagocytosis of mitochondria) and is thought to be occurring simultaneously 
with occurring ROS damage. Mitochondria tend to become larger with age as they become more 
dysfunctional. This theory basically states that because aged mitochondria are larger, produce 
less energy and ROS, they are less likely to be marked for autophagocytosis262. The thought is 
that because these dysfunctional mitochondrial are producing less energy, and as a result less 
ROS, they are less autophagocytosized because their membranes haven’t undergone as much 
oxidative damage261. There are other reasons for impaired autophagy of mitochondria with age, 
such as an increased inefficiency of the autophagosomal-lysosomal pathway with age. This in 
turn leads to an accumulation of large, dysfunctional mitochondrial in aged human skeletal 
muscle that should have been autophagocytosized 262. This theory is discussed in detail in two 
recent reviews238,262. Similarly, the capacity for mitochondrial fission and fusion may decline 
with age. Fission and fusion are vital processes to ensure the health and function of mitochondria 
and to maintain proper mitochondrial turnover263.  
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Mitochondrial function may also decline to a decrease in mitochondrial protein content. 
Mitochondrial protein content has been shown to decrease with age by both decreased enzyme 
activity and my more direct measures. Maintaining mitochondrial protein content is important 
for maintaining mitochondrial function, because it is the function of these proteins that drives the 
energy producing processes of the mitochondria. As mentioned above, it is important for 
mitochondrial function to maintain proper rates of protein degradation and protein synthesis. 
Regulatory proteins such as PGC1α, AMPK, COX, those in the SIRT family and other may also 
be implicated in decreasing mitochondrial energy production with a age. Research concerning 
mitochondrial protein maintenance  is discussed in more detail in this review263.  
Experimental evidence has shown that mutations or deletions in mtDNA do in fact lead to 
mitochondrial dysfunction and reductions in ATP production and subsequently activate pathways 
that lead to apoptosis238,239,241,259 . For example, two labs observed three to eight fold increases in 
the rate of mtDNA mutations in mice where the mtDNA proofreading subunit polgA, of the 
mtDNA polymerase γ (pol- γ) (POLG mice) was deficient264,265. Subsequent impairments in ATP 
production in the heart and skeletal muscle were observed, along with a sarcopenic phenotype266.  
Additionally, in rhesus monkeys and rats, mtDNA deletions have been shown accumulate with 
age and are associated with decreased ATP production in skeletal muscle267-269. In humans, 
correlations between accumulated mtDNA mutations and deletions with a decreased capacity for 
oxidative capacity in skeletal muscle have been observed270-272. However, longitudinal evidence 
is needed to establish the causal role of mtDNA mutations in humans. There is also some 
evidence that over time, activation of apoptotic pathways, attributable to mitochondrial 
dysfunction, may lead to nuerodegeneration and could contribute to declines in muscle mass with 
age239-241,248. These mtDNA mutations have been shown to appear in humans between the age of 
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60 and 70273. There are several very nice reviews on the role of mitochondrial DNA mutations in 
apoptosis, sarcopenia and aging that discuss the potential underlying process and biochemistry in 
more detail236,238,239,241,274.   
1.2.9 Methods for Assessing Mitochondrial Function 
 Briefly, there are several markers that researchers can measure to quantify mitochondrial 
function including: mRNA content for mitochondrial proteins, mitochondrial RNA (mtRNA) and 
mitochondrial DNA (mtDNA) content, mitochondrial protein synthesis, mitochondrial enzyme 
activity, mitochondrial respiration and energy production. The most common markers used to 
measure mitochondrial function are the activity of certain oxidative enzymes including, citrate 
synthase, succinate dehydrogenase, cytochrome c oxidase and others. The activity of these 
enzymes is an indirect measure of the oxidative capacity of the mitochondria because they reflect 
electron transport chain (ETC) activity. They also reflect mitochondrial content. Citrate synthase 
is a common marker and is usually said to reflect mitochondrial content, however, some 
researchers use it as a measure of mitochondrial function. The important thing to note is that 
enzyme’s such as citrate synthase are markers of mitochondrial oxidative capacity and are not 
directly measuring ATP production. Enzyme activity is measured in vitro using specific assays in 
isolated skeletal muscle tissue obtained from needle biopsy.  
 A more direct measure of mitochondrial function is mitochondrial respiration (oxygen 
consumption) and ATP production. Traditionally, mitochondria’s ability to consume oxygen or 
produce ATP is measured using in vitro assays applied to isolated mitochondria or permeabilized 
muscle fibers from muscle samples. This in vitro technique measures the mitochondria’s ability 
to consume oxygen or produce ATP in the presence of certain fuels. This method can directly 
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assess respiratory capacity at different location in the ETC and can also be used to assess 
uncoupling. There is also a method called Firefly luciferase, which can be used to directly 
measure ATP production in isolated mitochondria. Firefly luciferase uses a luminometer to 
measure maximal ATP production rate by catalyzing reactions249.  
The main limitations of in vivo methods are actually the parameters they are designed to 
measure. Their physiologic relevance, because they are conducted in isolated mitochondria or 
muscle tissue obtained from muscle biopsy, is often questioned. That is, how well do these 
markers reflect actual ATP production in vivo. Studies have shown that ATP production from 
31P MRS methods is closely related to oxidative enzyme activity. However, in vivo measures of 
ATP production are considered to be more physiologically relevant. That being said, in vitro 
methods provide important mechanistic information concerning mitochondrial function that in 
vivo methods cannot provide, such as abundance of mtDNA, deletions and mutations present in 
mtDNA, the activity of specific regulatory enzymes and proteins, as well ROS production and 
markers of apoptosis263. 
1.2.9.1 31P Magnetic Resonance Spectroscopy 
This method is an in vivo technique which directly measures mitochondrial function 
noninvasively and was utilized to measure the primary outcome for two of the three papers 
described in this dissertation. This method is a companion technique to traditional magnetic 
resonance imaging (MRI) scan and maximum mitochondrial ATP production in vivo (ATPmax, 
mM ATP/s produced) can be calculated. This technology involves little participant burden, 
whereas the traditional method of muscle needle biopsy is highly invasive, induces considerable 
participant burden and must be performed by a physician. Additionally, mitochondrial 
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measurements using biopsy may not accurately reflect actual mitochondrial function in the living 
human body. 
31P MRS measures the regeneration of phosphocreatine (PCr) after a short bout of 
exercise to quantify mitochondrial ATP production. PCr is a high energy phosphate that can be 
readily converted to ATP and vice-versa via the creatine kinase reaction (PCr + ADP H+ ↔ ATP 
+ Cr). PCr is the initial full-source of skeletal muscles. It has been shown that a linear 
relationship links change in PCr with exercise to mitochondrial oxidative phosphorylation 
rate275,276.  The model shows that at full PCr depletion, skeletal muscle mitochondria should be 
functioning at their maximum oxidative capacity156. Therefore, measuring the dynamics of the 
PCr shuttle provides a method to estimate muscle oxidative capacity in vivo156,277. Furthermore, 
this method has been confirmed to be a good measure of oxidative capacity in rodent and human 
studies showing that ATPmax varies in direct proportion to the activity of oxidative enzymes in 
healthy muscle 278,279. It has also been shown to reflect mitochondrial content in human skeletal 
muscle280. The amount of ATP production from glycolysis (which does not involve the 
mitochondria) has been shown to be minimal in resting skeletal muscle (<8%)237. Regardless, 
this method can tease out the amount of ATP production by glycolysis by determining the pH 
from the chemical shift of the Pi peak relative to the PCr peak281. H+ ions, which would lower the 
pH, are a byproduct of glycolysis.  
Briefly, the exercise protocol utilized by the two studies in this dissertation takes place in 
a typical MRI magnet. Participants lay flat on their backs with the knee of the right leg (unless 
contraindicated) supported so that the leg is slightly elevated at a ~30 o degree angle. Straps are 
place over their legs and a 2.5” surface RF coil tuned to 31P is placed over the right quadriceps. 
At two different points during the scan, they are asked to kick repeatedly as hard and as fast as 
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they can, producing fast contractions at the highest rate possible for ~30s, followed by a 6 minute 
rest period. The protocol is designed to deplete PCr stores by at least 33-66% without lowering 
pH. PCr recovery rate is measured during this rest period. A figure depicting a cross-sectional 
spectra and PCr depletion and recovery can be seen in Figures 2 and 3. 
This method has several strengths. First, as mentioned previously, this technique involves 
little participant burden compared the traditional method of muscle needle biopsy, which is 
highly invasive, induces considerable participant burden and must be performed by a physician. 
It is a measure of functional mitochondrial performance in the sense that it is a measurement of 
what is actually going on in living tissue as opposed to mitochondrial performance under perfect 
conditions in mitochondria isolated from skeletal muscle. This technique has also been shown to 
be both valid and reliable and has been confirmed to be a good measure of oxidative capacity in 
rodent and human studies showing that ATPmax varies in direct proportion to the activity of 
oxidative enzymes in healthy muscle 278,279. It is also easy to obtain a measure of muscle mass or 
volume and fat depots by implementing a MR image sequence at the end of the protocol. This 
method can also be paired with oxygen occlusion measurements, to study the effects of oxygen 
delivery on mitochondrial function. Similarly, near infrared techniques can be used to measure 
oxygen delivery to skeletal muscle; these techniques can be used to measure in vivo oxygen 
delivery to skeletal muscle and can be used to identify pathologies underlying mitochondrial 
dysfunction. 
This technique has limitations as well. First, the actual mathematical modeling techniques 
used to glean important physiologic information from the spectra can be questioned. Secondly, 
participants with bilateral knee replacements cannot participate, even if these replacements are 
MR safe, the implants interfere with spectra acquisition. Claustrophobia is also exclusion, as 
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participants of average height are almost fully position in the bore of the magnet. Additionally, 
participants with tattoos or any MR unsafe implants would be excluded from participation. This 
particular exercise protocol may not be conducive to more frail older adults, as they are required 
to kick as hard and as fast as they can for 36s, which may not be possible in the oldest and 
frailest of adults. However, this method has been conducted using electrically stimulated muscle 
contractions, which may provide a way to implement this in extremely disabled populations. 
This method is subject to all other exclusions associated with MRI, such abundance of mtDNA, 
deletions and mutations present in mtDNA, the activity of specific regulatory enzymes and 
proteins, as well ROS production and markers of apoptosis or efficiency cannot be measured 
using this technique.  
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 Figure 2. Cross-sectional 31P MRS spectra with Labeled Free Phosphorous (Pi), PCR and ATP 
Peaks 
 
 
Figure 3. Longitudinal Depiction of PCr Dynamics at Rest, During Exercise (Kicking Bout), and 
during Recovery 
End exercise, begin rest 
Exercise begins 
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1.2.10 Other Factors that may potentially affect Mitochondrial Function 
Several other health factors and diseases, other than specific mitochondrial disorders and 
diseases, have been shown to negatively affect mitochondrial function. This information is 
presented below. The administration of antiretroviral medication in HIV patients has been shown 
to negatively affect mitochondrial function by affecting the replication of certain genes involved 
in glycolysis and lipid oxidation which can lead to mitochondrial dysfunction282,283. Additionally, 
it has been shown in vitro that HIV patients have a significantly lower ratio of mitochondrial to 
nuclear DNA in the peripheral blood cells than non-infected controls284; which suggested 
mitochondrial necrosis due to HIV viral infection. 
Mitochondrial dysfunction has been hypothesized to be both a cause and effect of certain 
neurological disorders including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral 
sclerosis (ALS) and Huntington’s disease248. It has been shown that specific interactions and 
overlap exist between disease related proteins  and proteins involved in  mitochondrial 
function248. Mitochondrial respiration, in mice with advanced peripheral arterial disease (PAD) 
was shown to be lower when compared to mice with PAD285. Participants with multiple sclerosis 
(MS), have been shown to have slowed mitochondrial biogenesis using 31P MRS compared to 
controls without MS; indicating impaired oxidative capacity of skeletal muscle in those with 
MS286.  It is fairly well established that mitochondrial function is lower in individuals with worse 
insulin resistance, type 2 diabetes and obesity287-290 and similar to neurological diseases – 
mitochondrial dysfunction has been hypothesized to be both a cause and effect of insulin 
resistance and type 2 diabetes. Severe burn trauma has been shown to result in mitochondrial 
dysfunction291. Patients with severe chronic heart failure have been shown to have 20% lower 
mitochondrial volume and surface density of mitochondrial cristae as well as significantly 
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decrease cytochrome oxidase activity, indicating lower mitochondrial function compared to 
health participants292. Mitochondrial function in circulating lymphocytes and in platelets was 
shown to be lower in smokers compared to non-smokers293,294. In the study examining 
lymphocytes, participants were matched for age, sex and physical activity level171.  
 Alcoholism, specifically the effects of ethanol, has been shown to induce morphological 
changes in skeletal muscle mitochondria295. It has also been shown that men experience greater 
mitochondrial dysfunction than women. This is because mitochondrial in women produce less 
ROS than men, due to the mediating role of estrogen296-299. This work has mostly been conducted 
in rodents and the role of estrogen in regulating mitochondrial function is relatively poorly 
understood296. However, some studies have shown no difference in oxidative stress and 
mitochondrial function between men and women in both human and rodents298,300.  
The effects of current and previous smoking and alcohol exposure as well as some of the 
health conditions mention that may affect mitochondrial function into old age should be 
examined in large epidemiologic studies of aging such as Health ABC and BLSA. Previous work 
in this area as tended to be in rodents or in very small samples of humans or in specific diseased 
populations. These large epidemiologic prospective cohort studies should begin to add measures 
of mitochondrial function. Implementing noninvasive techniques, such as 31P MRS (which will 
be discussed in great detail later), might be the best approach, as noninvasive techniques would 
be more conducive to an older adults population as opposed to the more invasive techniques of 
muscle biopsies. However, ideally, both noninvasive and biopsy techniques would be 
implemented, as certain things, such as such as abundance of mtDNA, deletions and mutations 
present in mtDNA, the activity of specific regulatory enzymes and proteins, as well ROS 
production and markers of can currently only be measured in isolated mitochondria. Either way, 
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measures of mitochondrial function should start being implemented in longitudinal prospective 
cohort studies, especially those that will follow or are following participants into old age. 
1.2.11 Physical Activity to Improve Mitochondrial Function in Aged Skeletal Muscle 
The following section will briefly describe the population, mode of intervention and pertinent 
results for exercise intervention trials designed to measure change in mitochondrial function in 
older adults. It is important to describe the population and mode of intervention used in each 
trial, as these aspects may have immense implications regarding the observed changes in 
mitochondrial function. This information can also be found in Table 4. It is important to note that 
mitochondrial function refers to the capacity of the mitochondria to produce energy in the form 
of ATP and whereas mitochondrial biogenesis refers to the production of new mitochondrial.  
The first trial was designed to measure changes in mitochondrial function following either a 6-
month resistance or endurance training intervention in older adults (69.2 ± 0.6 years) 301. This 
study also included a control group for comparative purposes. The resistance training was 
primarily performed using a two-legged leg press machine and also included exercises involving 
the arms and shoulders. Participants in this group completed 3 sessions per week. Training 
intensity was increased in phases as the trial progressed; resistance was increased while the 
number of sets was decreased. The endurance training group also attended 3 sessions per week. 
They trained primarily on a stair-stepper machine and a kayaking-type exercise machine. 
Participants progressed as rapidly as possible to 20 minutes for each exercise and to an intensity 
of 80-85% of heart rate reserve. The investigators found large increases in oxidative capacity (as 
measured by MRS – PCr recovery rate) in both the resistance (57% increase, p<0.05) and 
endurance (31% increase, p<0.05) training groups. The investigators also observed a decrease in 
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glycolytic ATP synthesis in the endurance training group, following the intervention. This 
decrease in glycolytic (anaerobic) activity is indicative of an increase in oxidative energy 
production. Additionally, this study by Jubrias et al. showed that mitochondrial volume density 
(Vv(mt,f)) but not oxidative capacity per Vv(mt,f) was increased following resistance training. 
Conversely, in the endurance training group no increase in Vv(mt,f) was observed but an 
increase in oxidative capacity per Vv(mt,f) was recorded. This study established that muscle 
energetics can change significantly in elderly skeletal muscle following regular physical activity 
of different modes. 
This next study included healthy men and woman with a wide age-range (21-87 years) 
and randomized who were randomized into either a 16-week aerobic exercise intervention or 
control group 302. The 16-week intervention started with 3 sessions per week, eventually 
progressing to 4, and was performed on a stationary cycle. The intensity and duration of the 
training was gradually increased over the course of the intervention. This study was designed to 
measure changes in mitochondrial enzyme activity (citrate synthase (CS) and cytochrome c 
oxidase) and mRNA levels of genes involved in mitochondrial biogenesis (cytochrome c oxidase 
(COX4), NADH dehydrogenase subunit 4 (ND4), PGC-1α, NRF-1 and TFAM). This study 
showed that mitochondrial enzyme activity and biogenesis, indicated by higher levels of 
mitochondrial mRNAs that regulate mitochondrial biogenesis, increased significantly following 
the 16-week intervention with no age-dependent effect. Thus, the response of skeletal muscle 
mitochondria to physical activity was similar across all age ranges.  
The primary aim of this next study was to determine the effect of an 8-week exercise 
program on mitochondrial function in a cohort (n=10) of older adults (71.0 ± 2.0 years) with 
chronic obstructive pulmonary disorder (COPD)303. The investigators measured mitochondrial 
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function in vivo using MRS. The primary measure of mitochondrial function was defined as PCr 
recovery rate. The exercise intervention consisted of cycling, walking and leg extensions. 
Sessions were conducted 2 times per week for approximately 75 minutes each and intensity was 
increased gradually. The investigators included a group of healthy control participants (n=10), 
who did not participate in the exercise intervention. At baseline, the COPD group showed 
impaired mitochondrial function as compared to the healthy control group (19 ± 8% lower, 
p<0.05). Following 8 weeks of structured exercise, the COPD group increased their 
mitochondrial function, as measured by PCr recovery rate, by 38 ± 12% (p=0.003). This study 
showed that with exercise, older adults with COPD can increase their mitochondrial function to 
equal or exceed that of healthy control participants – who did not participate in structured 
exercise.   
Menshikova et al. conducted a study consisting of eight healthy, sedentary older adults 
(67.3 ± 0.6 years) deigned to measure changes in mitochondrial function following a 12-week 
structured exercise program 304. Participants in this study were required to complete four to six 
exercise sessions weekly, of which 3 were supervised. The exercise was performed using 
treadmills, stationary cycles or walking outside. Intervention sessions were 30 minutes to start 
and progressed in both duration and intensity over the course of the trial. Mitochondrial function 
was measured in vitro in tissue obtained from muscle biopsy. Investigators measured 
Nicotinamide adenine dinucleotide (NADH) oxidase as a measure of overall electron transport 
chain activity and succinate oxidase as a measure of complex II-IV activity. The investigators 
also chose to examine mitochondrial function among distinct mitochondrial subpopulations 
within skeletal muscle, namely subsarcolemmal (SS) and intermyofibrillar (IMF) mitochondria.  
In this study, succinate oxidase activity increased significantly, with more prominent increases 
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observed in SS compared to IMF mitochondria. Overall ETC activity, as measured by NADH 
oxidase activity, also increased significantly following a structured exercise program.  
Williams et al. conducted a trial in older adults (70±8 years) in which 7 chronic heart 
failure patients participated in a resistance training intervention for 11 weeks305. This study 
showed a significant increase in in vitro mitochondrial ATP production, CS activity, as well as 
increases in VO2 peak. The investigators also showed very strong correlation between change in 
mitochondrial ATP production and change in VO2 peak (r = 0.875; p<0.0001). This shows that 
increases in mitochondrial energy production explain about 76.6% of the variance in 
improvements in VO2 peak; which suggests that mitochondrial function may play a large role in 
age-related declines in aerobic capacity or fitness. However, it is important to keep in mind that 
these are chronic heart failure patients, and these results may not be generalizable to healthier 
populations of older adults. 
Two separate studies conducted by Parise et al. showed no improvements in CS activity 
following both 12-306 and 14-weeks307 of resistance training in older adults. However, following 
14-weeks of resistance training, complex IV activity of the electron transport chain was 
significantly increased, which suggests an increase in electron transport chain activity without an 
increase in mitochondrial volume307. The 12-week intervention study showed a significant 
increase in antioxidant enzyme activity306. This suggests that resistance training can increase the 
antioxidant capacity of aged skeletal muscle. However, this study did not measure ROS 
production, so this may be a counter-measure to increased ROS activity, due to an increase in 
mitochondrial activity in response to the increase in physical activity. Future studies are needed 
to examine the antioxidant effects of resistance training in aged-human skeletal muscle. It is 
worth noting that in POLG mice (described previously), who possess a defect in the mtDNA 
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proofreading enzyme polymerase gamma, endurance training has been shown to induce an 
extraordinary phenotypic rejuvenation of many mitochondrial processes. These included 
increases mitochondrial biogenesis (production of new mitochondria), prevented mtDNA 
depletion and mutations compared to unexercised POLG mice, increased mitochondrial 
oxidative capacity and prevented pathological levels of apoptosis308. These results are very 
promising and suggest that participating in endurance exercise can prevent age-related 
mitochondrial function caused by mutations and deletions to mtDNA. These findings need to be 
replicated in humans. 
Additionally, other studies have shown an increase in markers, specifically cytochrome c 
oxidase (COX) and PGC1-α, of marker of mitochondrial biogenesis following both endurance 
training. In fact, Konopka et al. actually showed a decrease in PGC1-α protein content309, while 
Short et al. showed an increase PGC1-α mRNA level302. However, both of these studies found an 
increase in COX-4 levels, suggesting an increase in mitochondrial biogenesis. Perhaps PGC1-α 
is not necessary to induce mitochondrial biogenesis in aged human skeletal muscle309. Marcuello 
et al. found increased in PGC1-α and a decrease in the ratio of mtDNA/nDNA 310. They 
suggested that this decreases in mtDNA/nDNA may be a signaling mechanism to induce 
mitochondrial biogenesis. This finding concerning an increase in COX levels and activity is 
interesting, as COX negative fibers are one of the hallmark manifestations in ragged red  skeletal 
muscle fibers present in those with mitochondrial myopathies311. This is further evidence that 
exercise training can rejuvenate mitochondria in aged skeletal muscle.  
In summary, increases in in vitro mitochondrial enzyme activity302, in vivo oxidative 
capacity (PCr 1/2t), mitochondrial volume 301, rate of PCr recovery 303 and mitochondrial mRNAs 
302 were all reported. Participants were primarily healthy older adults in their 60s and 70s. The 
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studies in Table 4 indicate that different aspects of mitochondrial function ranging from the 
mtDNA to the energy (ATP) production level can be improved with increased physical activity. 
There is also evidence that physical activity may increase mitochondrial biogenesis in human 
skeletal muscle, indicated by increases in PGC-1α and COX-IV mRNA and protein levels. The 
work Parise et al. also suggests that resistance training may covey certain antioxidant benefits in 
aged human skeletal muscle. However, this needs to be studied in more detail, employing direct 
measures of both antioxidant enzyme activity and ROS production. Studies that include lower 
function and older adults aged 85 and older are also lacking. Studying skeletal muscle energetics 
in lower function and older adults aged 85 and older is important. Studies in lower function and 
older adults aged 85 should examine whether or not mitochondrial function is lower than adults 
in their 60s and 70s and how it affects physical performance. 
As illustrated in table 4, improvements in mitochondrial function were achieved despite 
differences in both mode and intensity of the physical activity interventions. These trials suggest 
that mitochondrial function can be improved with a resistance, endurance or combination 
intervention. Jubrias et al. showed that mitochondria respond differently to resistance training 
and endurance training 301 (described above). However, overall oxidative capacity measured by 
PCr recovery was increased in both groups but to a greater degree in the resistance training 
group. Mitochondrial response to different modes and intensities of activity needs to be studied 
in more detail. In summary, it is clear that both mitochondrial content and function can improve 
with different modes, intensities and durations of exercise training in the elderly, but studies in 
the oldest (age ≥85) and frailest of older adults are lacking. 
Future studies should include both in vivo and in vitro measures of mitochondrial 
function and incorporate the most valid and up-to-date methods of data collection and 
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calculation. Including both in vivo and in vitro measures of mitochondrial function will allow 
researchers to obtain information concerning both physiologically relevant ATP production, as 
well as underlying mechanisms impacting in vivo energy production. Including in vitro measures 
will permit the quantification of changes to mtDNA, markers of antioxidant activity, ROS 
production and apoptotic activity following exercise.  Also, the composition of the inner 
mitochondrial membrane needs to be studied in further detail, as it has been shown that 
permeability of mitochondrial membranes to protons increases in aged muscle tissue 260. This 
could further contribute to decreases in ATP production with age, as a stable proton gradient is 
imperative for proper oxidative phosphorylation activity.  
It is imperative that any future longitudinal or controlled trials include validated 
performance measures of physical function. There have been no trials relating improvements in 
mitochondrial function to improved mobility or physical function. There have only been three 
studies that have examined the cross-sectional relationship between mitochondrial function and 
physical function in older adults312-314. All three of these found a positive relationship. 
Longitudinal studies that incorporate the many aspects of mitochondrial function, from mtDNA 
to energy (ATP) production are needed. These studies are needed to determine which changes in 
mitochondrial function occur the most rapidly and have the highest potential to cause cellular 
damage. Intervention studies incorporating a variety of mitochondrial measures would provide 
insight into which of these aspects are the most preventable or reversible and the most closely 
associated with improved physical function. Finally, there is a great need for additional 
intervention studies designed to measure changes in mitochondrial function following different 
modes and intensities of physical activity. For example, perhaps a period of resistance training, 
resulting in increased mitochondrial biogenesis and volume, followed by a period of aerobic 
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exercise to train these mitochondrial would be ideal. It is vital that researchers design practical 
interventions to maximize the generalizability of their studies. Interventions that include 
exercises or interventions that can be conducted in the home or include over-ground walking are 
ideal.   
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Table 4. Physical Activity to Improve Mitochondrial Function and Markers/Genes of Mitochondrial Function 
Author Age N Sex Mode of Intervention 
Length of 
Intervention 
Mitochondrial 
Measurement Muscle Percent Change 
Jubrias301  69±0.6 17M, 23M 
Resistance 
Training 6-months/3x per 
week 
31P MRS, PCr recovery 
rate VL 
+57% (p<0.05) 
Endurance 
Training +31% (p<0.05) 
Mckeough303   71±2 6M, 4F w/ COPD 
Cycling, walking 
and leg 
extensions 
8-weeks/2x per 
week 
31P MRS, PCr recovery 
rate quad +38% (p<0.05) 
Short302  21-87 65 M,F Cycling 16-week/3x per week 
 CS COX activity 
 mRNA Levels: COX4, 
ND4, PGC 1α,  NRF-1 
and TFAM 
VL 
CS +45% 
COX +76% 
COX4/ND4 +66% 
PGC 1α +55% 
NRF-1 +15% 
TFAM 85% 
Menshikova 
304 67±0.6 5M, 3F 
Treadmill/out-
door walking 
and cycling 
12-weeks/4-6x per 
week 
NADH Oxidase and 
Succinate Oxidase 
Activity 
VL NADH +50% SO +62%  
Williams305 67±9 7 CHF patients n/a 
Resistance 
Training 11-weeks 
ATP Production rate 
and CS activity VL 
MAPR +30% (p<0.05) 
CS +40% (p<0.05) 
Parise307 68±5 15m, 15F Resistance Training 
14-weeks/3x per 
week CS activity VL 8.2%, NS 
Parise306 71±7 12M Resistance Training 
12-weeks/3x per 
week CS activity VL -3.1%, NS 
Puente-
Maestu315 67±8  
11w/ 
COPD n/a Cycling 1-2-weeks 
mtDNA/nDNA ratio 
PGC-1α mRNA content VL 
Decreased mtDNA/nDNA 
Increased PGC-1α mRNA 
Konopka309 70±2  9F Cycling 12-weeks 
COX IV protein, 
TFAM mRNA and 
PGC-1α protein 
VL 
COX IV +33%  
PGC-1α -20%  No change in 
TFAM mRNA 
Abbreviations: N= number; m= male; x= number of times; PCr= phosphocreatine; VL= vastus lateralis; P= phosphorous; MRS= magnetic resonance spectroscopy; quad= 
quadriceps; f= female; CS= citrate synthase; COX= cytochrome c oxidase; mRNA= Messenger RNA; ND4= NADH dehydrogenase subunit 4; PGC 1 α= Peroxisome 
proliferator-activated receptor γ coactivator 1; NRF-1= nuclear transcription factor1; TFAM= transcription factor A, mitochondrial; NADH= Nicotinamide adenine 
dinucleotide; SO= succinate oxidase; mtDNA= mitochondrial DNA; nDNA= nuclear DNA; ATP= adenosine triphosphate; 
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1.3 FATIGUE AND FATIGABILITY IN OLDER ADULTS 
This dissertation deals directly with fatigability, whole-body fatigue, referenced to an activity of 
a specific intensity and duration. The term whole-body is used here to emphasize that 
fatigability, in the context of this dissertation, is an overall feeling of fatigue following a specific 
activity of a specified intensity and duration, as opposed to skeletal muscle fatigability. A review 
of muscle fatigability in aged skeletal muscle can be found here316. Most of the research 
concerning fatigue in older adults has focused on global fatigue, which can be thought of as a 
general overall lack of energy, not referenced to a specific task or activity. Thus, the 
epidemiology of global fatigue will be summarized briefly. Additionally, the rationale for the 
field moving towards measuring fatigability in lieu of global fatigue, especially when interested 
in physical performance and disability, will be discussed. 
1.3.1 Epidemiology of Fatigue in Older Adults 
Fatigue is common complaint among older adults. However, prevalence rates vary considerably 
from as low as 5% to as high 68%, mostly due to the lack of a standardized measurement tool 
and definition11,317-319.  Fatigue has been defined in a number of ways. These include, a sense of 
diminished energy and the increased need to rest, perceived lack of physical energy and 
weariness resulting from exertion and subjective lack of physical and/or mental energy, or 
excessive weakness or tiredness, perceived to interfere with usual and desired activity11,12.  In a 
study by Hardy et al. in community dwelling older adults, 43% reported tiredness, 40% reported 
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sleepiness, 42% reported a lack of energy and 29% reported weakness320. For the purposes of 
this dissertation, these definitions can be thought of as global fatigue. As mentioned previously, 
global fatigue is measured using a variety of instruments, batteries and questions11,238,239,319. A 
review of tools used to measure global fatigue can be found elsewhere321,322.  
Fatigue is a common symptom of many chronic and acute illnesses323,324. Specifically 
fatigue is a symptom of cancer, inflammatory or auto-immune disorders, stroke, 
cardiorespiratory disorders and neurologic diseases11. In older adults from the Jerusalem 
Longitudinal Study of Aging, those with who report fatigue were also more likely to report poor 
sleep, lower levels of physical activity, back or joint pain, impaired cognitive function, 
depression and had less education318. A majority of fatigue can be attributed to underlying 
diseases; however a large portion cannot9. Therefore, there are also central causes that have been 
hypothesized to cause fatigue in older adults. These include but are not limited to 
neurotransmitter deregulation, inflammation and oxidative stress11. This dissertation will 
examine the relationship between fatigability and mitochondrial function in older adults, as 
mitochondrial dysfunction may underlie age-related increases in fatigue and fatigability. This 
relationship will be discussed in more detail in the section after next. 
1.3.2 Fatigue vs. Fatigability and the Disablement Pathway  
Research has shown that fatigue is significantly related to physical function and disability 
independent of disease status8. More recently, it has been suggested that researchers attempting 
to understand the relationship between fatigue and physical function should measure fatigability 
as opposed to fatigue12. As defined previously, fatigability is a whole-body sensation induced by 
an activity of a specific intensity and duration, e.g. brisk walking for 30 minutes. It has been 
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suggested that referencing fatigue to specific activities is necessary to control for self-pacing 
bias. Eldadah uses the finding by Willis et al., who showed that adults are likely to select a 
preferred walking speed that is very close to minimum levels of perceived exertion as an 
example of self-pacing325. Similarly, older adults may titrate their activity levels to minimize 
their fatigability levels.  Self-pacing bias may explain why no consistent relationship between 
fatigue and age has been established, as some research shows an increase318,326,327,  no change328 
and some even a decrease319,329 in global fatigue levels with age.  
In the same vein, fatigability, as opposed to global fatigue, may be a better indicator of 
the degree to which an individual is limited functionally due to fatigue. The following example 
can be used to illustrate this. An older adult master’s athlete who regularly participates in athletic 
competition and an older adult who is mostly sedentary may both report usual energy levels of 9 
out of 10 or neither may report a lack of energy. Then, when the relationship between fatigue and 
physical function is examined, it is possible that none would be observed. If fatigability were 
measured, in lieu of global fatigue, e.g. by asking how fatigued would you feel after walking 30 
minutes at a brisk pace, it is unlikely the two individuals would give the same response. As a 
result, a relationship between fatigability and physical performance may in fact be observed and 
greater insight into the degree to which fatigue is limiting one functionally can be ascertained. 
Similarly, fatigability’s role in the disablement pathway may be in contributing to lower levels of 
activity as an attempt to limit one’s usual fatigue level. This would then lead to lower levels of 
fitness, and in turn lead to functional decline and ultimately physical disability. While fatigability 
has been shown to be associated with lower levels of fatigability cross-sectionally330, 
longitudinal studies are needed to established temporality and causality.  
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Fatigability may also be an important domain to measure in intervention studies, lifestyle 
or pharmaceutical12. It is possible that an intervention may appear to increase global fatigue 
levels, which would then deem the intervention as having a side-effect of fatigue. However, if 
the intervention is also aimed at increasing activity levels or improving energy levels or pain 
with the goal of increasing activity or function, this increase in fatigue may be an artifact of 
increased activity. Conversely, this intervention may have actually decreased fatigability, or 
increased exercise tolerance, which would be a positive effect of the intervention12. A more 
accurate measure of the degree to which one is limited functionally can be ascertained if 
investigators measure fatigability, in lieu of global fatigue. Furthermore, fatigability may also be 
a more useful parameter to determine, because if one is able to tolerate more activity, one may be 
more likely to do more activity. Increasing physical activity levels has many well documented 
benefits, including improved and preventing declines in muscle performance and physical 
performance148,194,199,331. Longitudinal studies are needed to determine if lowering fatigability 
levels results in a lasting increase in physical activity levels.  
Few intervention studies have actually examined fatigability in older adults. However, 
there have been some that have measured changes in fatigue in older adults. For example, the 
effects of L-carnatine, which is a component of the inner mitochondrial membrane that facilitates 
beta oxidation of fatty acids, on change in fatigue measured by questionnaire have been studied. 
L-carnatine supplementation has been shown to decrease fatigue in centenarians332 and in older 
adults meeting criteria for chronic fatigue syndrome333. Interestingly, the l-carnatine group in the 
centenarian study significantly improved their 6-minute performance and those with chronic 
fatigue syndrome (CFS) significantly improved their self-reported physical function. 
Additionally, 12-weeks of lipid replacement antioxidant therapy (specifically a dietary 
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supplement called NTFactor®) has been shown to decrease fatigue levels by about 35.5% on the 
Piper Fatigue Scale in older adults (age 68.9±4.2) who had moderate to high levels of fatigue at 
baseline334. Interestingly, mitochondrial function, determined by transport and reduction of the 
dye Rhodamine-123, was also increased by 23.7% in these participants334. Yoga has also been 
reported to decrease fatigue to a greater degree than walking and usual care335. Fatigue was 
measured using the SF-36. Eldadah also reported that no differences in change in self-reported 
fatigue between the exercise group and successful aging health education control group in the 
Lifestyle Interventions and Independence for Elders Pilot Study, were observed after a year12. 
However, none of these studies measured fatigability. Future intervention studies in older adults 
should, if possible, employ measures of both performance and self-reported fatigability. 
There are several ways to measure fatigability including performance, perceived and a 
combination of the two, which will be referred to as perceived performance fatigability. First, 
there is self-reported fatigability. This would be a questionnaire that asks how fatigued an 
individual feels after activities of specific intensities and duration.  There are currently no 
published and validated instruments to measure self-reported fatigability in older adults. 
Although one has been developed and validated by our group at the University of Pittsburgh and 
should be in press this year, 2013336,337. There are however, examples of a few instruments that 
are designed to measure fatigability in other populations or that measure a certain domain of 
fatigability, but fail to specify intensity or duration of activities. Avlund et al. developed a 
tiredness scare (MOB-T), which asks participants if they get tired while performing each of 15 
ADL activities338. While these activities all correspond to functional limitations from which 
older adults may suffer, the MOB-T is probably inappropriate for high functioning older adults. 
Also, questions are simply answered with a yes or no response, which limits the ability of the 
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instrument to establish degrees of fatigability. Similarly, the Dutch Exertion Fatigue Scale asked 
participants if they feel fatigued after conducting 9 different tasks339. However, only 2 of these 9 
items have a duration attached to them and all of the tasks are subject to self-pacing biases as 
intensity is not specified. The Situational Fatigue Scale (SFS) contains well-designed questions 
to assess fatigability; however, this questionnaire was designed for younger populations, as its 15 
items included activities such as ball sports and jogging340. The SFS also contains questions that 
do not specify intensity, which is a major component of fatigability and helps to eliminate self-
pacing biases. 
Fatigability can also be measured following a standardized performance measure and is 
defined as perceived performance fatigability. For example, Schnelle et al. established a measure 
where the participant is asked how tired they feel after walking on a treadmill at their self-
selected pace for 10 minutes330. Their tiredness level was then divided by the amount of distance 
they walked, which yielded a fatigability score330. Similarly, Simonsick et al (in press) validated 
a method, in the BLSA, where participants are asked their Rating of Perceived Exertion (RPE), 
using the Borg scale341, after walking on a treadmill for 5 minutes at 0.67m/s (1.5mph). A cut-
point of a RPE >9 was established to categorize older adults has having high fatigability. The 
perceived performance fatigability method developed by Simonsick et al. was utilized in the 
third paper presented in this dissertation.  
Finally, fatigability can be measured objectively during a performance test and is defined 
as performance fatigability. Schnelle et al. also validated a method where the distance 
individuals walked during the 10 minute treadmill bout was assessed in 2.5 minute intervals330. 
This allowed the investigators to calculate walking speed in 2.5 minute intervals. Percent change 
in walking speed was then calculated and divided by total distance walked to “calculate change 
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in performance in the context of physical activity”330. This number was then used a performance 
fatigability score. Similarly, Simonsick et al., (in press), validated a method in the BLSA to 
measure performance fatigability during the long distance corridor walk, a 400m walk done as 
quickly as possible. This walk is done in 10 40m lap segments and split times for each lap were 
recorded. Percent change between the 2nd and 9th lap is then calculated; those whose lap 9 times 
were 6.5% or more slower than their second lap were considered to have slowed, and thus were 
characterized has having a high level of performance fatigability. Performance measures of 
fatigability are ideal, as they are completely objective and activity level and duration can be 
controlled and standardized. But, they are time-consuming, require trained staff, as well as in-
person clinic visits. They also may not be appropriate for more frail older adults. Studies 
involving older adults should employ, when possible, both performance and perceived measures 
of fatigability to avoid healthy participant biases and losses to follow-up. 
Fatigability likely shares the same risk factors as fatigue, as fatigability is a measure of 
fatigue, simply normalized to activity. Thus, it is likely that underlying diseases cannot fully 
explain age-related increases in fatigability. Age-related mitochondrial dysfunction may 
contribute to higher levels of fatigability. This dissertation will examine this hypothesis directly. 
The possible relationship between fatigue and fatigability and mitochondrial function is 
discussed below. 
1.3.3 Fatigue, Fatigability and Mitochondrial Function 
A majority of fatigue can be attributed to underlying diseases; however a large portion cannot. 
For example, in a study of ambulatory primary care patients aged 60 years and over, 38.3% of 
fatigue cases could not be attributed to comorbidities or physiological disorders9. Similarly, in 
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the InCHIANTI study (n= 1,055, age 65-102), fatigued compared to non-fatigued men and 
women had a similar average number of comorbidities: 2.1 vs. 1.7 in men and 1.7 vs. 1.7 in 
woman8. Although this was a statistically significant difference among men (p=0.02), it further 
illustrates how a large proportion of fatigue in older adults cannot be attributed to underlying 
diseases. 
Fatigue is primarily considered an energy disorder, thus it has been hypothesized that 
age-related decreases in mitochondrial function may contribute to higher levels of fatigability in 
older adults11,12. The capacity for oxidative phosphorylation in skeletal muscle and mitochondrial 
function has been shown to decrease significantly with age, mainly due to mutations and/or 
mtDNA from prolonged exposure to reactive oxygen species4. Diseases involving mutations or 
deletions to mtDNA result in increased levels of fatigability and exercise intolerance311. For 
example, mitochondrial gene ANT1-knockout mice, which are a model for chronic ATP 
deficiency, have been shown to display exercise intolerance and fatigability342,343. Additionally, 
one of the hallmark symptoms of humans with mitochondrial myopathies is significantly higher 
levels of exercise intolerance311,344.  A review of mitochondrial myopathies and exercise 
intolerance has been published elsewhere311. Similarly, age-related mitochondrial dysfunction 
may contribute to age-related increases in fatigability.  
As mentioned previously, VO2 peak has also been shown to decrease significantly with 
age, independent of muscle loss and decreases in physical activity levels231. The ability of 
skeletal muscle mitochondrial to produce ATP with the oxygen delivered to them via the 
cardiorespiratory system is one of two major components comprising V02 peak. VO2 peak is also 
one of the hallmark manifestations of mitochondrial disorders345,346. Thus, mitochondrial 
dysfunction may contribute to higher levels of fatigability via lower aerobic capacity due partly 
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to decreases in mitochondrial energy production. Oxidative damage resulting in mutations to 
mtDNA may also play a role in this pathway. The relationship between mitochondrial energetics 
and fatigability in older adults has not been previously examined. This dissertation will address 
this important gap in knowledge by examining the relationship between oxidative capacity of 
mitochondria present in the quadriceps (ATPmax) and oxidative capacity of the quadriceps 
(ATPmax*muscle volume), measured by 31P MRS, and perceived performance fatigability. 
1.4 SPECIFIC AIMS 
1.4.1 Relationship between Changes in Body Composition and Physical Function 
Controversy exists as to whether older adults should lose weight and whether overall body 
weight or particular aspects of body composition should be targeted168-170.  Intentional and 
unintentional weight-loss may target lean and fat mass differently. Unintentional and age-related 
weight loss is associated with greater decreases in lean than fat mass100. Conversely, intentional 
weight loss combined with a moderate physical activity intervention has been shown to decrease 
fat mass to a greater degree than lean mass48,174-176. Intentional weight loss may also target 
particularly harmful fat depots. Specifically, aging is associated with increases in visceral 
(VAT)165,166 and intermuscular (IMAT) adipose tissue independent of overall body mass 
change83,122,145. VAT is strongly associated with insulin resistance independent of overall 
adiposity and higher proinflammatory cytokine levels, which negatively affect muscle 
performance52,347,348. IMAT has been shown to be related to insulin resistance and the metabolic 
syndrome independent of overall adiposity and has been described as being similar to VAT in 
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size52,146,161; however it has not been consistently linked to muscle performance.  Intentional 
weight loss may target these particularly harmful fat depots. Few studies have shown specific 
composition data following intentional weight loss in older adults173,175, but the few that do seem 
to support this hypothesis.  
Specific Aim 1: To examine the relationship between changes in regional body 
composition measured by computed tomography (CT) and physical performance in older adults, 
who participated in a one year intervention study of physical activity combined with weight loss 
(PA+WL) compared to physical activity combined with a successful aging health education 
program (PA+ SA).  
Hypothesis:  Decreases in IMAT, VAT and intramuscular adipose tissue (IMF) will be 
associated with improvements in physical function following one year of intervention, regardless 
of intervention group. 
1.4.2 Mitochondrial Function and Walking Performance in Older Adults 
Although many risk factors for disability in older adults are known, the role of changes in the 
neuromuscular system in decreasing physical performance and physical disability in older adults 
is still unclear. Therefore, exploring the cellular and physiologic bases of mobility and functional 
decline in older adults is important. Studies of mitochondrial function have tended to be small 
and lack performance measures of physical function. Three studies in older adults have examined 
the relationship between mitochondrial function and physical function in older adults312.  All 
three showed a relationship between mitochondrial function and physical function. One was in 
patients with PAD, one included a small number of older adults, some of whom were 
hospitalized and the other was in high functioning older adults. These results need to be 
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replicated in a non-disease specific group of community older adults with a wide-range of 
function.  
Specific Aim 2: To examine the relationship between mitochondrial function, as 
measured by 31P Magnetic Resonance Spectroscopy, and time to walk 400m in older adults with 
a wide range of function 
Hypothesis: Higher levels of mitochondrial energy production will be related to faster 
walk-times. 
1.4.3 Relationship Between Mitochondrial Function and Fatigability in Older Adults 
Fatigue is often assumed to be the manifestation of underlying co-morbid conditions. However, a 
large proportion of self-reported fatigue cannot be attributed to underlying diseases9,10. Research 
has also shown that fatigue is significantly related to physical function and disability, 
independent of disease status8.  Therefore, fatigue is an independent risk factor for age-related 
declines in physical function and disability. It is important to study the etiology of age-related 
increases in fatigue in order to determine the most effective ways to treat it. Fatigue is primarily 
considered an energy disorder, thus it has been hypothesized that decreased mitochondrial 
function with age may be a major contributor to the onset of fatigability12. Yet, there is no 
objective data to support this. 
Specific Aim 3: To determine the relationship between mitochondrial function, as 
measured by 31P MRS, and fatigability, assessed following a standardized exercise bout, in older 
adults.  
Hypothesis: Higher levels of mitochondrial energy production will be related to lower 
levels of fatigability.  
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2.0  INTERMUSCULAR ADIPOSE TISSUE CHANGE IS RELATED TO IMPROVED 
PHYSICAL PERFORMANCE IN OLDER ADULTS 
The prevalence of obese (BMI ≥30) older adults was shown to be 30.5% in the National Health 
and Nutrition Examination Survey data from 2005-2006. The high prevalence of obesity in older 
adults is a major public health concern, as obesity worsens age-related declines in physical 
function, which increase the risk of institutionalization and increases health care costs. There are 
currently no agreed upon guidelines for intentional weight loss in older adults. Studying the 
relationship between changes in specific fat depots following intentional weight-loss and 
physical activity and how they impact physical function in older adults is important. The aim of 
this study was to determine the relationship between changes in body composition and physical 
function in older adults following a one-year physical activity + weight loss (PA+WL) or 
physical activity + successful aging health education (PA+SA) intervention. Thirty-six 
overweight to moderately obese, sedentary older adults were randomized into a one-year 
PA+WL or PA+SA intervention. The PA intervention focused on walking, supplemented with 
leg resistance and balance exercises. The WL intervention focused on caloric restriction, 
specifically calories from fat. Measurements were conducted at baseline (BL) and 12-months 
(12) and included body composition by computerized tomography (CT), short physical 
performance battery (SPPB), and gait-speed (GS). Visceral adipose tissue (VAT) of the 
abdomen, intermuscular fat (IMAT) and muscle density (HU), and indirect measure of 
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intramyocellular fat, were quantified. The relationship between concurrent changes in body 
composition and physical function, from BL-12, were determined using multivariate linear 
regression. After adjustment for age, sex, race, baseline body composition and SPPB, 6- and 12-
month change in IMAT, HU, SUBQ adipose of the thigh, total thigh fat, VAT and total 
abdominal fat were all significantly related to 6- and 12-month change in SPPB. Changes in 
IMAT, HU and VAT were significantly associated with improvements in change in function. 
Despite losing some lean mass, participants were able to improve their function (SPPB). This 
suggests that intentional weight-loss, supplemented with moderate intensity PA, is beneficial to 
older adults. 
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2.1 INTRODUCTION 
In 2010, men and woman age 60 and older possessed the highest prevalence rates of obesity 
compared to any other age group, with rates of 42.3% and 36.6% respectively349. Obesity has 
been shown to exacerbate physical disability in older adults163,164 and is associated with other 
comorbidities including diabetes, heart disease and osteoarthritis350. Therefore, studying the 
effects of weight loss in old-age is important. Previously, weight-loss in old age was thought to 
be detrimental to health, as findings from observational studies showed a positive association 
between weight-loss in old age and mortality171. However, more recently, Shea et al. have 
published findings from a randomized controlled trial showing that intentional weight-loss in old 
age is not associated with increased mortality49. Additionally, randomized controlled trials have 
shown that weight-loss (WL) in combination with moderate physical activity (PA) improves 
physical function in older adults to a greater degree than physical activity alone49,172, weight-loss 
alone49 and normal care173. Additionally, WL in conjunction with PA has been shown to improve 
components of frailty, including physical function, in obese frail older adults 174. Controversy 
still exists as to whether older adults should lose weight and whether overall body weight or 
particular aspects of body composition should be targeted168-170.  
Aging is associated with increases in adipose tissue (VAT)165,166 and IMAT independent 
of overall body mass change83,122,145. VAT, found within the abdominal cavity surrounding 
organs, is strongly associated with insulin resistance independent of overall adiposity and with 
higher levels of proinflammatory cytokines, which can negatively affect muscle 
performance52,347,348. IMAT, fat present inside the muscle fascia surrounding skeletal muscle, has 
been shown to be related to insulin resistance and the metabolic syndrome independent of overall 
adiposity and has been described as being similar in size to VAT 52,146,161. However, higher 
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IMAT levels in the calf and thigh have been inconsistently linked to lower muscle power and 
physical performance145,151,351,352. For example, Buford et al. showed that when muscle CSA of 
the thigh is accounted for, IMAT of the thigh and calf are not independent predictors of SPPB 
score or gait-speed145. However, in two other studies, IMAT levels of the calf were shown to be 
strongly related muscle power151 and physical function151,352 in older adults.  In addition to 
IMAT, higher levels of intramyocellular fat (HU), lipid droplets present within muscle fibers, 
have been linked to insulin resistance and worse functional performance in older 
adults30,144,150,351.  
Intentional weight-loss and physical activity may target these particularly harmful fat 
depots. Few studies have specifically examined change in regional body composition following 
intentional weight-loss in older adults and/or physical activity148,173,175, but the few that do seem 
to support this hypothesis. Intentional weight-loss, both with and without moderate physical 
activity interventions, has been shown to decrease fat mass to a greater degree than lean 
mass48,174-176. A study comparing a weight-loss only (WL) to a weight-loss plus resistance 
training group (WL-RT) showed statistically similar decreases in IMAT in both groups, with the 
decrease in the WL-RT group reaching significance (-18.5 vs. -9.6%).  In this study, both groups 
improved similarly in terms of physical performance measures173. This may have been due to 
improvements in regional body composition, specifically decreases in IMAT, HU and VAT, but 
these mechanistic relationships were not explored. To understand the mechanisms underlying 
improvements in physical function following weight-loss and physical activity interventions, it is 
important to explore the relationships between improvements in physical function and changes in 
regional body composition.  
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 The purpose of the research described in this paper was to determine the relationship 
between changes in regional body composition measured by computed tomography (CT) and 
physical performance in older adults who participated in a one year intervention study comparing 
physical activity combined with weight-loss (PA+WL) to physical activity combined with a 
successful aging health education program (PA+ SA). We hypothesized that decreases in IMAT, 
VAT and a marker of intramyocellular fat (HU) will be associated with improvements in 
physical function following one year of intervention, regardless of intervention group. 
Additionally, we hypothesized that subcutaneous, or gluteofemoral fat loss as well as change in 
muscle mass will not be associated with changes in physical function. This research will provide 
important insight into the mechanisms by which intentional weight-loss improves physical 
function in older adults. This research will provide clinicians and public health professionals 
with important information they can utilize to prevent age-related physical disability. 
2.2 MATERIALS AND METHODS 
2.2.1 Participants 
Community dwelling older men and woman age 60 and over, who were overweight to 
moderately obese (body mass index between 28.0 and 39.9 kg/m2) and living a sedentary 
lifestyle (formal exercise less than 3x/week for a total of less than 90 min/week), were recruited 
from the greater McKeesport, PA area to participate in a one-year randomized clinical trial. 
Initial eligibility criteria included the self-reported ability to walk ¼ mile (2-3 blocks), 
completion of a 400-meter walk in less than 15 minutes without assistance from another person 
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or the use of an assistive device, successful completion of a behavioral run-in, which included an 
activity log and food diary, the willingness to be randomized to either intervention group as well 
as attend meetings and physical activity sessions in McKeesport, PA. Participants were excluded 
if they failed to provide informed consent, had diabetes requiring insulin, history of diabetic 
coma, uncontrolled diabetes (defined as a fasting blood sugar greater than 300 mg/dl), severe 
kidney disease that requires dialysis, or severe hypertension (systolic blood pressure > 180 
mmHg or diastolic blood pressure > 100 mmHg).  Further, significant cognitive impairment 
(known diagnosis of dementia or a Modified Mini-Mental State Exam score < 80) and other 
conditions impairing understanding and communication were also exclusion criteria.  Other 
significant co-morbid diseases severe enough to impair one’s ability to participate in an exercise-
based intervention resulted in exclusion.  Any person who developed chest pain or severe 
shortness of breath during 400m walk test was also excluded. Participants were also ineligible if 
a member of their household was already enrolled in the study, if they were currently 
participating in another intervention trial, planned to move in the next year, had lost more than 
10 pounds in the past 4 months, or were taking any drugs for the treatment of obesity. 
Participants who met the above were randomly assigned into one of two intervention 
programs: physical activity plus weight-loss (PA+WL) or physical activity plus a successful 
aging health education program (PA+SA).  Randomization was done using a Microsoft Access-
based random-number generating algorithm with stratification by age and sex to further ensure 
balance between groups (Microsoft® Redmond, Washington).   All of the methods described in 
this paper were implemented following approval by the University of Pittsburgh’s Institutional 
Review Board. 
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All participants, with the exception of one in the PA+SA group, were followed up to their 
6FU visits. The participant dropped out of the study for personal reasons before starting the 
intervention and is excluded from all longitudinal and change analyses. Three additional 
participants, all three in the PA+WL group were lost to follow-up before their 12-month clinic 
visit. One moved out of the study area to take care of a family member, one stopped coming to 
intervention sessions and did not return phone calls from study staff and one dropped out due to 
dissatisfaction with the program. In summary 14/15 (93.3) participants in the PA+SA group, 
18/21 in the PA+WL group (85.7), for a total of 32/36 (88.9%) were followed until study end.  
2.2.2 Physical Activity Program 
All participants, regardless of the randomized group assignment, participated in an identical 
physical activity program. The PA program combined aerobic, strength, balance and flexibility 
exercises 37.  The PA program focused on treadmill walking for at least 150 min/wk as the 
primary mode of activity. To complement the walking, participants completed lower extremity 
resistance training, balance training exercises and stretching.    
 The program was divided into three phases: adoption (weeks 1-8), transition (weeks 9-
24), and maintenance (weeks 25-52), which were designed to gradually transition exercise out of 
the clinic setting and into the participant’s daily routine. During the adoption phase, all 
participants were required to attend three center-based exercise sessions per week, which 
averaged 60 minutes per session. For the transition phase, center-based sessions were reduced to 
two sessions per week. During this phase, the center-based sessions were supplemented with one 
or more home-based sessions. The home-based sessions were to be similar to the center-based 
sessions. During the maintenance phase of the program, participants were invited to attend an 
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optional exercise session at the center once per week, but were expected to engage in physical 
activity at least three times per week. 
The intervention was designed to transition into the home after the first 6-months. 
Participants were not required to attend any clinic based exercise sessions, but were permitted to 
come once per week, after the first 6-months. At 6FU, self-reported moderate PA increased 
uniformly in both intervention groups (by 222.9 ± 329.2 min/week in PA+WL and 199.0 ± 
319.1 min/week in PA+SA), indicating an equally strong adherence to the PA program by both 
groups at 6FU.   
2.2.3 Weight-loss Program 
Those randomized into the PA+WL arm participated in a healthy-eating WL intervention, in 
addition to the PA program described above. Participants attended 24 weekly, 2 bi-monthly, and 
5 monthly sessions, which were lead by the study nutritionist. During these meetings, strategies 
to achieve the recommended caloric intake were discussed and performance in the weight-loss 
intervention was assessed. The nutritionist scheduled one-on-one sessions if a participant was 
having difficulty adhering to the WL intervention. 
The WL intervention was designed to promote weight reduction and decrease lipid levels. 
The calorie and fat gram goals were developed by the Diabetes Prevention Program 353. 
Participants were assigned one of the following daily goals based on baseline weight,:  1200 
calories and 33 fat grams, 1500 calories and 42 fat grams, 1800 calories and 50 fat grams, or 
2000 calories and 55 fat grams. Total daily fat intake was limited to approximately 25% of total 
calories. An emphasis was put on the consumption of mono- and polyunsaturated fats while 
limiting saturated fat and cholesterol.  In addition, participants were asked to include at least 5 
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servings of fruits or vegetables and 6 servings of grains, especially whole grains, in their daily 
diets. To ensure that participants met daily nutrient recommendations, age-appropriate 
multivitamin/mineral and calcium/vitamin D supplementation was recommended. 
The goal of the WL intervention was a 7% reduction in body weight at the rate of 1 to 2 
pounds per week during the first six months of the intervention. The goal for the remaining six 
months was to assist participants in achieving and maintaining their weight goal. Participants 
were required to keep food diaries at least six days per week during the first six months of the 
intervention and then for a minimum of once a month for the remainder of the study. Self-
monitoring of caloric intake was emphasized and participants were encouraged to weigh 
themselves weekly at home. In addition, participants were weighed once a week by the study 
nutritionist at the start of the nutrition sessions. Overall adherence to this arm of the intervention 
was gauged by examining the percentage of participants who met the weight-loss goal.  
At 6FU, 8 of the 21 (38.1%) participants in the PA+WL group, followed to 6FU, had 
achieved their 7% weight-loss goal. Upon study end, the PA+WL group maintained a -5.5%± 
weight reduction on average, which was 1.5% shy of the 7% weight-loss goal. At 12FU, 7 of the 
18 (38.9%) participants in the PA+WL group, followed to 12FU, had achieved and maintained 
their 7% weight-loss goal. 
2.2.4 Successful Aging (SA) Health Education Intervention 
Participants randomized into the PA+SA intervention participated in a successful aging health 
education workshop series in addition to the PA program described above. The workshops were 
based on “The Ten Keys to Healthy Aging™” 354, and the SA intervention used in the Lifestyle 
Interventions and Independence for Elders Pilot Study (LIFE –P)37. Topics included cholesterol, 
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diabetes, blood pressure, bone and muscle health, smoking, cancer screening, social contact, 
depression, immunizations, and physical activity. Participants enrolled in this study arm attended 
1 session per month, for a total of 12 sessions in addition to their physical activity sessions. 
2.2.5 Clinical Measurements 
At the baseline (BL) screening visit, 6- and 12-month follow up visits (6FU and 12FU), body 
height (cm), measured using  a wall-mounted stadiometer, and body weight (kg),  measured 
using a standard certified calibrated scale,  were used to calculate BMI (weight (kg)/height (m2)). 
Waist circumference (cm) was also measured at BL and follow-up using the Gulick II Tape 
Measure (Country Technology Inc., Gray Mills, WI). Waist circumference was measured twice 
and rounded to the nearest 0.1 cm; if the two measurements had a difference greater than 5 cm, 
then a third measurement was obtained. The Short Physical Performance Battery (SPPB), a 
validated measure of lower extremity functional disability in older adults, was performed and 
included a 4m walk, chair stands and a balance. More details concerning the SPPB can be found 
elsewhere 23. Participants also completed questionnaires on socio-demographic data, medical and 
hospitalization history, and the Community Healthy Activities Model Program for Seniors 
(CHAMPS) physical activity questionnaire 355. The CHAMPS questionnaire was used to 
quantify  physical activity and assess adherence to the PA program 331. Activities performed at or 
above 3.0 metabolic equivalents (METs) were defined as moderate physical activity; the type of 
physical activity the program was designed to deliver.  A resting ECG, physical exam and 
interview with a nurse practitioner were conducted before subjects were medically cleared to 
participate in the physical activity intervention by the study physician. 
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2.2.6 Dual Energy X-ray Absorptiometry (DXA) 
At BL, 6FU and 12FU, total body fat mass, percent body fat, total lean body mass, appendicular 
lean body mass,  total body bone mineral density (BMD) and total hip BMD were assessed using 
DXA(Hologic QDR 4500, software version 12.3; Bedford, MA).  Bone mineral content was 
subtracted from the total and appendicular lean mass to define total non-bone lean mass, which 
represents primarily skeletal muscle in the extremities 356. Appendicular lean mass was defined 
as the sum of upper and lower extremity lean mass 95. Two participants, one in each group, did 
not complete hip scans due to hip replacements. Two participants are missing 6-month DXA 
data. One in the PA+SA group dropped out before starting the intervention and one in the 
PA+WL group refused because of concerns over radiation exposure. Four participants are 
missing 12-month DXA data, all were lost to follow-up. 
2.2.7 Computed Tomography (CT) 
At BL, 6FU and 12FU, axial CT scans (9800 Advantage, General Electric, Milwaukee, WI) were 
obtained and used to measure cross-sectional abdominal visceral and subcutaneous adipose 
tissue (VAT and SAT) areas using an established method357.  Briefly, a cross-sectional scan at 
10 mm thickness was obtained, centered at the L4-L5 vertebral disc space using 170 mÅ with a 
scanning time of two seconds and a 512 matrix. The visceral and subcutaneous AT boundary was 
defined using a manual cursor, and adipose tissue areas were determined using commercially 
available software (Slice-O-Matic, Tomovision, Montreal, Canada).CT was also used to measure 
cross-sectional area (CSA) of mid-thigh muscle and adipose tissue and to characterize muscle 
attenuation. An anterior-posterior scout scan of the entire femur was used to localize the mid-
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thigh position. With the subject supine, a 10 mm cross-sectional scan of the dominant leg was 
obtained at the midpoint. The scanning parameters for this image were 120 kVp and 200–
250 mÅ. This protocol has been utilized elsewhere148. Image analysis of adipose tissue and 
skeletal muscle CSAs of the thigh were calculated from the axial CT images using commercially 
available software (Slice-O-Matic, Tomovision, Montreal, Canada). Briefly, the mean 
attenuation coefficient values of muscle within the regions outlined on the images were 
determined by averaging the CT number (pixel intensity) in Hounsfield units (HU). The 
methodological variability of this measure is quite small85. Skeletal muscle and adipose tissue 
areas were calculated by the range of attenuation values for skeletal muscle (0 to 100 HU), 
normal density muscle (35–100 HU), and adipose (–190 to –30 HU) tissue. Intermuscular 
adipose tissue (IMAT), fat that is visible within the muscle fascia, surrounding skeletal muscle, 
was distinguished from the subcutaneous (SUBQ) adipose tissue by manually drawing a line 
along the deep fascial plane surrounding the thigh muscles. Quadriceps muscles were separated 
from hamstring muscles with manual tracing. Two additional reviewers’ analyzed thigh and 
abdominal scans from five randomly selected participants from this project and inter-rater 
reliability was assessed using a two-way mixed effects ANOVA model with SPSS 17.0 (SPSS 
Inc., Chicago, IL). The interclass correlation coefficient (ICC) was non-significant (P =0.99). 
At baseline, two participants, one in each group, are missing abdominal scans due to 
metal deposits in the body. Similarly, two participants, one in each group are missing baseline 
thigh scans due to metal deposits in the body. At 6-months, four participants are missing 
abdominal and thigh scans; two due to metal deposits, one refused and one was lost to follow-up. 
At 12-months, seven participants are missing thigh scans, two due to metal, one refusal, and four 
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were lost to follow-up. Six participants are missing 12-month abdominal scans, two due to metal 
deposits and four were lost to follow-up.  
2.2.8 Isokinetic Strength Testing 
At baseline and follow-up visits, isokinetic strength of the knee extensors was determined at 
60°/s with a dynamometer (model 125 AP, Kin-Com, Chattanooga, TN). The right leg was tested 
unless it was injured or weaker by self-report or restricted in motion. After instruction on the 
procedure, the participant was positioned so that the lateral femoral epicondyle of the knee joint 
was aligned with the rotational axis of the dynamometer. The participant’s leg was weighed for 
gravity correction, and start-stop angles were set at 90° and 30°. Two practice trials were 
performed at 50% effort to familiarize the participant with the procedure and to provide a warm-
up period. Each participant performed at least three maximal efforts. Beginning with the first 
maximal effort, the torque production over the entire range of motion was plotted, and the plot of 
each subsequent effort was overlaid on the previous efforts until three similar curves were 
obtained. Participants were not asked to perform more than six trials. Maximal torque production 
was recorded as the mean peak torque production from three similar trials. This methodology 
was used in the Health ABC Study144. Additionally, specific torque was calculated for each 
participant (knee extensor strength per unit cross-sectional area of the quadriceps) and used as a 
measure of muscle quality in the quadriceps.  
Strength data is missing for one participant at baseline due to bilateral total knee 
replacement.  Four participants are missing strength data at 6-months, one due to bilateral total 
knee replacement, two due to an examiner error and one was lost to follow-up. Six participants 
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are missing 12-month strength data, one due to bilateral total knee replacement, one due to 
severe pain in both knees and four were lost to follow-up.  
2.2.9 Statistical Analyses 
Univariate statistics including means and standard deviations were generated for each variable. 
Changes from baseline to 12-months (12-baseline) were calculated and the significance of 
changes both within groups and between groups were calculating using t-tests, paired t-test, chi-
squared tests and nonparametric tests where appropriate. Generalized Estimating Equations were 
used to assess the relationship between 6- and 12-month changes in body composition with 
change in physical function as measured by the SPPB. Six and twelve month change scores, as 
opposed to value at each time point by time interaction terms, were used in models due to the 
small sample size of this study. Intervention groups were pooled for these analyses to address the 
specific aim of determining the mechanisms, in terms of changes in body composition, 
underlying improved physical function regardless of intervention group. The effect of adjusting 
for intervention assignment and the significance of the beta coefficient associated with 
randomization assignment were assessed. Adjusting for intervention assignment had little to no 
effect on the relationship between changes in specific body composition depots. Additionally, the 
beta coefficient associated with randomization assignment was not significant in any model.  
Analyses were conducted using SAS v9.3.  
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2.3 RESULTS 
2.3.1 Baseline 
Study participants (N = 36) were 70.3 ± 5.9 years of age, weighed 87.9 ± 8.9 kg with a BMI of 
32.9 ± 3.2 kg/m2, classifying them as overweight to moderately obese at baseline358. All 
participants were nonsmokers. Study participants were 16.7% black and 16.7% male (Table 5). 
There were no statistically significant differences between the PA+WL and PA+SA groups in 
regard to baseline demographic, anthropometric, body composition, bone, strength, and 
functional characteristics, except for total SPPB score and total abdominal fat CSA (Tables 5 and 
6), which were marginally higher in the PA+WL group at baseline. Also, no significant 
differences at BL between intervention groups in self-reported PA levels as measured by the 
CHAMPS questionnaire (P = 0.17) were found. 
2.3.2 Change in Anthropometrics and Body Composition (DXA) 
The PA+WL intervention was designed to induce weight-loss within the first 6-months of the 
trial and subsequently maintain this weight-loss for the remainder of the study period. This is 
displayed in Table 8, which shows change that occurred from the six-month follow-up visit 
(6FU) to twelve months (12FU). No significant changes in body composition were observed in 
the PA+WL group and borderline significant decreases in IMAT and an increase in HU were 
observed in the PA+SA group from 6FU to 12FU. Baseline to six-month follow-up results have 
been published elsewhere14. This paper will focus on changes that occurred over the entire 12-
month study period, which are displayed in Table 7.  
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Participants in the PA+WL group significantly decreased their body weight (-4.9 ± 6.1 
kg, p =0.002) and BMI (-1.7 ± 2.3 kg/m2, p=0.002) from BL to 12FU whereas the PA+SA group 
did not. Significant between group differences for 12-month change in body weight and BMI 
(Table 7) were found.  Participants in both groups did not significantly decrease their waist 
circumference (Table 7).  
 Participants in the PA+WL significantly reduced their percent body fat (-2.9 ± 3.4%, p 
<0.001) from BL to 12FU as measured by DXA whereas the PA+SA group did not (0.8% ± 
1.6%, p=0.09). Similarly, total body fat mass decreased by 13.1% (p=0.003) in the PA+WL 
group over the course of the study, which was significantly greater than the 3.2% decrease 
observed in the PA+SA group (p=0.06). Total body lean mass also decreased significantly by 
2.5% (p=0.01) in the PA+WL group, but not in the PA+SA group (-0.2%, p=0.81, Table 7); 
however, these changes did not differ significantly between groups. The PA+WL group 
experienced over a 5-fold greater percent decrease from BL to 12FU in total body fat mass 
compared to lean mass (-13.1% vs. -2.5%, Table 7). 
2.3.3 Change in Body Composition (CT) 
Mean and percent changes, by group assignment, in regional body composition measured by CT 
can be found in Table 7. Significant 12-month decreases in total (-81.5 ± 104.8 cm2, p= 0.006), 
SUBQ (-56.6 ± 62.8 cm2, p=0.02) and visceral (-34.8 ± 40.4 cm2, p= 0.004) adipose tissue were 
observed in the PA+WL group but not in the PA+SA group (Table 7). Additionally, significant 
between-group differences were observed in 12-month change in VAT and total abdominal 
adipose tissue CSA, but not abdominal SUBQ adipose tissue. The PA+WL lost a greater 
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proportion of VAT (-16.0%) compared to SUBQ abdominal adipose tissue (-12.8%). This is 
depicted in Figure 4.  
 Significant 12-month decreases in IMAT, SUBQ and total adipose tissue CSA of the 
thigh were observed in the PA+WL group, but no significant between group differences were 
observed for these measures. As depicted in Figure 4, the PA+WL experienced a 2-fold greater 
percent decrease from BL to 12FU in IMAT compared to SUBQ adipose tissue in the thigh (-
24.6% vs. 11.6%). A significant 12-month decrease in IMAT (-1.8 ± 2.6 cm2, -14.5%, p=0.03) 
was also observed in the PA+SA group; none of the other thigh fat depots decreased significantly 
in this group. Neither group significantly increased thigh muscle HU (Table 7). Decreases is 
thigh muscle CSA were observed in both groups, with both the between group difference and 
decrease in the PA+WL group reaching significance (-5.0 ± 6.4 cm2 vs. -2.1 ± 5.7 cm2), between 
group p=). From BL to 12FU, the PA+WL group lost over twice the proportion of total fat CSA 
compared to muscle CSA in thigh (-12.7% vs. -4.9%). 
2.3.4 Relationship between 6- and 12-month Change in Body Composition with Change in 
Physical Function 
Intervention groups were combined for these analyses. Pooled change in total and regional body 
composition, strength, specific torque and physical function can be found in Table 9. After 
adjustment for age, sex, race, baseline body composition and SPPB, 6- and 12-month decrease in 
IMAT, SUBQ adipose of the thigh, total thigh fat, VAT and total abdominal fat were all 
significantly related to 6- and 12-month improvements in SPPB (Table 10). An increase in HU 
HU (muscle density), indicating a decrease in intramyocellular fat, was also associated with an 
increase in SPPB score after adjustment for age, sex, race, baseline body composition and SPPB 
96 
(Table 10). Models for IMAT and HU were also adjusted for total thigh muscle CSA. Decreases 
in SUBQ abdominal fat and total thigh muscle CSA were not significantly related to 
improvements in SPPB. Decreases in IMAT (stb -0.3829, p=0.005) and VAT (stb -0.4407, 
p=0.0013), in terms of standardize beta size, had the strongest relationship with improved SPPB. 
Adjustment for randomization assignment had minimal effects on these relationships and 
actually increases the standardize beta coefficients and lowers p-values for IMAT and VAT. 
Additionally, the intervention term was non-significant in all models. Similarly, adjustment for 
body height has minimal to no effect on these relationships and was not significant in any of the 
models.  
Additionally, after adjustment for age, sex, race, baseline body composition and SPPB, 6- 
and 12-month change in specific torque, or muscle quality, of the quadriceps (stb. 0.2876, 
p=0.005) and change in total fat mass (stb. -0.3268, p=0.0156) from DXA were significantly 
related to 6- and 12-month change in SPPB. Six- and twelve-month change in total body mass 
from DXA was borderline significantly associated with change in SPPB (stb. -0.2260, p=0.056). 
Change in total lean mass from DXA was not related to change in SPPB (Table 10).  
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 Table 5. Baseline and Demographic Characteristics 
 Weight-loss + 
Physical Activity 
(N= 21) 
Physical Activity + 
SA Education 
(N=15) 
p-
Value 
    
Age 70.6 (± 5.9) 69.9 (± 5.9) 0.80 
Gender   0.68 
Male    4 (19.0%) 2 (13.3%)  
Female 17 (81.0%) 13 (86.7%)  
 
Race 
   
0.20 
White 19 (90.5%) 11 (73.3 %)  
African American 2 (9.5%) 4 (26.7 %)  
 
Education 
   
0.84 
High School/GED 13 (65.0%) 10 (66.7%)  
College 6 (30.0 %) 2 (13.3%)  
Other 1 (5.0%) 3 (20.0%)  
 
Household Income 
($thousand/year) 
  
0.99 
<$50K 13 (61.9%) 9 (60.0%)  
>$50K 3 (14.3%) 3 (20.0%)  
Don’t 
Know/Refused 
5 (23.8%) 3 (20.0%)  
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 Table 6.  Baseline Anthropometric, Body Composition, Muscle Strength and Physical Function by  
Intervention Group 
 
 Weight-loss +  
Physical Activity  
(N= 20) 
Physical Activity +  
SA Education  
(N=14) 
p-
Value 
Anthropometric    
Waist Circumference, cm 108.8 (7.2)# 105.1 (8.8) 0.22 
Body Weight, kg 89.8 (10.0) 85.4  (6.5) 0.21 
Height, cm 164.1 (8.4) 163.2 (5.2) 0.77 
BMI,  kg/m2 33.6 (3.3) 32.1 (3.0) 0.30 
DXA    
Percent Body Fat 43.0 (5.4) 42.5 (6.1) 0.73 
Total Fat Mass, kg 38.0 (5.9) 35.9 (6.5) 0.61 
Total Lean Mass, kg 48.2 (7.6) 46.1 (5.2) 0.55 
Appendicular Lean Mass, 
kg 20.6 (3.7) 19.7 (2.8) 
0.47 
Total body BMD,  g/cm2 1.14 (0.12) 1.11 (0.15) 0.53 
Total Hip BMD,  g/cm2 0.93 (0.11) 0.93 (0.15) 0.91 
Abdominal CT    
Total, cm2 661.5 (± 134.1) 569.5 (97.6) 0.04* 
Visceral Fat, cm2 217.7 (± 61.3) 179.8 (47.9) 0.06 
Subcutaneous Fat, cm2 443.7 (± 124.5) 389.1 (93.4) 0.17 
Right Thigh CT    
Total Fat, cm2 150.8 (± 52.4) 137.9 (47.8) 0.47 
Subcutaneous, cm2 133.2 (± 52.8) 119.8 (47.4) 0.45 
Inter-muscular Fat, cm2 12.5 (± 3.6) 13.4 (5.5) 0.57 
Muscle Mass (CSA), cm2 102.3 (± 23.2) 102.5 (90.2) 0.99 
Muscle Density, HU 39.6 (± 3.1) 40.1 (3.3) 0.62 
NDM, cm2 68.8 (± 18.9) 71.7 (21.1) 0.64 
Knee Extensor Strength    
Peak Torque, N·m 105. 9 (32.2) 110.8 (23.7) 0.66 
Specific Torque, N·m/cm2 2.2 (± 0.3) 2.2 (0.5) 0.65 
SPPB     
Total 9.7 (1.4) 10.7 (1.1) 0.05* 
   #  ± Standard Deviation, *Significant at p<0.05 
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Table 7. Mean Change in Anthropometric, Body Composition, Bone Mass, Muscle Strength and Physical Function from Baseline to 12 Month 
by Intervention Group 
 
 
Weight-loss +  
Physical Activity  
(N= 18) 
Physical Activity +  
Successful Aging  
(N=14) 
 Mean Change (12FU-BL) 
% Change 
from BL p-
V
alue 
Mean Change 
(12-BL) 
% Change 
from BL p-
V
alue 
Anthropometric       
Waist Circumference, cm  -2.5 (7.8)# -2.1% 0.18 0.1 (10.5) 0.2% 0.62 
Body Weight, kg -4.9 (6.1)§ -5.5% 0.002* -0.8 (3.0)§ -1.0% 0.32 
BMI, kg/m2 -1.7 (2.3)§ -5.2% 0.002* -0.2 (1.1)§ -0.6% 0.71 
DXA       
Percent Body Fat -2.9 (3.4)§ -7.2% <0.001* -0.8% (1.6)§ -1.8% 0.09 
Total Fat Mass, kg -4.8 (4.6)§ -13.1% <0.003* -1.2 (2.2)§ -3.2% 0.06 
Total Lean Mass, kg -1.2 (1.7) -2.5% 0.01* -0.1 (1.2)  -0.2% 0.81 
Abdominal       
Total Fat, cm2  -81.5 (104.8)§ -11.0% 0.006* -26.5 (77.8)§ -5.9% 0.24* 
Visceral Fat, cm2 -34.8 (40.4)§ -15.1% 0.004* -1.0 (29.3)§ 2.1% 0.91 
Subcutaneous Fat, cm2 -56.6 (62.8) -8.2% 0.02* -24.8 (63.8) -8.7% 0.19 
Right Thigh       
Total Fat, cm2 -19.1 (24.4) -13.7% 0.007* -3.4 (7.8) -2.4% 0.15 
Subcutaneous, cm2 -15.4 (23.7) -12.3% 0.02* -1.5 (7.5) -0.7% 0.49 
IMAT, cm2 -3.2 (2.2) -23.6% <0.001* -1.8 (2.6) -14.5% 0.03* 
Muscle Mass, cm2 -5.0 (6.4)§ -5.0% 0.008* -2.1 (5.7)§ -2.5% 0.21 
Muscle Density, HU 0.7 (1.5) 1.8% 0.11 0.2 (1.4) 0.6% 0.55 
NDM Mass, cm2 -1.7 (5.3) -2.3% 0.32 -0.8 (6.0) -1.7% 0.50 
Knee Extensor Strength       
Peak Torque, N·m -17.6 (22.3) -14.8% <0.001* -7.9 (16.6) -7.7% 0.17 
Specific Torque, N·m/cm2 -0.2 (0.4) -7.2% 0.12 -0.2 (0.3) -5.8% 0.27 
SPPB Score 0.8 (1.4) 10.0% 0.02* 0.1 (1.6) 1.7% 0.86 
400m Walk Time, s -20.56 (63.07) -3.9% 0.32 11.07 (61.6) 2.9% 0.51 
# ± Standard Deviation, * Significant change from baseline, p<0.05, § Denotes a significant difference between intervention groups, p<0.05 
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Table 8. Mean Changes in Anthropometric, Body Composition, Bone Mass, Muscle Strength and Physical Function Measures from 6 to 12 
Month Follow-up by Intervention Group 
 
 
Weight Loss  
+ Physical Activity  
(N= 19) 
Physical Activity 
 + Successful Aging  
(N=13) 
 Mean Change (12FU-6FU) % Change 
p-
V
alue 
Mean Change 
(12FU-6FU) % Change 
p-
V
alue 
Anthropometric       
Waist Circumference, cm 2.2 (7.1)# 2.3% 0.17 -0.6 (8.7)# -0.5% 0.81 
Body Weight, kg 0.5 (4.5) 0.6% 0.81 0.2 (2.7) 0.2% 0.71 
BMI, kg/m2 0.2 (1.7) 0.6% >0.99 0.1 (1.0) 0.6% 0.50 
DXA       
Percent Body Fat, % -0.7 (2.2) -1.8% 0.35 -0.7 (2.2) -1.7% 0.17 
Total Fat Mass, kg -0.5 (2.6) -1.8% 0.58 -0.6 (2.5) -1.6% 0.39 
Total Lean Mass, kg 0.5 (1.9) 1.0% 0.32 0.6 (1.2) 1.3% 0.12 
Abdominal       
Total Fat, cm2  -9.0 (49.6) -0.7% 0.47 -31.7 (73.5) -6.1% 0.39 
Visceral Fat, cm2 1.9 (26.5) 1.2% 0.77 -6.5 (24.3) -1.1% 0.91 
Subcutaneous Fat, cm2 -10.9 (36.3) -2.1% 0.23 -25.2 (71.7) -7.3% 0.23 
Right Thigh       
Total Fat, cm2 -0.2 (12.2) 0.6% 0.96 2.1 (8.5) 1.8% 0.15 
Subcutaneous, cm2 0.4 (13.9) 1.6% 0.90 3.4 (8.6) 3.7% 0.19 
IMAT, cm2 -0.8 (1.7) -5.5% 0.13 -1.2 (1.9) -9.8% 0.048* 
Muscle Mass, cm2 -2.0 (7.1) -2.4% 0.27 -3.6 (5.7) -3.9% <0.01* 
Muscle Density, HU -0.7 (1.4) -1.5% 0.07 -0.7 (1.2) -1.6% 0.08 
NDM Mass, cm2   -2.7 (5.9) -3.7% 0.09 -3.5 (4.1) -5.7% 0.01* 
Knee Extensor Strength       
Peak Torque, N·m -3.7 (14.1) -2.5% 0.08 -4.4 (17.2) -5.3% 0.39 
Specific Torque, N·m/cm2 -0.0 (0.4) 0.7% 0.81 -0.1 (0.3) -5.8% 0.11 
SPPB Score 0.2 (1.3) 6.7% 0.56 -0.4 (1.2) -3.6% 0.28 
400m Walk Time, s 24.44 (33.23) 3.4% 0.01* 32.21 (49.09) 9.1% 0.03* 
# ± Standard Deviation, * Significant change from baseline, p<0.05, § Denotes a significant difference between intervention groups, p<0.05 
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Table 9. Mean Changes in Anthropometric, Body Composition, Bone Mass, Muscle Strength and 
Physical Function Measures from Baseline to 12-month Follow-up 
 
 Entire Cohort 
 Mean Change (12FU-BL) % Change 
p-
V
alue 
Anthropometric    
Waist Circumference, cm -1.4 (9.0) -1.1% 0.40 
Body Weight, kg -3.1 (5.3) -3.5% 0.002 
BMI, kg/m2 -1.0 (2.0) -3.2% 0.004 
DXA     
Percent Body Fat, % -2.0 (2.9) -4.8% <0.0001 
Total Fat Mass, kg -3.2 (3.9) -8.8% 0.89 
Total Lean Mass, kg -0.7 (1.6) -1.5% 0.58 
Abdominal     
Total Fat, cm2  -57.7 (96.6) -8.8% 0.003 
Visceral Fat, cm2 -20.1 (40.7) -7.7% 0.01 
Subcutaneous Fat, cm2 -37.2 (69.2) -8.4% 0.006 
Right Thigh     
Total Fat, cm2 -12.1 (20.2) -8.6% 0.0002 
Subcutaneous, cm2 -9.1 (19.3) -7.1% 0.005 
IMAT, cm2 -2.6 (2.5) -19.5% <.0001 
Muscle Mass, cm2 -3.7 (6.2) -3.9% 0.003 
Muscle Density, HU 0.5 (1.5) 1.3% 0.02 
NDM Mass, cm2   -1.3 (5.5) -2% 0.59 
Knee Extensor Strength     
Peak Torque, N·m -13.7 (20.5) -11.9% 0.0001 
Average Torque, N·m -9.6 (16.1) -10.1% 0.001 
SPPB Score 0.5 (1.5) 6.4% 0.07 
400m Walk Time, s -6.7 (63.4) -1.0% 0.55 
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Table 10. 12-Month Change in Regional Body Composition Predicting 12-Month Change in SPPB 
Score using GEE 
 
Variable Std ß estimate SE p 
Δ Intermuscular Fat**  -0.3829 0.1365 0.0050 
Δ Muscle Attenuation** 0.2758 0.1094 0.0117 
Δ Thigh SUBQ Fat* -0.2802 0.0956 0.0034 
Δ Total Thigh Fat -0.3069 0.0943 0.0011 
Δ Abdominal SUBQ Fat* -0.1660 0.1029 0.1065 
Δ Visceral Adipose Tissue*  -0.4407 0.1374 0.0013 
Δ Total Abdominal Fat -0.3335 0.1184 0.0049 
Δ Muscle CSA*  0.0994 0.1692 0.5202 
Δ Specific Torque* 0.2876 0.1270 0.0236 
Δ Lean Mass, DXA* -0.0730 0.0792 0.3561 
Δ Fat Mass, DXA* -0.3268 0.1352 0.0156 
Δ Total Mass, DXA* -0.2260 0.1180 0.0555 
*Models are adjusted for Age, Sex, Race, baseline Body Composition and SPPB Scores 
** Models are also adjusted for baseline thigh muscle cross-sectional area. 
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 Figure 4. 12-Month Percent Changes in Specific Fat Depots of the Thigh and Abdomen 
 
 
 
 
 
#absolute change in cm2 
^ absolute change in HU’s 
* significant change from BL, p<0.05 
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 Figure 5. Change in SPPB score by Time Point 
 
 
 
 
 
 
 
 
 
*Significant change from baseline 
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2.4 DISCUSSION 
The primary aim of the current study was to determine the relationship between changes in 
regional body composition and physical performance in order to gain insight into the possible 
mechanisms underlying improvements in physical performance, regardless of intervention group. 
Consistent with our hypotheses, decreases in IMAT, HU and VAT were all significantly 
associated with improvements in physical performance as measured by the SPPB (Table 10). To 
our knowledge, this is the first study to show that changes in specific fat depots, in older adults, 
are associated with improvements in physical function. Decreases in SUBQ abdominal fat and 
total thigh muscle CSA were not significantly related to change in SPPB; however decreases in 
SUBQ thigh fat were related to increased physical function. Thigh SUBQ, or gluteofemoral fat, 
has been shown to possess certain protective properties including independent associations with 
lower total and low-density lipoprotein cholesterol as well as vascular health benefits, such as 
decreased aortic calcification and arterial stiffness359-362. The fact decreases in SUBQ fat were 
shown to be associated with improvements in physical function may be due to the fact that the 
spearman correlation coefficient between 12-month change in total and SUBQ thigh fat was 0.97 
(p <0.0001). Thus, almost all of the variance in change in SUBQ fat is explained by change in 
total thigh fat, suggesting that a more optimal lean to fat mass ratio in the thigh is underlying 
improvements in physical function and not a specific decrease in SUBQ thigh fat. This study is 
consistent with and expands upon previous cross-sectional work showing that IMAT, VAT and 
HU are associated with worse muscle or physical performance and adverse health conditions that 
may negatively affect muscle or physical performance52,161,347,348,363. In a study by Villareal et al., 
obese older adults participating in a 12-month weight-loss plus physical activity intervention 
participants in the weight-loss plus exercise group improved their physical function to a greater 
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degree than the weight-loss only, exercise only and control groups. The authors suggested that 
positive changes in body composition may be underlying these improvements in physical 
function48. The results of this study corroborate this hypothesis.  
The results of this study also show that a dietary weight-loss intervention in conjunction 
with a moderate physical activity intervention results in decreases in total body lean and fat 
mass. The PA+WL group experienced a 5-fold greater percent decrease in total body lean 
compared to fat mass (Table 7). This is consistent with other studies that used DXA to measure 
total body lean and fat mass following a weight loss and physical activity intervention48,173. For 
example, a study by Avila et al. showed that older adults (age 67 ± 4 years) participating in a 
weight-loss plus resistance training intervention lost ~11.6% of their baseline fat mass while 
gaining a slight amount of lean mass (1.5%)173. The fact that participants in the Avila study 
gained lean mass and those in the PA+WL group in the current study lost a significant amount of 
lean mass, is likely attributable to differences in the PA intervention. The PA intervention in the 
Avila study consisted exclusively of upper and lower body resistance training, whereas the study 
described in this paper implemented a PA intervention consisting primarily of treadmill walking, 
supplemented with lower extremity resistance and balance training. In the study by Villareal et 
al., described previously, obese older adults participating in a 12-month weight-loss plus 
physical activity intervention lost 16% of their fat mass compared to 3% of their lean mass over 
the course of the trial8.  
Results of this study also show that weight-loss in conjunction with moderate physical 
activity appears to preferentially target the harmful fat depots of IMAT compared to SUBQ fat in 
thigh (-23.6% vs. -12.3%) and VAT compared to SUBQ abdominal adipose tissue (-15.1% vs. -
8.2%). This is consistent with previous studies showing that both weight-loss induced via caloric 
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restriction, exercise and in combination result in decreases in IMAT and VAT147,173,175,177. For 
example, a study by Murphy et al. showed  that both exercise induced weight-loss and caloric 
restriction reduced weight loss result in a greater reduction of IMAT compared to SUBQ thigh 
fat 177. However, this same study showed that exercise induced weight-loss, but not caloric 
restriction induced weight-loss, resulted in greater reductions in VAT compared to SUBQ 
abdominal adipose tissue177. Finally, it is important to note that the Murphy et al study showed 
that exercise induced weight-loss, compared to caloric restriction reduced weight-loss, resulted 
in greater decreases in IMAT and VAT. The physical activity intervention implemented in the 
study described in this paper was not designed to induce weight-loss. However, the results from 
the current study are consistent with the Murphy et al. study, as the PA+SA group lost a 
significant amount of IMAT (-14.5%), despite not losing significant amounts of any other fat 
depot. The current study was not equipped to test whether or not physical activity in addition to 
weight-loss is necessary to induce reductions in these fat depots, as there was no weight-loss 
only group. However, these results while taken into consideration with the results of the Murphy 
et al. study, suggest that physical activity, in addition to weight-loss, may be necessary in order 
to optimize body composition remodeling177. Additionally, in a randomized controlled trial 
comparing a moderate physical activity intervention, not designed to induce weight-loss, to an 
education control group, the education control group gained a significant amount of 
intermuscular fat (IMAT), whereas the moderate physical activity group did not.  Another study 
highlighting the effect of physical activity on IMAT showed that healthy humans, following 4-
weeks of single leg immobilization, gained significant amounts of IMAT, in both the calf and 
thigh, in the immobilized leg despite a statistically significant decrease in total body mass363. 
Additionally, in a randomized controlled trial comparing a moderate physical activity 
108 
intervention, not designed to induce weight-loss, to an education control group, the education 
control group gained a significant amount of IMAT, whereas the moderate physical activity 
group did not148. 
The biological mechanisms by which decreasing these specific fat depots may improve 
physical performance are unclear. VAT is strongly associated with insulin resistance independent 
of overall adiposity and with higher levels of proinflammatory cytokines52,347,348. Therefore, 
decreases in VAT may result in improvements in metabolic and inflammatory states, which may 
positively affect muscle and physical performance. Similarly, IMAT and HU have been shown to 
be related to insulin resistance and the metabolic syndrome52,146,161,351; therefore, decreasing 
IMAT and HU levels may result in a more optimal metabolic state, resulting in improved 
physical performance. A few recent trials conducted in younger adult men (age 30-65) and 
women (age 20–41) have shown that decreases in VAT are associated with improvements in 
insulin resistance364 and decreases in inflammatory markers365. Additionally, in HIV+ patients 
receiving Tesamorelin, a growth hormone-releasing hormone analogue, percent decrease in VAT 
was associated with changes in lipid levels and glucose homeostasis366. These studies did not 
examine how these changes affected muscle or physical performance. To our knowledge, the 
relationship between decreases in the fat depots present in skeletal muscle, IMAT and HU, and 
metabolic and inflammatory markers has not been examined. Further intervention trials are 
needed examining the specific relationships between decreases in IMAT, HU and VAT with 
inflammatory and metabolic markers and how they impact physical function in older adults.  
The current study has several strengths. First, both interventions were effective, as 
participants in the PA+WL group lost a significant amount of total body weight on average and 
both groups substantially increased their physical activity levels during the adoption and 
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transition periods of the intervention. Physical performance was measures objectively using the 
well validated and widely used SPPB, rather than self-reported physical function. This eliminates 
any potential recall bias. The assessment staff was blinded to the intervention assignments of the 
participants. The gold standard method of CT was used to measure regional body composition 
depots. This study also measured body composition with DXA. DXA is widely used and well 
validated; implementing it allowed comparison of results with many other studies. This study 
also has a few limitations. First, this study lacks a weight-loss only group and a true control 
group. Including these two groups would have allowed the exclusive affects of weight-loss to be 
compared to those of physical activity and the combination of both to a control group.  The 
participants were mostly white females (84.3%), fairly healthy and high functioning at baseline, 
thus the findings may not be as relevant to minority, male or more frail older adults. Finally, this 
study had a relatively small sample size.  
 In conclusion, weight-loss in conjunction with physical activity resulted in significant 
improvements body composition, which were related to improved physical function in older 
adults. Physical activity, consisting primarily of treadmill walking, supplemented with lower 
extremity resistance and balance training, seems to target IMAT. Decreases in the regional fat 
depots of IMAT, HU and VAT, regardless of intervention assignment, were significantly related 
to improved physical performance in older adults. Therefore, targeting these fat depots may be of 
particular importance when aiming to improve physical function or prevent physical disability in 
older adults. The results of this study have important public health implications as men and 
woman age 60 and older have higher prevalence rates of obesity compared to any other age 
group349 and obesity is a well-known independent risk factor for age-related physical 
disability163,164. This study provides important and novel insights into the mechanisms by which 
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intentional weight-loss in combination with moderate physical activity may improve physical 
performance in older adults. Weight-loss and physical activity appear to target the particularly 
harmful fat depots of IMAT and VAT and we’ve shown for the first time that decreases in these 
depots were related to improvements in physical function. The results of this research provides 
clinicians and public health professionals with important information they can utilize to prevent 
age-related physical disability. 
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3.0  THE RELATIONSHIP BETWEEN MITOCHONDRIAL ENERGY 
PRODUCTION AND MOBILITY IN OLDER ADULTS WITH A WIDE RANGE OF 
FUNCTION 
A portion of age-related declines in gait-speed may be attributable to mitochondrial dysfunction. 
Mitochondria produce over 90% of ATP needed for movement and the capacity for oxidative 
phosphorylation decreases with age. We examined the association between mitochondrial 
function and walking performance in older adults. Phosphocreatine (PCr) recovery in the 
quadriceps was measured following an exercise-bout using 31P magnetic resonance 
spectroscopy and ATPmax (mM ATP/s) was calculated. Participants were from an ancillary to 
the Lifestyle Interventions and Independence for Elders (LIFE) Study (n=36), which recruited 
functionally impaired participants (Short Physical Performance Battery (SPPB, 0-12), 7.9±1.2) 
and also from the Study of Energy and Aging (SEA, n=29), which enrolled higher functioning 
participants (SPPB, 10.9±1.4).Walking performance was defined as time (s) to walk 400m over 
level-ground at usual-pace and participants were asked if anything was bothering them upon 
completion. Participants were aged 77.6±5.3 years, 64.2% female, 67.2% white and SPPB scores 
ranged from 3-12 (9.2±2.0). In linear regression analyses, walk-time was significantly related to 
ATPmax in the SEA cohort (β -209.02, p=0.02), but not in the combined (β -65.31, p=0.32) nor 
the LIFE (β 42.70, p=0.74) cohorts. When we examined those who reported no discomfort at the 
end of the walk separately, walk-time was significantly related to ATPmax in the combined 
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cohort (β -160.02, p=0.04) and the relationship in LIFE was β -127.38, p=0.27.This suggests that 
oxidative capacity of skeletal muscle mitochondria may limit walking performance in higher 
functioning older adults and functionally impaired older adults able to walk 400m without 
experiencing discomfort. 
3.1 INTRODUCTION 
Mitochondria produce over 90% of ATP needed for movement7. The capacity for oxidative 
phosphorylation in skeletal muscle, mitochondrial function and mitochondrial content has been 
shown to decrease significantly with age156,249,290,367. Gait-speed has also been shown to  decrease 
with age by about 0.21-0.29 m/s per decade with considerable individual variation and is slower 
gait is associated with an increased risk for mortality41,368.  Age-related decreases in skeletal 
muscle mitochondrial energy production may contribute to declines in muscle and ultimately 
walking performance in older adults367. Experimental evidence has shown that the accumulation 
of mutations or deletions in mtDNA lead to mitochondrial dysfunction and reductions in ATP 
production239,259. Additionally, poorer mitochondrial function has been shown to be 
independently related to lower physical function in a study involving hospitalized and 
community-dwelling older adults312. More recently, Coen at el. showed that both in vivo 
mitochondrial function measure by 31P magnetic resonance spectroscopy (MRS) and 
mitochondrial efficiency calculated from 31P MRS and state 3 respiration measured in isolated 
mitochondria obtained from muscle biopsy, were significantly associated with walking speed in 
older adults314. 
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Many reasons exist for age-related slowing and why some decline more than others; 
however the role of age-related changes to skeletal muscle is still unclear. Sarcopenia, the loss of 
muscle mass with age, was thought to be the primary cause of decreasing mobility and physical 
function with age; however, longitudinal evidence suggests that decreasing muscle mass only 
modestly predicts mobility in older adults369 and other muscle qualities are related to mobility 
independent of muscle mass30. Furthermore, Fleg et al. has shown in the Baltimore Longitudinal 
Study of Aging that maximum aerobic capacity (VO2 peak) normalized to fat-free mass 
decreases with age at similar rates across those who report low, intermediate and high levels of 
physical activity231. This suggests that decreases in aerobic capacity cannot be fully explained by 
changes in body composition and lower levels of physical activity.  One of the major 
components of aerobic capacity is the ability of skeletal muscle mitochondria to convert oxygen 
to energy in the form of ATP. This finding by Fleg et al. suggests the importance of exploring 
the cellular and energetic bases of mobility and functional disability in older adults. 
The purpose of this paper is to expand upon the findings presented by Coen et al. by 
examining the relationship between mitochondrial energetics and functional performance in 
older adults with a wide range of functional capacities. Two separate study cohorts were utilized. 
The first cohort is from the Study of Energy and Aging (SEA), which contained high 
functioning, physically active older adults and was the focus of the study conducted by Coen et 
al314. The second is a subset of participants participating in The Lifestyle Interventions and 
Independence for Elders (LIFE) Study, which contains functionally impaired sedentary older 
adults39. Combining these two cohorts provides a unique opportunity to examine the relationship 
between skeletal muscle mitochondrial energetics and physical performance in a population of 
older adults with a wide-range of functional abilities. Both studies implemented the non-invasive 
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and direct measure of 31P Magnetic Resonance Spectroscopy (MRS) to measure ATP generation 
by mitochondria present in the quadriceps. This research is an important step towards the 
development of a non-invasive biomarker of declining function and may identify a new 
therapeutic target to treat and prevent declining physical function in older adults. 
3.2 METHODS 
3.2.1 Participants 
For these analyses, participants from two separate studies were examined. The cohorts were 
examined both separately and in combination. Rationale for examining these two cohorts in 
combination is presented below. The first study was the cross-sectional Study of Energy in 
Aging-Pilot (SEA), conducted from May through August 2011. The second study was the 
randomized controlled trial: The Lifestyle Interventions and Independence for Elders (LIFE) 
Study. A subset of LIFE participants who completed an ancillary study is included in the current 
study. LIFE baseline data only, collected between June and August of 2011, are included in these 
analyses. The reason these studies were examined in combination are two-fold. First, because the 
SEA population was highly active and high functioning and the LIFE participants were 
functionally limited and sedentary by design. Combing the two cohorts would allow for the 
examination between ATPmax and time to walk 400m in older adults with a wide range of 
functional capacity. Second, the primary outcome of time to walk 400m and the primary 
predictor of oxidative capacity of the quadriceps (ATPmax), measured by 31P MRS were 
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identical. These two studies as well as definitions for combined measures will be described 
below. 
SEA participants were community-dwelling (n=37) men and women aged 70–89 years 
from the Pittsburgh, PA area. Eligibility was determined via a standardized telephone screening 
interview. The inclusion criteria were age 70–89 years; body weight less than or equal to 285 lbs. 
for men and less than or equal to 250 lbs. for women; body mass index 20–32 kg/m2; ability to 
walk without the assistance of a device or another person; free of basic activities of daily living 
disability, defined as no difficulty getting in and out of bed or chairs, and no difficulty walking 
across a small room; no history of hip fracture; no heart attack, angioplasty, or heart surgery 
within the past 3 months, no cerebral hemorrhage within the past 6 months, stroke within the past 
12 months, or chest pain during walking in the past 30 days; no symptomatic cardiovascular or 
pulmonary disease; no regular pain, aching, or stiffness in the legs, hips, knees, feet, or ankles 
when walking; no bilateral difficulty bending or straightening fully the knees; not regularly 
taking Coumadin, Plavix, Aggrenox, Ticlid, or Agrylin/Xagrid. They had to be able to have a 
magnetic resonance scan (able to lie still on back for 1 hour; and no metal or other implants, 
artificial joint replacements, or tattoos. They had to be able to wear the armband activity monitor 
(no disability in right arm; no swimming or water aerobics ≥ 3 times/week; and no supplemental 
oxygen use in household); and have ability to understand and sign an informed consent. 
Additionally, to qualify as an enrollee, participants had to provide written informed consent and 
complete the first day of the clinic visit, including the clinic questionnaire, height and weight, 
blood pressure and pulse, leg extensor strength (1-repetition maximum) and power, physical 
exam, short physical performance battery (SPPB), and the 400 meter walk.   All participants 
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provided written informed consent. The study was approved by the University of Pittsburgh 
Institutional Review Board.  
The LIFE Study is a multi-center randomized controlled trial; design, methods and 
rationale have been described in detail elsewhere39. Participants included in this study completed 
an ancillary study exclusive to the Pittsburgh site (n=39). Briefly, the LIFE Study eligibility 
criteria were designed to target older persons (age 70–89) who (a) were sedentary, as defined as 
spending less than 20 min/wk in the past month getting regular PA and reporting less than 125 
min/wk of moderate PA370; (b) were at high risk for mobility disability based on objectively 
assessed lower extremity functional limitations assessed by the Short Physical Performance 
Battery (SPPB; score of ≤9)25,39,67; (c) could walk 400 m in 15 minutes without sitting, leaning, 
or the help of another person; and (d) could safely participate in the intervention. These analyses 
include baseline data for cross-sectional examination only.  Potential participants were screened 
by telephone. Those who remained eligible following the telephone screening were invited to 
attend a group or individual prescreening visit during which the LIFE Study was presented in a 
lecture or individual format. Following a question and answer session, attendees were invited to 
review and sign a prescreening consent form. Those still eligible after administration of the 
SPPB and the Community Healthy Activities Model Program for seniors (CHAMPS-18) PA 
questionnaire370 were invited to attend the first screening visit. If still eligible, participants 
attended a second and final screening visit, at the end of which they were randomized.  
Approximately halfway through LIFE recruitment, participants from the Pittsburgh site 
only were informed about the opportunity to participate in an ancillary study following their 
randomization into the LIFE study. The ancillary study included one separate visit to perform a 
31P Magnetic Resonance Spectroscopy scan to measure oxidative capacity of the quadriceps 
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(ATPmax). This method will be described in detail below. To be eligible for the ancillary, 
participants had to be enrolled in the LIFE study, and be able to have the magnetic resonance 
(MRI) scan (not claustrophobic, able to lie still on back for 1 hour; and no metal or other 
implants, or bilateral artificial joint replacements, or tattoos). Participants had to be able to 
understand and sign a separate consent in order to participate in the ancillary study. The ancillary 
study was approved by the LIFE study’s emerging science committee and data management and 
coordinating center as well as by the University of Pittsburgh’s Institutional Review Board.  
3.2.2 Clinic Examination and Measurements 
Participants from both studies were examined at the Health Studies Research Clinic at University 
of Pittsburgh, Center for Aging and Population Health. As mentioned previously, LIFE study 
design and methods have been described in detail elsewhere39. In both SEA and LIFE 
participants, body height (cm) was measured using a wall-mounted stadiometer and body weight 
(kg)with a standard certified calibrated scale and were used to calculate BMI (weight (kg)/height 
(m2)). Participants in both studies completed questionnaires concerning demographic information 
and self-reported medical history. Questions were asked in a similar manner in both studies, with 
a few exceptions. These exceptions will be described immediately below. History of arthritis was 
measured slightly differently, in SEA the question was “has a doctor ever told you that you had 
arthritis or rheumatism”, in LIFE it was “have you seen a Dr. in the past 6-months for arthritis or 
rheumatism. For self-reported health status, SEA participants were asked “compared to people 
your own age, would you rate your overall health as, excellent, good, fair , poor or very poor” 
whereas LIFE used the more standard “would you say your health is excellent very good, good 
fair or poor” from the SF-12371. To describe the combined cohort, this question was 
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dichotomized into those who responded fair or worse and those who responded good or better. 
As a measure of global fatigue, SEA participants were asked “during the past 4 weeks how much 
of the time do you feel tired from 0-6”, where 0 is all of the time and 6 is none of the time; 
whereas LIFE participants were asked “during the past week how often have you felt tired, all of 
the time, most, a good bit, some or a little bit of the time. To describe the combined cohort, 
global fatigue was dichotomized into those who were tired some of the time or more in LIFE or 
answered 4 or less in SEA, compared to those who responded a little bit of the time in LIFE or 5 
or 6 in SEA. Alcohol consumption, in drinks per week, was categorized in SEA and open-ended 
in LIFE. To describe the combined cohort, alcohol was dichotomized into those who consume 6 
or more drinks per week and those who do not.  
Finally, the last discrepancy has to do with how physical activity was measured in the 
two studies. 7-day free living physical activity was measured objectively in both studies. In the 
LIFE study, the Actigraph™ accelerometer, model GT3X, was used and in the SEA study, the 
multi-sensor Sensewear™ (Bodymedia Pittsburgh, PA) armband was used. The instruments were 
used to calculate minutes per-day spent in different modes of activity – sedentary, light and 
moderate and above physical activity. NHANES cut-points were used to categorize Actigraph 
counts into minutes per day and the Sensewear’s manufacturer devolved proprietary algorithm 
was used to categorize minutes per-day.  In order to describe the combined cohort, minutes per 
day spent in different intensities of physical activity were combined.  
As mentioned previously, objective lower extremity function was measured by the SPPB 
in both studies. The SPPB includes a 4m walk, chair stands and a balance23. 
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3.2.3 400-Meter Walk 
Time to walk 400m is the primary outcome for these analyses. The 400m walk protocol for both 
SEA and LIFE have been described elsewhere39,314. Briefly, the test was conducted on level 
ground using a 20-meter course. Participants were instructed walk at their usual pace and without 
overexertion for10 laps (20m up and back). Participants were reminded to walk at their usual 
pace every lap. Participants were required to complete the walk in less than 15-minutes. Seated 
blood pressure and pulse were reviewed for safety before the walk. There was one discrepancy in 
regard to the walk protocol between LIFE and SEA. In SEA, participants were not permitted to 
stop and rest during any portion of the test. However, since LIFE was designed to recruit 
functionally limited older adults, participants were permitted to rest standing in place, without 
touching the wall. Participants were still required to complete the walk in 15 minutes. 
Participants in both studies were asked if “anything was bothering them at the end of the walk”. 
Discomfort following the walk was defined as responding yes when asked by the examiner “Is 
anything bothering you?” upon completing the walk. In SEA, the question was categorical, and 
in LIFE it was opened ended. In LIFE, 13 (36.1%) participants reported discomfort at the end of 
the walk (Table 11): three reported back pain or  hip pain/discomfort, 2 reported knee pain, two 
reported light headedness, one reported being tired and experienced foot pain and one person 
reported discomfort during the walk and requested their straight cane (groups not mutually 
exclusive). In SEA, 5 (17.2%) reported discomfort at the end of the walk: reported calf or back 
pain, two reported shortness of breath, one reported hip, foot or knee pain and four reported other 
(groups not mutually exclusive). 
 Total time in seconds was used for these analyses. In order to eliminate the skewedness 
caused by participants stopping during the test, quartiles of 400m walk time were generated and 
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time to walk 400m was treated as both a categorical and continuous variable.  One participant 
from the SEA study is excluded from analyses due to being unable to complete the 400m walk. 
3.2.4 Determination of ATPmax by 31P MRS 
31P MRS measures the regeneration of phosphocreatine (PCr) after a short bout of exercise to 
characterize mitochondrial ATP production. PCr is a high energy phosphate that can be readily 
converted to ATP and vice-versa via the creatine kinase reaction (PCr + ADP H+ ↔ ATP + Cr). 
PCr is the initial full-source of skeletal muscles. A linear relationship links change in PCr with 
exercise to mitochondrial oxidative phosphorylation rate275,276.  Therefore, measuring the 
dynamics of the PCr shuttle provides a method to estimate muscle oxidative capacity in 
vivo156,277. Furthermore, this method has been confirmed to be a good measure of oxidative 
capacity in rodent and human studies showing that ATPmax varies in direct proportion to the 
activity of oxidative enzymes in skeletal muscle 278,279. It has also been shown to reflect 
mitochondrial content in human skeletal muscle280. The amount of ATP production from 
glycolysis has been shown to be minimal in resting skeletal muscle (<8%)237. Regardless, this 
method can tease out the amount of ATP production by glycolsis by determining the pH from the 
chemical shift of the free phosphorous peak relative to the PCr peak281. H+ ions, which would 
lower the pH, are a byproduct of glycolysis.  
Briefly, the exercise protocol took place in a typical MRI magnet (3T TIM Trio magnetic 
resonance scanner, Siemens’ Medical System). Participants laid flat on their backs with the knee 
of the right leg (unless contraindicated) supported so that the leg was slightly elevated at a ~30 
degree angle. Straps were place over the legs and a 2.5” surface RF coil tuned to 31P is placed 
over the right quadriceps. At two different points during the scan, they were asked to kick 
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repeatedly as hard and as fast as they can, producing fast contractions at the highest rate possible 
for ~30s, followed by a 6 minute rest period. The protocol was designed to deplete PCr stores by 
at least 33-66% without lowering pH below 6.80 during the recovery period. PCr recovery rate 
was measured during this rest period. 
Phosphorus spectra was collected using a 3T TIM Trio magnetic resonance scanner 
(Siemen’s Medical System, Erlanger, Germany), this has also been described elsewhere314. A 
standard one pulse experiment was used to determine the levels of PCr, ATP, Pi, and pH 
throughout exercise and recovery. PCr, Pi, and ATP peak areas in the fully relaxed spectra were 
measured by integration using Varian VNMR 6.1C software (Varian Medical Systems, Palo 
Alto, CA). Areas of the PCr and Pi peaks were expressed relative to the ATP peak and quantified 
using a resting PCr value of 27mM as determined from biopsies of human vastus lateralis 
muscle156. Changes in PCr and Pi peak areas during the tests were analyzed as previously 
described372,373.  
Six participants from SEA and three participants from LIFE are missing ATPmax data 
due to either inadequate PCr breakdown or pH levels dropping too low during the recovery 
period. SEA and LIFE participants were tested using the same magnet and the scans were 
conducted by the same technician in both studies.  
3.2.5 Statistical Analyses 
Baseline characteristics including means and standard deviations for continuous variables and 
frequencies and percent’s for categorical variables were generated for each study separately and 
combined. T-test, non-parametric, chi-squared and Fischer’s exact test were used, where 
appropriate, to test for any between study differences. The primary aim of these analyses was to 
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determine the relationship between ATPmax and time to walk 400m, in each study separately 
and then combined. This was done using multiple linear regression to predict time to walk 400m 
using ATPmax.  Univariate and models adjusted for age, sex, race and BMI. Since it is well 
documented that those with type 2 diabetes have significantly lower mitochondrial function, we 
also examined the affect that diabetes has on the relationship between ATPmax and time to walk 
400m. Adding diabetes to the model containing ATPmax, age, sex, race and BMI has very 
minimal effect and the p-value corresponding to the beta coefficient for diabetes was 0.95. 
Additionally, the interaction term containing ATPmax and diabetes status was not significant 
(p=0.21). Finally, we examined models stratified by diabetes; ATPmax was not a significant 
independent predictor of ATPmax in either model.   
Since the relationship between ATPmax and walk-time were drastically different in the 
SEA and LIFE cohorts, we conducted further analyses to gain insight into possible confounding 
factors present in the LIFE cohort. To identify possible confounders, we compared those LIFE 
participants with the unexpected relationship of being in the highest two quartiles of ATPmax 
and the lowest two quartiles of walk-time to those in both the highest two quartiles of ATPmax 
and walk-time (Table 14). These analyses prompted us to examine the relationship between 
ATPmax stratified by discomfort at the end of the 400m. All analyses were performed with SAS 
version 9.3.  
As mentioned previously, six participants from SEA and three participants from LIFE are 
missing ATPmax data due to either inadequate PCr breakdown or pH levels dropping too low 
during the recovery period. One SEA participant was also unable to complete the 400m walk. 
This yields a final analytic dataset of 29 SEA participants and 36 LIFE participants. 
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3.3 RESULTS 
3.3.1 Baseline Composition of SEA and LIFE Studies 
Baseline characteristics of both the SEA and LIFE studies are depicted in Table 11. As 
evidenced by the data presented in Table 11, these two studies were designed to recruit dissimilar 
populations of older adults. Participants in the LIFE study were significantly more overweight, 
more fatigued, less active, lower functioning, as determined by the SPPB, and had slower 4m 
gait speed (Table 11). The LIFE study also contained a significantly larger proportion of those 
with diabetes, less with a history of cancer and less who reported drinking 6 or more drinks per 
week, compared to the SEA participants. Finally, the LIFE study contained a significantly larger 
proportion of both females and African Americans compared to the SEA study. There were no 
statistical differences between the two study population in regard to age, self-reported discomfort 
at the end of the 400m walk, history of peripheral arterial disease, congestive heart failure, 
myocardial infarction, chronic pulmonary disorder or arthritis. Finally, the two study populations 
had very similar ATPmax values. 
3.3.2 Relationship between ATPmax and 400m Walk-time 
ATPmax was not significantly related to time to walk 400m (p=0.43) in the combined SEA and 
LIFE cohorts. However, ATPmax was significantly related to time to walk 400m in the higher 
functioning, normal weight, physically active SEA population (p=0.02), but not in the 
functionally limited, obese sedentary LIFE population (p=0.74, Table 12). In fact, a reciprocal 
relationship between ATPmax and walk-time was evident (ß= -209.02), indicating higher 
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ATPmax levels were associated with shorter (faster) walk-times (as hypothesized) in SEA; but 
the opposite relationship (ß=42.70) was observed in LIFE. These relationships are depicted 
graphically in Figure 6.  When age, sex, race and BMI were adjusted for, ATPmax remained 
borderline significantly associated with time to walk 400m (p=0.08) in the SEA population, but 
not in the LIFE or combined SEA and LIFE populations (p=0.12 and 0.85). In the SEA 
population, ATPmax, age, sex, race and BMI collectively explained 30% of the variance in time 
to walk 400m (Table 12).  
ATPmax was also examined across quartiles of walk-time (Table 13). In contrast to the 
linear regression models, a test for trend in ATPmax across quartiles walk-time was not 
significant in SEA (p=0.16), LIFE (p=0.40) or combined (p=0.48). However, when examining 
mean ATPmax across quartiles in the SEA population, the trend of increasing ATPmax with 
faster walk-time is evident, with the exception of those in the second fastest quartile having the 
highest ATPmax. Similarly, in LIFE, the trend of increasing ATPmax with faster walk-time is 
also evident; however, the slowest quartile of walk-time actually had second highest ATPmax 
levels on average (Table 13). These relationships are also presented graphically in Figure 7.  
The relationship between ATPmax was very different in the SEA compared to the LIFE 
population (Table 12). Either a protocol difference or study effect is unlikely, since identical 
protocols were used and the participants were seen in the same research clinic. MRS scans were 
also conducted by the same technician and in the same magnet for both studies. Additionally, 
tests were excluded if in adequate PCr breakdown or too low pH levels were observed. However, 
the drastically different results may be attributable to confounders concerning participant 
characteristics present in the LIFE but not SEA cohort.  
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In order to gain further insight into why the relationship between ATPmax and time to 
walk 400m was drastically different in the LIFE compared to SEA population, we compared 
those LIFE participants with the unexpected relationship of being in the highest two quartiles of 
ATPmax and the lowest two quartiles of walk-time to those in both the highest two quartiles of 
ATPmax and walk-time (Table 14). LIFE participants in the highest two quartiles of ATPmax 
and lowest two quartiles of walk-time reported a significantly higher proportion of discomfort 
following the 400m walk compared to the rest of the LIFE participants (87.5% vs. 21.4%., p 
=0.01) and those in both the highest two quartiles of ATPmax and walk-time (87.5% vs. 20.0%, 
p=0.02).  
Models stratified by experiencing or not experiencing discomfort at the end of the walk, 
by study and in combination, can be found in Table 15. In SEA participants without discomfort, 
ATPmax was borderline associated with time to walk 400m (p=0.06), but not in LIFE 
participants (p=0.27). However, in the LIFE participants not experiencing discomfort higher 
ATPmax levels were related to shorter walk-times (ß=-127.38, Table 15), compared to the entire 
LIFE population (ß=42.70, Table 13) and those experiencing discomfort (ß=113.11, Table 15) 
where ATPmax was associated with longer walk-times. These relationships are depicted 
graphically in Figure 8. This is important, because we hypothesized that a higher ATPmax would 
be associated with a shorter (faster) walk-time. Additionally, in the SEA and LIFE combined 
population, higher levels of ATPmax were significantly related to shorter walk-times (ß=-160.02, 
p=0.04). After adjusting for age, race, sex, BMI and study cohort, higher levels of ATPmax 
remained borderline significantly related to shorter walk-times (ß=-132.98, p=0.07), in those 
without discomfort. In both the LIFE participants experiencing discomfort and in the combined 
SEA and LIFE population experiencing discomfort, ATPmax was not significantly related to 
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time to walk 400m. In fact, in the LIFE participants experiencing discomfort, higher levels of 
ATPmax were associated with slower walk times (ß=113.11, p=0.12). 
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Table 11. Baseline Characteristics by Study and in Combination 
 SEA-Pilot (N=30) 
Mean (SD) or N (%) 
LIFE (n=36) 
Mean (SD) or N (%) 
Combined (n=66) 
Mean (SD) or N (%) 
Age, yrs 78.5 (5.0) 76.5 (5.5) 77.6 (5.3) 
Sex , female 14 (46.7)* 29 (78.4)* 43 (64.2) 
Race, white 16 (93.3)* 17 (46.0)* 45 (67.2) 
BMI, kg/m2 25.9 (2.7)* 30.8 (5.2)* 28.6 (4.9) 
Smoker Current/Former 10 (33.3) 11 (29.7) 21 (31.3) 
Alcohol Intake, 6+ 
drinks•week-1 8 (27.7)* 2 (5.4)* 10 (14.9) 
How often Felt Tired, 
some or more 7 (23.3)* 24 (64.9)* 31 (46.3) 
Diabetes, yes 1 (3.33)* 10 (27.0)* 11 (16.4) 
History of PAD 0 (0) 0 (0) 0 (0) 
History of CHF 1 (3.3) 1 (2.7) 2 (3.0) 
History of MI 3 (10.0) 1 (2.7) 4 (6.0) 
History of COPD 1 (3.3) 4 (10.8) 5 (7.5) 
History of Arthritis 11 (28.9) 9 (23.7)  
History of Cancer 16 (53.3)* 9 (24.3)* 25 (37.3) 
Health Rating, Fair or 
worse 2 (6.7) 4 (10.8) 6 (9.0) 
Sedentary Activity, 
min•day-1 685.3 (123.3)* 627.0 (110.1)* 654.1 (118.5) 
Light Activity, min•day-1 245.8 (70.9)* 204.8 (66.2)* 223.0 (71.2) 
Moderate Activity, 
min•day-1 71.2 (66.5)* 1.5 (2.0)* 34.1 (57.2) 
All  Activity, min•day-1 320.9 (104.4)* 204.3 (66.6)* 259.0 (103.9) 
SPPB, 0-12 10.9 (1.4)* 7.9 (1.2)* 9.2 (2.0) 
5 Chair-Stand Time, s 11.4 (3.3)* 16.7 (5.8)* 14.3 (5.4) 
Gait Speed, , m•s-1 1.2 (0.2)* 0.8 (0.2)* 1.0 (0.3) 
Time to Walk 400m, s 343.8 (65.5)* 467.5 (107.1)* 410.3 (108.0) 
Discomfort at End of 
400m Walk, yes 5 (17.2) 13 (36.1) 18 (27.7) 
ATPmax,  mM•s-1 0.52 (0.13) 0.54 (0.14) 0.53 (0.14) 
*between group difference at p<0.05    
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Table 12. Association between ATPmax and Time to Walk 400 meters by Study and in Combination 
Model Beta SE STB p-value Model R2 
SEA Only - Unadjusted  -209.02 82.79 -0.43 0.02 0.19 
SEA Only - Adjusted for age, race, sex and 
BMI -176.96 95.29 -0.37 0.08 0.30 
      
LIFE Only - Unadjusted  42.70 128.69 0.06 0.74 0.003 
LIFE Only - Adjusted for age, race, sex and 
BMI 168.40 106.56 022 0.12 0.44 
      
Combined, Unadjusted*  -65.31 82.0 -0.08 0.43 0.32 
Combined - Adjusted for age, race, sex and 
BMI*  -14.73 76.90 -0.02 0.85 0.46 
*adjusted for study      
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Table 13. Mean 400m Walk-time by Quartiles of ATPmax – SEA/LIFE Combined 
ATPmax Quartile (n) 400m Walk-Time 
Standard 
Error 
F-Test for 
Trend  
(p-value) 
SEA 
  
0.22 
Lowest ATPmax (8) 361.9 22.5  
3rd Highest ATPmax (6) 368.2 26.0  
2nd Highest ATPmax (8) 344.6 22.5  
Highest ATPmax (7) 301.0 24.0  
LIFE 
  
0.82 
Lowest ATPmax (10) 444.6 34.6  
3rd Highest ATPmax (8) 491.8 38.7  
2nd Highest ATPmax (9) 469.3 36.5  
Highest ATPmax (9) 454.9 36.5  
Combined 
  
0.19 
Lowest ATPmax (17) 383.5 25.8  
3rd Highest ATPmax (16) 457.1 26.6  
2nd Fastest Walk-time (16) 414.5 26.6  
Fastest Walk-time (16) 387.6 26.6  
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Table 14. Comparison of LIFE participants in Highest two Quartiles of ATPmax and Slowest two 
Quartiles of 400m Walk-Time with those in Highest two Quartiles of both ATPmax and 400m Walk-
Time 
 
 
High ATPmax and 
Slower Walk-time 
(n=8) 
High ATPmax and 
Faster Walk-time 
(n=10) 
P-value 
Age, yrs 74.9 (6.2) 76.5 (5.8) 0.49 
Sex , female 8 (100.00)* 5 (50.0)* 0.04 
Race, white 3 (37.5) 5 (50.0) 0.66 
BMI, kg/m2 32.8 (5.9) 29.1 (4.6) 0.14* 
Smoking Status, Current/Former 0 (0.0) 4 (40.0) 0.09 
Alcohol Intake, 6+ drinks/week 0 (0.0) 1 (10.0) >0.99 
Tired, some or more 5 (62.5) 8 (80.0) 0.61 
Diabetes 1 (12.5) 6 (60.0) 0.07* 
Dr. for Arthritis last 6-months, yes 2 (25.0) 2 (11.1) >0.99 
Muscle/Joint  Stiffness last 6-
months,yes 7 (87.5)* 2 (20.0)* 0.02* 
Muscle Strain/Soreness last 6-
months,yes 4 (50.0)* 2 (20.0)* 0.32 
Foot pain last 6-months, yes 2 (25.0) 2 (20.0) >0.99 
History of PAD 0 (0.0) 0 (0) >0.99 
History of CHF 0 (0.0) 0 (0.0) >0.99 
History of MI 0 (0.0) 1 (10.0) >0.99 
History of COPD 0 (0.0) 0 (0.0) 0.55 
History of Cancer (non skin) 0 (0.0)* 2 (20.0)  0.48 
Health Rating, Poor/V Poor/Fair 0 (0.0) 3 (30.0) 0.22 
Minutes of Mod PA 1.3 (1.5) 1.7 (1.5) 0.29 
Minutes of Light PA 223.2 (53.9) 195.1 (78.4) 0.33 
Minutes of Sed. PA 591.4 (47.8) 639.0 (124.2) 0.25 
SPPB, 0-12 7.4 (2.1) 8.4 (0.5) 0.37 
5 Chair-Stand Time, s 22.9 (9.1)* 14.3 (3.8)* 0.09*  
Unable to do 5 Chair Stands 1 (12.5) 2 (20.0) >0.99 
Gait Speed, m/s 0.77 (0.18) 0.91 (0.19) 0.28 
Time to Walk 400m, s 542.4 (142.2) 398.0 (34.2) 0.003 
Discomfort at End of 400m Walk, 
yes 7 (87.5)* 2 (20.0)* 0.02* 
ATPmax, mM ATP/s 0.65 (0.13, 0.51 - 0.90) 0.65 (0.10, 0.54 - 0.84) >0.99 
*between group difference at p<0.05 
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Table 15. Association between ATPmax and time to Walk 400 meters by study and in Combination 
Stratified by Discomfort at the end of the 400m Walk 
 
Model Beta SE STB p-value 
Model 
R2 
In those without Discomfort      
SEA Only - Unadjusted  -194.60 99.28 -0.39 0.06 0.15 
SEA Only - Adjusted for age, race, sex and BMI -185.52 117.11 -0.37 0.13 0.26 
      
LIFE Only - Unadjusted  -127.38 112.47 -0.24 0.27 0.06 
LIFE Only - Adjusted for age, race, sex and 
BMI -75.85 125.30 -0.14 0.55 0.34 
      
Combined, Unadjusted*  -160.03  74.32  -0.26  0.04  0.37  
Combined - Adjusted for age, race, sex and 
BMI*  
-132.98  72.67  -0.22  0.07  0.47  
      
In those with Discomfort      
SEA Only - Unadjusted  -340.02 183.16 -0.73 0.16 0.53 
SEA Only - Adjusted for age, race, sex and BMI -671.31 0.0 -1.44 <0.01 1.0 
      
LIFE Only - Unadjusted  135.03 174.44 0.24 0.46 0.06 
LIFE Only - Adjusted for age, race, sex and 
BMI 195.86 159.10 0.23 0.21 0.61 
      
Combined, Unadjusted*  -18.94 213.48 -0.02 0.93 0.32 
Combined - Adjusted for age, race, sex and 
BMI*  184.37 156.43 0.20 0.26 0.77 
*adjusted for study      
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A.  
B.  
C.  
Figure 6. Relationship between ATPmax and 400m Walk in SEA (A), LIFE (B) and Combined (C) 
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A.  
B.  
C.  
Figure 7. 400m Walk-time across Quartile of ATPmax in SEA (A), LIFE (B) and Combined (C) 
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A.  
B.  
Figure 8. Relationship between ATPmax and Time to Walk 400m in those in LIFE without 
discomfort (A) and with Discomfort (B) at the End of the Walk 
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3.4 DISCUSSION 
We demonstrated that the relationship between ATPmax and walking performance in older 
adults varies by physical function and walking ability. This study was designed to extend and 
expand upon previous work from our group showing that functional oxidative capacity of 
mitochondria present in the quadriceps (ATPmax) was significantly associated with usual 
walking speed over a 400m in higher functioning, physical active older adults (SEA study) 314. 
Contrary to our hypotheses ATPmax was not associated with time to walk 400m in neither the 
LIFE population nor the combined SEA and LIFE population (Table 12 and Figure 6). Coen et 
al. showed in the SEA study, that ATPmax was significantly associated with walking speed 
during the 400m walk314. This is shown in a slightly different manner in Table 12 and Figure 6, 
Panel A.   
 These results conflict with previous studies in addition to the work conducted by Coen et 
al. For example, a study conducted by Bourdel-Marchasson et al312 showed that shorter half-time 
for PCr recovery (higher mitochondrial function), measured by 31P MRS, was related to shorter 
times to complete a modified get-up and go-test in hospitalized and community dwelling older 
adults. Similarly, a study conducted in PAD patients showed that higher mitochondrial ATP 
production rate measured in isolated mitochondria obtained from the gastrocnemius medialis 
muscle via biopsy was related to a longer duration of time walked during a maximal treadmill 
test313.  However, both of these studies measured mitochondrial function in the gastrocnemius 
muscle, whereas the current study used the quadriceps. Additionally, walking performance was 
measured differently in each of the three studies. Although these are important differences, the 
drastically different results observed in the current analyses are unlikely attributable to them.  
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Since identical protocols, MR magnets, technicians and MR spectroscopy analysts were 
used for the LIFE and SEA studies, we hypothesized that confounding characteristics were 
present in the LIFE cohort. To indentify these potential confounding factors, we examined those 
with the unexpected relationship of high ATPmax and slow walk-times in comparison to those 
with high ATPmax and faster walk times. Since a significantly higher proportion of those with 
higher ATPmax and slower walk times reported being in discomfort at the end of the 400m walk, 
we examined models stratified by discomfort status. In LIFE participants not reporting 
discomfort at the end of the walk, ATPmax was not statistically significantly associated with 
walk-time. However, interestingly, the direction of the relationship between ATPmax and time to 
walk 400m was reversed, indicating higher ATPmax was associated with faster walk-times  in 
these individuals. This is the opposite relationship that was observed in the entire LIFE cohort 
and those in LIFE experiencing discomfort. In the SEA and LIFE combined population without 
discomfort, higher levels of ATPmax were significantly related to shorter walk-times. After 
adjusting for age, race, sex, BMI and study, higher levels of ATPmax remained borderline 
significantly related to shorter walk-times in the combined population not experiencing 
discomfort.  
Interestingly, the relationship between ATPmax and time to walk 400m was similar in 
those SEA participants both with and without discomfort at the end of the walk. This is in 
obvious contrast to the LIFE population. The combination of being lower functioning, sedentary 
and obese may affect the relationship between ATPmax and walk-time in those experiencing 
discomfort at the end of the walk. That is, these characteristics, along with the discomfort, are 
resulting in slower walking speeds than ATPmax would predict; meaning that the LIFE 
participants are not physically robust enough to overcome their discomfort in order to continue to 
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ambulate at their preferred pace. In contrast, the reason ATPmax is related to time to walk 400m 
in SEA participants with discomfort and not LIFE may have to do with the SEA participants 
being physically robust enough to overcome their discomfort and walk at their preferred pace. 
Thus, oxidative capacity of the mitochondria present in the quadriceps (ATPmax) is a limiting 
factor in these SEA participants, but not in LIFE participants with discomfort. We then compared 
the characteristics of those experiencing discomfort in SEA to those experiencing discomfort in 
LIFE and the data presented seem to support this hypothesis, as participants in LIFE with 
discomfort had slower 4m gait-speeds, slower 400m walk-times, higher BMI (not statistically 
significant, but clinically significant) lower SPPB score and lower levels of moderate PA.  
To our knowledge, this is the only study to have examined mitochondrial function in 
older adults with and without discomfort during an objective walking test. This is a novel and 
important finding. The current study supports the hypothesis that mitochondrial function is 
related to physical function in older adults and expands upon previous work in this area312-314. 
Specifically, this study suggests that declines in mitochondrial function may be an early marker 
of functional decline in high functioning older adults or older adults able to walk a longer 
distance without discomfort. Thus, preserving mitochondrial may be particularly effective in 
preventing declines in physical function and physical or mobility disability in older adults who 
are still functionally adept, or beginning to decline functionally, but are still able to walk a 
quarter of a mile (400m) without experiencing discomfort.   
We have several possible explanations for why ATPmax was significantly related to time 
to walk 400m in those without discomfort after the walk, but in neither those experiencing 
discomfort in LIFE, nor in the entire SEA and LIFE cohort. First, the presence of discomfort 
during the walk may have caused participants to slow down for reasons unrelated to oxidative 
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capacity of skeletal muscle. Higher mitochondrial energy production may not have been enough 
to overcome physical discomfort during the test.  Joint impairments374, arthritis65,375, knee 
pain376, back pain377 and bodily pain378 are associated with slower walking speed and/or physical 
disability in older adults. Likewise, those reporting dizziness or lightheadedness likely slowed 
down during the walk for reasons unrelated to lower mitochondrial function. Again, these pain 
symptoms could have resulted in slower walk-times, “overriding” any benefit of higher oxidative 
capacity or mitochondrial energy production of the quadriceps.  
Secondly, we were lacking mitochondrial function data from biopsy and a measure of 
oxygen delivery to the quadriceps. In the study conducted by Coen et al, from the SEA study, 
mitochondrial efficiency was calculated as the ratio of functional, in vivo mitochondrial energy 
production from 31P MRS, over maximal mitochondrial function measured in mitochondria 
isolated from muscle fibers extracted from the quadriceps via muscle biopsy. Coen et al. also 
showed that mitochondrial efficiency (ATPmax/state 3 respiration) was related usual walking-
speed independent of aerobic capacity (VO2peak). The LIFE ancillary study did not take muscle 
biopsies. Lower mitochondrial efficiency, due inner mitochondrial membrane or electron 
transport chain impairments, may be related to walking speed in lower functioning older adults 
(LIFE) or older adults with a wide-range of function (LIFE and SEA combined).  Oxygen 
delivery to skeletal muscle is also crucial for mitochondrial energy production. We did not obtain 
a measure of oxygen delivery and it is possible that having a measure of O2 delivery and 
calculating the ratio of oxygen delivered to energy produced may be more related to walking 
speed than ATPmax. However, in the Coen et al. study state 3 respiration multiplied by quad 
volume explained about  33% of the variance in VO2 peak, which is the about the amount of 
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oxygen consumption the quadriceps has been shown to contribute; this suggests a lack of 02 
delivery impairment379. 
Finally, it is plausible that those with both higher levels of ATPmax and slower walk 
times are less biomechanically efficient than compared to other participants. Meaning they are 
producing more energy (ATP) to do less work; for example, producing more energy but walking 
more slowly. This hypothesis seems to be supported by the data presented in this study. First, in 
the LIFE population, those in the slowest quartile of walk-time also had the second high levels of 
ATPmax. Additionally, when we examined the relationship between ATPmax and walk-time in 
those reporting no discomfort at the end of the walk in the combined SEA and LIFE cohort, 
ATPmax was significantly related to walk-time and was not in the entire cohort. Additionally, 
higher levels of ATPmax were actually associated with slower walk-times in LIFE participants 
experiencing discomfort. These findings seem to support the hypothesis that the LIFE 
participants, due to being functionally limited, more obese, more sedentary and experiencing 
more discomfort at the end of the walking test were walking less biomechanically efficient. 
Therefore higher ATPmax levels may not have been associated with shorter walk-times because 
these participants were producing similar or larger amounts of ATP to do less work. We were 
able to account for some of this by eliminating those reporting discomfort after the walk.  
Discomfort during walk the walk resulting in slower walk-times than ATPmax would 
predict may, in part, explain why ATPmax was related to time to walk 400m in higher 
functioning, active SEA participants, but not in the lower functioning, sedentary LIFE 
participants nor the combined LIFE and SEA cohort. The two main theories of human 
ambulating, the six determinants of gait380 and the inverted pendulum theories both center around 
the idea that human gait is designed to move the body, or center of mass, in the most energy 
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efficient manner possible381,382. Alterations to normal gait, in terms of step-length, frequency and 
width may result in a less biomechanically efficient gait382. These alterations may be caused by a 
number of factors including joint pain, obesity and unsteadiness. Further studies designed to 
measure gait characteristics and efficiency, and how they affect and/or modify the relationship 
between ATPmax and walking-speed are needed. 
This study has numerous strengths. This study is that this is the largest study, to our 
knowledge, to examine the relationship between skeletal muscle mitochondrial energetics and 
walking performance in older adults. This study also examined this relationship in an older adult 
population with a wide-range of functional abilities, and also in a large number of both men and 
women and white and African Americans. The noninvasive and direct measure of 31P MRS was 
used to measure mitochondrial energy production in vivo. This technology involves little 
participant burden, whereas the traditional method of muscle needle biopsy is highly invasive, 
induces considerable participant burden and must be performed by a physician. Additionally, 
mitochondrial measurements using biopsy may not accurately reflect actual mitochondrial 
energy production in the living human body whereas MRS is a direct measure of in-vivo MEP. 
Also, physical function was measured objectively using the performance measure of time to walk 
400m. This study also has several limitations. The participants come from two separate studies; 
however, the primary outcome and predictor were identical. Also, study cohort was adjusted for 
in the combined multivariable regression models. Several of the limitations have been discussed 
previously, such as the lack of biopsy measures to calculate P/O and the lack of muscle mass 
quantification. Additionally, we were lacking a measure of muscle mass. Muscle mass may be a 
key “missing piece” from these analyses. For example, the LIFE participants have similar 
mitochondrial function to the SEA participants but this may not be resulting in faster walking 
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speeds due to lack of muscle mass to produce and utilize the ATP. Conley et al. have shown that 
ATPmax*muscle volume is closely associated with VO2peak379. Therefore, the reason ATPmax 
was related to time to walk 400m in higher functioning, active SEA participants, and not in the 
lower functioning, sedentary LIFE participants nor in the combined LIFE and SEA cohort may 
be due to differences in muscle mass between the SEA and LIFE participants. Finally, although 
this is the largest study of its kind to our knowledge, there were still a relatively small number of 
participants included.  
In summary, ATPmax (functional oxidative capacity of the quadriceps) was related to 
time to walk 400m in higher functioning, active SEA participants, but not in the lower 
functioning, sedentary LIFE participants, nor the combined LIFE and SEA cohort. However, 
when those reporting no discomfort at the end of the walk were examined separately, ATPmax 
was a significant predictor of walk-time the combined SEA and LIFE cohort. This suggests that 
oxidative capacity of skeletal muscle mitochondria limit walking speed in higher function older 
adults and functionally impaired older adults able to walk 400m without experiencing 
discomfort. Additionally, since both cohorts had similar mitochondrial function, this may suggest 
that lower functioning sedentary older adults, are less biomechanically efficient and production 
more energy to do less work, than higher functioning, active older adults.  
In conclusion, this study provides important novel insight into the effects of skeletal 
muscle mitochondrial function on walking performance in older adults. Specifically, 
mitochondrial dysfunction (impaired energy production) may be a marker of early functional 
decline in higher functioning older adults or older adults able to walker a longer distance without 
discomfort. Interventions, such as resistance and/or aerobic training, specifically designed to 
prevent mitochondrial dysfunction or promote mitochondrial energy production in aged skeletal 
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muscle may be particularly effective in preventing early declines in physical function in older 
adults. Larger studies examining mitochondrial energetics in older adults with wide ages (e.g. 
aged 50-85+), mitochondrial function and physical abilities are needed. These studies should be 
adequately powered to measure subgroups, such as high and low functioning, normal and 
abnormal gait and high and low muscle mass. 
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4.0  MITOCHONDRIAL FUNCTION IS RELATED TO FATIGABILITY IN OLDER 
ADULTS 
Fatigue is primarily considered an energy disorder and the capacity for oxidative 
phosphorylation in skeletal muscle and mitochondrial function has been shown to decrease 
significantly with age. Thus it has been hypothesized that age-related decreases in mitochondrial 
function may contribute to higher levels of fatigability in older adults. The relationship between 
fatigability, fatigue referenced to activities of specific intensities and durations, and 
mitochondrial function was examined in the Study of Energy and Aging-Pilot (N=30).  
Fatigability was defined as Rating of Perceived Exertion (RPE) at the end of a 5-min treadmill 
walk at 0.67m/s at 0% grade. Phosphocreatine recovery in the quadriceps was measured 
following an exercise-bout using 31P magnetic resonance spectroscopy and images of the 
quadriceps were captured and used to calculate quadriceps volume. ATPmax (mM ATP/s) and 
oxidative capacity of the quadriceps (ATPmax*Quadriceps Volume) were calculated. Maximal 
aerobic capacity (VO2 peak) was measured during a modified Balke protocol. Participants were 
78.5 ±5.0 years of age, 46.7% female, 93.3% white, BMI of 25.9±2.7kg/m2 and usual gait-speed 
of 1.2±0.2. ATPmax*quadriceps volume was 162.61mM ATP/s lower (p=0.03) in those with 
high (RPE 10) vs. low (RPE ≤9) fatigability. ATPmax 0.08mM ATP/s lower in those with high 
vs. low fatigability, p=0.09. Participants with high fatigability reached a significantly higher 
proportion of their VO2 peak during the treadmill walk compared to those with low fatigability 
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(58.7±19.4 vs. 44.9±13.2%, p<0.05). After adjustment for age and sex, higher ATPmax was 
associated with lower odds (OR: 0.34, 95% CI: 0.11-1.01, p=0.05) of having high fatigability. 
Similarly, ATPmax*quadriceps volume was associated with lower odds (OR:0.39, 95% CI:0.16-
0.96, p=0.04) of having high fatigability. Adjusting for age and sex attenuates this to borderline 
significance (OR:0.37, 95% CI:0.13-1.10, p=0.07). These relationships were attenuated when 
adjusting for either physical activity or VO2 peak. Decreased physical activity likely contributes 
to both lower mitochondrial function and higher fatigability. Mitochondrial function is one of the 
two primary components comprising peak VO2 peak. Therefore mitochondrial dysfunction, 
perhaps by contributing to lower VO2 peak, may lead to the onset of higher levels of fatigability 
in older adults.  
4.1 INTRODUCTION 
Fatigue is primarily considered an energy disorder, thus it has been hypothesized that age-related 
decreases in mitochondrial function may contribute to higher levels of fatigability in older 
adults11,12. The capacity for oxidative phosphorylation in skeletal muscle and mitochondrial 
function has been shown to decrease significantly with age, mainly due to mutations and/or 
deletions to mtDNA from prolonged exposure to reactive oxygen species236,241. Diseases 
involving mutations/deletions to mtDNA result in increased levels of fatigability and exercise 
intolerance311. Similarly, age induced mitochondrial dysfunction may contribute to age-related 
increases in fatigability. Additionally, VO2 peak has also been shown to decrease significantly 
with age independent of muscle loss and decreases in physical activity levels231. The ability of 
skeletal muscle mitochondrial to produce ATP with the oxygen delivered to them via the 
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cardiorespiratory system is one of two major components comprising V02 peak. Decreased VO2 
peak is one of the hallmark manifestations of mitochondrial disorders345,346. Thus, mitochondrial 
dysfunction may contribute to higher levels of fatigability via lower aerobic capacity due partly 
to decreases in mitochondrial energy production. A schematic illustration of this relationship can 
be found in Figure 9. 
Fatigue is a common complaint among older adults and a large proportion cannot be 
attributed to underlying diseases9,10. Research has also shown that fatigue is significantly related 
to physical function and disability, independent of disease status8. Therefore fatigue is an 
independent risk factor for functional decline and physical disability and is present in the 
disablement pathway. Recently, it has been suggested that fatigability, in lieu of global fatigue, 
should be measured in older adults12. Fatigability is fatigue referenced to a specific activity of a 
specific intensity and duration. Measuring fatigability provides better insight into the degree to 
which an individual may be limited functionally due to fatigue. Preventing or lowering fatigue 
levels in older adults may aid in preventing age-related declines in physical function and physical 
disability. In order to decrease age-related increases in fatigability, it is important for researchers 
to better understand its etiology. A recent focused on idiopathic fatigue and fatigue and 
fatigability in older adults have called for research aimed to reveal underlying causes of 
unexplained and increased fatigability11. 
 Higher levels of fatigability may cause older individuals to significantly decrease their 
activity levels330, increasing the risk of functional impairment and physical disability. In order to 
design interventions and treatments to lower fatigability levels, it is imperative to gain insight to 
its underlying causes. The research described in this paper aimed to determine if oxidative 
capacity of mitochondria present in the quadriceps (ATPmax) and oxidative capacity of the 
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quadriceps (ATPmax*muscle volume), measured by 31P MRS, is related to higher levels of 
fatigability, following a standardized physical performance test (Simonsick, et al., in press). 
Additionally, it has recently been shown by our group that mitochondrial efficiency (P/O, 
ATPmax/ State 3 respiration), which is a ratio of the amount of ATP produced in vivo over the 
maximal amount of ATP production determined by respiromerty, was related to walking speed in 
older adults314. This is a marker of energy conversion of O2 into ATP generation. The 
relationship between mitochondrial efficiency and fatigability was also examined. 
The primary hypothesis was that lower ATPmax and ATPmax*quadriceps volume would 
be associated with high levels of fatigability and that VO2 peak would mediate this relationship 
(Figure 9). Additionally, we hypothesized that objectively measured physical activity levels 
would likely explain a large proportion of the variance in the relationship between fatigability 
and mitochondrial function. The impact of physical activity levels on the relationship between 
age and mitochondrial function has been described elsewhere247. However, mitochondrial 
dysfunction may be a contributor as well as a consequence of age-related decline in physical 
activity. To our knowledge, this is the first study to examine the relationship between 
mitochondrial energy production and fatigability in older adults. 
4.2 METHODS 
4.2.1 Participants 
Participants were community-dwelling (n=37) men and women aged 70–89 years from the 
Pittsburgh, PA area. They were recruited from the Pittsburgh Claude D. Pepper Participant 
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Registry Eligibility was determined via a standardized telephone screening interview. The 
inclusion criteria were age 70–89 years; body weight less than or equal to 285 lbs. for men and 
less than or equal to 250 lbs. for women; body mass index 20–32 kg/m2; ability to walk without 
the assistance of a device or another person and free of basic activities of daily living disability. 
To be included, participants also had to have no symptomatic cardiovascular or pulmonary 
disease; no regular pain, aching, or stiffness in the legs, hips, knees, feet, or ankles when 
walking; no bilateral difficulty bending or straightening fully the knees. Finally, to be eligible, 
participants could not regularly taking Coumadin, Plavix, Aggrenox, Ticlid, or Agrylin/Xagrid. 
Exclusion criteria included a heart attack, angioplasty, or heart surgery within the past 3 months, 
or a cerebral hemorrhage within the past 6 months, stroke within the past 12 months, or chest 
pain during walking in the past 30 days. Participants also had to be able to have a magnetic 
resonance scan (able to lie still on back for 1 hour; and no metal or other implants, artificial joint 
replacements, or tattoos) They had to be able to wear the armband activity monitor (no disability 
in right arm; no swimming or water aerobics ≥ 3 times/week; and no supplemental oxygen use in 
household); and have ability to understand and sign an informed consent. The previous inclusion 
and exclusion criteria were assessed over the phone. 
 At the first clinic visit, to continue as a study enrollee, participants had to provide written 
informed consent and complete clinic visit, including the clinic questionnaire, height and weight, 
blood pressure and pulse, leg extensor strength (1-repetition maximum) and power, physical 
exam, short physical performance battery (SPPB), and the 400 meter walk. All participants 
provided written informed consent. The study was approved by the University of Pittsburgh 
Institutional Review Board. Additionally,  
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4.2.2 Clinical Examination and Measurements 
Participants were examined at the Health Studies Research Clinic at University of Pittsburgh, 
Center for Aging and Population Health. Body height (cm) was measured using a wall-mounted 
stadiometer and body weight (kg)with a standard certified calibrated scale and were used to 
calculate BMI (weight (kg)/height (m2)). Participants completed questionnaires concerning 
demographic information and self-reported medical history. History of diseases were self-report 
and phrased in the following manor: “Has a doctor ever told you that you had_____?”.  
 Object lower extremity function was measured by the Short Physical Performance 
Battery, which includes a 4m walk, chair stands and a balance. More details concerning the 
SPPB can be found elsewhere 23. Usual gait-speed was derived from the SPPB’s 4m walk. 7-day 
free living physical activity was measured objectively by the multi-sensor Sensewear™ 
(Bodymedia Pittsburgh, PA) armband. The manufacturer devolved proprietary algorithm was 
used to measure minute’s per-day of moderate intensity (≥3METs) physical activity. 
4.2.3 VO2 Peak Test  
Maximal oxygen consumption (VO2 peak) was determined by a graded treadmill exercise test383. 
A resting 12-lead electrocardiogram was conducted prior to the VO2 peak test to screen for 
cardiac arrhythmias. To ensure participant safety, continuous electrocardiogram monitoring was 
also performed during the VO2 peak test. During the test, the participant’s self-selected usual 
walking speed was used and the treadmill grade was increased by 2% every 2 minutes until 
attainment of peak volitional exhaustion. The test was terminated as per the criteria outlined in 
the American College of Sports Medicine guidelines383.   
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4.2.4 Determination of ATPmax by 31P MRS 
31P MRS measures the regeneration of phosphocreatine (PCr) after a short bout of exercise to 
characterize mitochondrial ATP production. PCr is a high energy phosphate that can be readily 
converted to ATP and vice-versa via the creatine kinase reaction (PCr + ADP H+ ↔ ATP + Cr). 
PCr is the initial full-source of skeletal muscles. It has been shown that a linear relationship links 
change in PCr with exercise to mitochondrial oxidative phosphorylation rate275,276.  Therefore, 
measuring the dynamics of the PCr shuttle provides a method to estimate muscle oxidative 
capacity in vivo156,277. Furthermore, this method has been confirmed to be a good measure of 
oxidative capacity in rodent and human studies showing that ATPmax varies in direct proportion 
to the activity of oxidative enzymes in skeletal muscle 278,279. It has also been shown to reflect 
mitochondrial content in human skeletal muscle280. The amount of ATP production from 
glycolysis has been shown to be minimal in resting skeletal muscle (<8%)237. Regardless, this 
method can tease out the amount of ATP production by glycolysis by determining the pH from 
the chemical shift of the free phosphorous peak relative to the PCr peak281. H+ ions, which 
would lower the pH, are a byproduct of glycolysis.  
Briefly, the exercise protocol took place in a typical MRI magnet (3T TIM Trio magnetic 
resonance scanner, Siemens’ Medical System). Participants laid flat on their backs with the knee 
of the right leg (unless contraindicated) supported so that the leg was slightly elevated at a ~30 
degree angle. Straps were place over the legs and a 2.5” surface RF coil tuned to 31P was placed 
over the right quadriceps. At two different points during the scan, they were asked to kick 
repeatedly as hard and as fast as they can, producing fast contractions at the highest rate possible. 
The first bout was for 30 seconds while the second was for 36 seconds. Both exercise bouts were 
followed by a 6 minute rest period. The protocol was designed to deplete PCr stores by at least 
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33-66% without lowering pH below 6.80 during the recovery period. PCr recovery rate was 
measured during this rest period. 
Phosphorus spectra was collected using a 3T TIM Trio magnetic resonance scanner 
(Siemen’s Medical System, Erlanger, Germany), this has also been described elsewhere314. A 
standard one pulse experiment was used to determine the levels of PCr, ATP, Pi, and pH 
throughout exercise and recovery. PCr, Pi, and ATP peak areas in the fully relaxed spectra were 
measured by integration using Varian VNMR 6.1C software (Varian Medical Systems, Palo 
Alto, CA). Areas of the PCr and Pi peaks were expressed relative to the ATP peak and quantified 
using a resting PCr value of 27mM as determined from biopsies of human vastus lateralis 
muscle156. Changes in PCr and Pi peak areas during the tests were analyzed as previously 
described372,373.  
Seven total participants are missing ATPmax data. Four are missing ATPmax data due to 
either inadequate PCr breakdown (<33%) or pH levels dropping too low (<6.80) during the 
recovery period. Additionally, three other participants are missing ATPmax data, one had a 
possible metal implant in their ear, one had possible metal in their eye, and one reported 
claustrophobia at their MR visit. Therefore, 30 of the 37 SEA-Pilot participants comprise the 
analytic sample used for these analyses. 
4.2.5 Determination of Muscle Size and Oxidative Capacity of the Quadriceps 
MRI was used to determine quadriceps cross-sectional area and volume according to a 
previously described method314,384. Using a 3T TIM Trio magnetic resonance scanner (Siemen’s 
Medical System), images were collected every 3cm from the hip to the thigh (15–25 slices per 
participant). The patient lay supine for imaging. The images were performed following the 
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execution of the MRS protocol. Standard stereologic techniques were used to determine the 
largest muscle cross-sectional area for the quadriceps384. Subcutaneous and intramuscular fat and 
other noncontractile tissues were excluded from the calculation of muscle contractile cross-
sectional area. Oxidative capacity of the quadriceps was calculated by multiplying the ATPmax 
(mM ATP/s) parameter by the quadriceps volume (mM ATP/s*mL).  
4.2.6 Muscle Biopsy Procedure and Preparation of Permeablized Muscle Fiber Bundles 
Percutaneous biopsies were obtained at the University of Pittsburgh’s Clinical Translational 
Research Center on a morning after an overnight fast. Participants were instructed not to perform 
physical exercise 48 hours prior to the muscle biopsy procedure. Muscle biopsy samples were 
obtained from the middle region of the musculus vastus lateralis as described previously385. 
Following the procedure, the biopsy specimen was immediately blotted dry of blood and 
interstitial fluid and dissected free of any connective tissue and intermuscular fat. A portion of 
the biopsy specimen (~10mg) was immediately placed in ice-cold BIOPS solution (10mM Ca–
EGTA buffer, 0.1M free calcium, 20mM imidazole, 20mM taurine, 50mM potassium 2-[N-
morpholino]-ethanesulfonic acid, 0.5mM dithiothreitol, 6.56mM MgCl2, 5.77mM ATP, and 
15mM phosphocreatine [PCr], pH 7.1). The individual muscle fibers in the sample were then 
gently teased apart in a petri dish containing ice-cold BIOPS solution using fine-nosed forceps 
and a dissecting microscope (Leica Microsystems, Heerbrugg, Switzerland). The fiber bundles 
were then permeabilized with saponin (2mL of 50 ug/mL saponin in BIOPS solution) for 20 
minutes at 4°C on an orbital shaker, and then washed twice for 10 minutes at 4°C with Mir05 
respiration medium (0.5mM EGTA, 3mM MgCl2·6H2O, 60mM K-lactobionate, 20mM taurine, 
10mM KH2PO4, 20mM HEPES, 110mM sucrose, and 1g/L BSA, pH 7.1) on an orbital shaker386. 
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The permeabilized muscle fiber bundles were then placed into the respiration chambers of an 
Oxygraph 2K (Oroboros Inc., Innsbruck, Austria). This procedure has been described 
elsewhere314.  
4.2.7 Mitochondrial Respiration Protocol 
Measurement of oxygen consumption in permeabilized fibers was conducted over a period of 
approximately 1 hour 40 minutes, at 37°C and in the oxygen concentration range 220–150 nmol 
O2/mL. Following the assay, the fiber bundles were recovered and dried. A dry weight was then 
determined with an analytical balance (Mettler Toledo, XS105). Steady state O2 flux for each 
respiratory state was determined and normalized to fiber bundle weight using Datlab 4 software 
(Oroboros Inc.). Further details regarding this procedure can be found elsewhere314.  
4.2.8 Determination of Fatigability and Measurement of VO2 during Test 
Fatigability level was determined following a 5-minute treadmill walking bout (steady state 
walk) at 1.5mph (.67 m/s) and at 0% grade. At the completion of the 5-minute walking bout, 
participants were asked to rate their level of perceived exertion (RPE), using the BORG scale (6-
18)341. Participants were categorized as having high fatigability if they reported an RPE ≥10 and 
as having low fatigability if they reported an RPE <10. This cut point was establish using 
empirical evidence in Baltimore Longitudinal Study of Aging showing that this threshold is 
associated with an elevated risk for functional decline (Simonsick, in press). Oxygen 
consumption (VO2), using the same equipment that was used to measure VO2 peak during, was 
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measured for the duration of the 5-minute treadmill walk. Average oxygen consumption for the 
duration of the test was calculated. 
4.2.9 Statistical Analyses 
The final analytic sample included 30 of the 37 original participants. Seven participants were 
missing the primary predictor of ATPmax for reasons discussed above. Univariate statistics, 
means and standard deviations or counts and percents where appropriate, were calculated for the 
entire cohort and for the high and low fatigability groups separately. Univariate statistics for 
predictors, covariates and other variables were compared between the high and low fatigability 
groups using t-tests, chi-squared tests and nonparametric tests where appropriate. Least squared 
means and standard errors, adjusted for age and sex, for ATPmax and ATPmax*quadriceps 
volume were also generated and compared between high and low fatigability groups. 
Multivariate logistic regression models were generated to determine the odds of having high 
fatigability associated with increases in the primary predictors of ATPmax and 
ATPmax*Quadriceps volume and Mitochondrial efficiency. Separate models for each primary 
predictor were generated. Standard deviation increases in ATPmax and ATPmax*Quadriceps 
Volume were used to generate odds ratios for ease of interpretation, as odds ratios using original 
units results in an upper limit that approached infinity. Several models for each predictor were 
examined. Model 1 was unadjusted, model 2 was adjusted for age and sex, model 3 was adjusted 
for age, sex and VO2 peak and model 4 was adjusted for age, sex and physical activity levels. In 
order to determine the relationship between quadriceps volume and fatigability level, models for 
quadriceps volume were also examined. All analyses were performed using SAS v9.3.  
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4.3 RESULTS 
4.3.1 Participant Characteristics 
Baseline demographic characteristics, medical history, physical function and mitochondrial 
function, both stratified by fatigue group and for the entire analytic sample, are described in 
Table 16. Participants were 78.5 ±5.0 years of age, 46.7% female, 93.3% white and BMI of 
25.9±2.7kg/m2. Participants had a range of physical function but were higher functioning on 
average with SPPB scores of 10.9±1.4 (range: 7.0 - 12) and usual gait-speeds of 1.2±0.2 (range: 
0.7-1.6). Similarly, participants had a wide range of aerobic capacities (fitness) with meanVO2 
peak 22.3±5.9 (range: 7.8-33.40 ml/kg/min (Table 16). Participants were also relatively healthy, 
with few having histories of PAD, CHF, MI, COPD or arthritis (Table 16); however 53.3% 
(n=16) reported a history of cancer (skin cancer included). Data concerning history of specific 
cancers were not obtained. Additionally, 27.7% (n=8) participants were current or former 
smokers and 27.7% (n=8) reported drinking 6 or more alcoholic beverages per week. Participants 
had a fairly wide range of oxidative capacity of mitochondria present in the quadriceps 
(ATPmax) and oxidative capacity of the quadriceps (ATPmax*quadriceps volume) with values 
of 0.52±0.13 mM ATP/s (range: 0.30 - 0.83) and 591.25±203.93 mM ATP/s*mL (range: 222.50 - 
965.04).  
4.3.2 Participant Characteristics by Fatigability Level 
A comparison of demographic characteristics, medical history, physical function and 
mitochondrial function between those determined to have high and low fatigability are presented 
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in Table 16.  Participants with high and low fatigability were fairly similar, except those with 
high fatigability had significantly lower moderate physical activity levels (36.8±24.5 vs. 
100.6±83.7min/day, p<0.05), lower VO2 peak’s (18.9±4.4 vs. 24.4±5.8ml/kg/min, p<0.05) and 
lower oxidative capacity of the quadriceps (493.69±203.95 vs. 656.30±181.19 mM ATP/s*mL, 
p<0.05) (Table 17) compared to those with low fatigability. ATPmax was borderline 
significantly lower in those with high fatigability compared to low fatigability (0.47± 0.12 vs. 
0.55±0.14, p=0.09, Table 17). Age and sex least squared adjusted mean ATPmax was 
significantly lower in those with high compared to low fatigability (0.46±0.03 vs. 0.56±0.03 
p=0.04). Average oxygen consumption during the steady state treadmill bout was nearly identical 
between those with high and low fatigability (10.4±1.8 vs. 10.4±1.0 ml/kg/min, p>0.99). 
However, those with high fatigability reached a significantly higher proportion of their VO2 peak 
during the steady state walk compared to those with low fatigability (58.7±19.4 vs. 44.9±13.2%, 
p<0.05, Table 17).  
A much higher proportion of those with low fatigability (44.4%, n=8) reported being a 
current or former smoker compared to those with high fatigability (16.7, n=2), but this did not 
reach statistical significance (p=0.23). Similarly, a much higher proportion of those with low 
fatigability (38.9%, n=7) reported consuming 6 or more alcoholic beverages per week compared 
to those with high fatigability (8.3%, n=1), but this also did not reach statistical significance 
(p=0.11). Finally, those with low compared to high fatigability reported significantly lower 
levels of perceived exertion following the 5 minute steady-state treadmill bout (7.9±0.9 vs. 
11.0±1.0 RPE, p<0.05). This was expected, as rating of perceived exertion (RPE) following the 5 
min steady state treadmill bout was used to categorize those as having low or high fatigability 
(Table 17). 
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4.3.3 Relationship between Fatigability and Mitochondrial Function 
Logistic regression was used to determine the odds of having high fatigability associated with 
mitochondrial function. High fatigability was 2.2 times lower (OR: 0.45, 95% CI: 0.20-1.17, 
p=0.11, Table 18) per standard deviation increase in ATPmax. After adjustment for age and sex, 
high fatigability was 2.94 times lower (OR: 0.34, 95% CI: 0.11-1.01, p=0.05, Table 18) per 
standard deviation increase in ATPmax. This relationship was completely attenuated when 
adjusting for either physical activity level or VO2 peak (Table 18). As mentioned previously, 
ATPmax was borderline significantly lower in those with high fatigability compared to low 
fatigability (0.47± 0.12 vs. 0.55±0.14, p=0.09, Table 17). A graphic comparison of ATPmax 
values between those with high and low fatigability is depicted in Figure 10.  
No relationship existed between mitochondrial efficiency and fatigability, neither 
univariately (OR: 0.67, 95% CI: 0.32-1.41, p=0.29, Table 19) nor when adjusted for age and sex 
(OR: 0.69, 95% CI: 0.31-1.53, p=0.36, Table 19). 
The odds of having high fatigability was 2.56 times (OR: 0.39, 95% CI: 0.16-0.96, 
p=0.04, Table 19) lower per standard deviation increase in oxidative capacity of the quadriceps. 
Adjusting for age and sex slightly attenuates this relationship to borderline significance (OR: 
0.37, 95% CI: 0.13-1.10, p=0.07, Table 20). Adjusting for physical activity or VO2 peak 
completely attenuates the relationship between fatigability and ATPmax*Quadriceps volume 
(Table 20). Oxidative capacity of the quadriceps by fatigability level is depicted graphically in 
Figure 11 and shows that levels of oxidative capacity of the quadriceps were significantly lower 
in those with high compared to low fatigability (p=0.04, Table 2 and Figure 11).  
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Quadriceps volume alone was not a significant predictor of fatigability, either 
univariately (OR: 0.69, 95% CI: 0.32-1.50, p=0.35, Table 21) or after adjustment for race and 
sex (OR: 1.02, 95% CI: 0.25-4.08, p=0.98, Table 21).  
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Figure 9. Conceptual Model of the Relationship between Physical activity, Mitochondrial Function, 
 Fitness and Fatigability in Older Adults 
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Table 16. Demographic Characteristic by High and Low Fatigability 
 Low Fatigability 
Group 
 (RPE ≤ 9, n=18) 
Mean (SD) or 
N (%) 
High Fatigability 
Group 
(RPE ≥ 10, n=12) 
Mean (SD) or 
 N (%) 
Entire Cohort 
(n = 30) 
Age, years 78.2 (5.3) 79.0 (4.6) 78.5 (5.0) 
Gender, % female 38.9 (7) 58.3 (7) 14 (46.7) 
Race, % white 88.9 (16) 100 (11) 16 (93.3) 
BMI 25.7 (2.6) 26.2 (3.0) 25.9 (2.7) 
Moderate Physical Activity, min/day 100.6 (83.7)* 36.8 (24.5) 71.2 (66.5) 
Smoker Current/Former 44.4 (8) 16.7 (2) 27.7 (8) 
Alcohol Intake, 6+ drinks•week-1 38.9 (7) 8.3 (1) 23.3 (7) 
Diabetes, yes 4.8 (1) 0 (0.0) 3.3 (1) 
History of PAD 0.0 (0) 0 (0.0) 0.0 (0) 
History of CHF 0.0 (0) 8.3 (1) 3.3 (1) 
History of MI 5.46 (1) 16.7 (2) 10.0 (3) 
History of COPD 0.0 (0) 8.3 (1) 3.3 (1) 
History of Arthritis 16.7 (3) 50.0 (6) 28.9 (11) 
History of Cancer 61.1 (11) 41.7 (5) 53.3 (16) 
Depressed, CESD Score >10 11.1 (2) 25.0 (3) 16.7 (5) 
Health Rating, Fair or worse 0.0 (0) 16.7 (2) 6.7 (2) 
CESD Score 6.8 (2.8) 7.7 (3.3) 7.2 (3.0) 
Usual Gait Speed, m/s 1.3 (0.2) 1.1 (0.2) 1.2 (0.2) 
SPPB Score, 0-12 10.9 (1.3) 10.8 (1.5) 10.9 (1.4) 
 *significant difference between fatigability groups, p<0.05 
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Table 17. Perceived Exertion, Aerobic Capacity, Muscle Size and Mitochondrial Function by High 
and Low Fatigability 
 
 Low Fatigability 
Group 
 (RPE ≤ 9, n=18) 
Mean (SD) 
High Fatigability 
Group 
(RPE ≥ 10, n=12) 
Mean (SD) 
Entire Cohort 
(n = 30) 
RPE at end of Steady State Walk, 6-20 7.9 (0.9)* 11.0 (1.0) 9.2 (1.8) 
VO2
 
peak, ml/kg/min 24.4 (5.8)* 18.9 (4.4) 22.3 (5.9) 
VO2 peak, ml/min  1739.0 (447.1)* 1310.8 (358.0) 1577.0 (460.2) 
Avg VO2 during Steady State Walk, 
ml/kg/min 10.4 (1.8) 10.4 (1.0) 10.4 (1.5) 
Avg VO2 during Steady State Walk, 
ml/min  738.8 (156.9) 744.3 (150.4) 741.0 (151.8) 
% of Peak VO2 Reached during Steady 
State Walk 44.9 (13.2)* 58.7 (19.4) 50.2 (16.9) 
ATPmax, mM ATP/s 0.55 (0.14) 0.47 (0.12) 0.52 (0.13) 
Quadriceps Volume, mL 1204.05 (307.91) 1081.16 (427.09) 1154.9 (358.5) 
Oxidative Capacity of the Quadriceps 
(ATPmax*Quad Volume), mM 
ATP/s*mL  
656.30 (181.19)* 493.69 (203.95) 591.3 (203.9) 
State 3 Respiration, (pmol/s*mg DW) 177.16 (79.46) 171.49 (56.10) 174.6 (68.3) 
Mitochondrial Efficiency, (mM 
ATP/s/pmol O2/s*mg DW)*1000 3.92 (2.21) 2.96 (0.88) 3.5 (1.8) 
*significant difference between fatigability groups, p<0.05 
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 Table 18. Odds of having High Fatigability as Predicted by Mitochondrial Function 
Model Odds 
Ratio 
95% Confidence 
Intervals 
Wald X
2
 
P-value 
Likelihood Ratio 
X
2
 (p-value) 
Model 1, unadjusted 0.45 0.20 – 1.17 0.11 3.06 (0.08) 
Model 2, age and sex    6.10 (0.11) 
ATPmax* 0.34 0.11 – 1.01 0.05  
Age 0.97 0.81 – 1.17 0.77  
Sex, male 0.22 0.04 – 1.36 0.10  
Model 3, Age, sex and VO2 peak  9.93 (0.04) 
ATPmax* 0.57 0.18 – 1.84 0.35  
Age 0.88 0.7 1– 1.09 0.25  
Sex, male 0.40 0.06 – 2.91 0.36  
VO2 peak, ml/kg/min 0.78 0.61 – 1.01 0.06  
Model 4, Age, sex and Physical Activity*  16.17 (0.002) 
ATPmax* 0.41 0.09 – 1.83 0.24  
Age, 5 yr 083 0.63 – 1.10 0.19  
Sex, male 0.15 0.02 – 1.37 0.09  
Physical Activity, 
min/day >3METs 0.94 0.89 – 1.00 0.04  
*per std. increase 
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Table 19. Odds of having High Fatigability as Predicted by Mitochondrial Efficiency 
Model Odds 
Ratio 
95% Confidence 
Intervals 
Wald X
2
 
P-value 
Likelihood Ratio 
X
2
 (p-value) 
Model 1, unadjusted 0.67 0.32 – 1.41 0.29 1.54 (0.22) 
Model 2, age and sex    1.93 (0.59) 
Mitochondrial 
Efficiency 0.69 0.31 – 1.53 0.36  
Age 1.04 0.84 – 1.28 0.72  
Sex, male 0.57 0.07 – 4.41 0.59  
Model 3, Age, sex and VO2 peak  12.01 (0.02) 
Mitochondrial 
Efficiency 0.33 0.08 – 1.39 0.13  
Age 0.69 0.42 – 1.13 0.13  
Sex, male 0.75 0.03 – 16.66 0.85  
VO2 peak, ml/kg/min 0.50 0.24 – 1.05 0.07  
Model 4, Age, sex and Physical Activity*  12.30 (0.02) 
Mitochondrial 
Efficiency 1.24 0.49 – 3.16 0.65  
Age, 5 yr 0.82 0.51 – 1.32 0.41  
Sex, male 0.05 <0.001 – 3.04 0.15  
Physical Activity, 
min/day >3METs 0.92 0.83 – 1.02 0.10  
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 Table 20. Odds of having High Fatigability as Predicted by ATPmax*Quadriceps Volume 
Model Odds 
Ratio 
95% Confidence 
Intervals 
Wald X
2
 
P-value 
Likelihood Ratio 
X
2
 (p-value) 
Model 1, unadjusted 0.39 0.16 – 0.96 0.04 5.02 (0.03) 
Model 2, age and sex    5.10 (0.16) 
ATPmax*Quad 
Volume* 0.37 0.13 – 1.10 0.07  
Age 0.98 0.82 – 1.16 0.77  
Sex, male 1.08 0.17 – 6.89 0.94  
Model 3, Age, sex and VO2 peak  10.64 (0.03) 
ATPmax*Quad 
Volume* 0.46 0.13 – 1.59 0.22  
Age 0.87 0.70 – 1.08 0.20  
Sex, male 1.28 0.14 – 11.86 0.83  
VO2 peak, ml/kg/min 0.77 0.59 – 0.99 0.04  
Model 4, Age, sex and Physical Activity*  15.00 (0.005) 
ATPmax*Quad 
Volume* 0.62 0.14 – 2.71 0.53  
Age, 5 yr 0.85 0.66 – 1.11 0.23  
Sex, male 0.448 0.03 – 6.74 0.56  
Physical Activity, 
min/day >3METs 0.947 0.902 – 0.995 0.03  
*per std. increase 
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Table 21. Odds of having High Fatigability as Predicted by Quad Volume 
Model Odds 
Ratio 
95% Confidence 
Intervals 
Wald X
2
 
P-value 
Likelihood Ratio 
X
2
 (p-value) 
Model 1, unadjusted 0.69 0.32 – 1.50 0.35 0.89 (0.35) 
Model 2, age and sex    1.36 (0.71) 
Quad Volume* 1.02 0.25 – 4.08 0.98  
Age 1.04 0.88 – 1.23 0.63  
Sex, male 0.43 0.03 – 6.37 0.54  
Model 3, Age, sex and VO2 peak  9.28 (0.05) 
Quad Volume* 0.63 0.12 – 3.40 0.59  
Age 0.87 0.69 – 1.09 0.22  
Sex, male 1.25 0.04 – 37.68 0.90  
VO2 peak, ml/kg/min 0.74 0.56 – 0.97 0.03  
Model 4, Age, sex and Physical Activity  15.38 (0.004) 
Quad Volume* 2.57 0.31 – 21.34 0.38  
Age, 5 yr 0.88 0.67 – 1.15 0.34  
Sex, male 0.04 <0.001 – 4.37 0.18  
Physical Activity, 
min/day >3METs 0.94 0.89 – 0.992 0.03  
*per std increase 
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 Figure 10. ATPmax by Low and High Fatigability 
  
 
 
 
 
 
 
 
 
 
 
p=0.09 
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 Figure 11. Oxidative Capacity of the Quadriceps by Low and High Fatigability 
 
 
 
 
 
 
 
p=0.04 
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4.4 DISCUSSION 
To our knowledge, this is the first study to examine the relationship between in vivo 
mitochondrial energetics and fatigability in older adults. Both functional oxidative capacity of 
mitochondria in the quadriceps (ATPmax) and oxidative capacity of the quadriceps 
(ATPmax*muscle volume) were significantly lower in older adults with higher levels of 
fatigability. This is consistent with mitochondrial disorder patients possessing higher levels of 
exercise intolerance311,344,311. This is also consistent with animal models, specifically, 
mitochondrial gene ANT1-knockout mice which are a model for chronic ATP deficiency, 
display lower exercise tolerance and higher fatigability compared to wild type342,343.  
Another important finding of this research was the fact that those with high and low 
fatigability consumed nearly identical amounts of oxygen on average during the steady state 
treadmill test. This suggests that the energy cost of walking, per kilogram of body weight, was 
similar throughout the test in both those with low and high fatigability. However, those with high 
fatigability were working significantly closer to their maximum aerobic capacities. Therefore, 
they were likely reaching the threshold where energy supply, in the form of ATP, was starting to 
diminish, and thus the body began to generate a sensation of fatigue. This phenomenon is 
described in greater detail by Alexander et al.11.  Briefly, Alexander et al. state that in some older 
adults, certain activities may approach maximum aerobic capacity (V02 peak) or energy, and then 
while performing such an activity, the brain senses this and elicits a feeling of fatigue which 
causes the individual to decrease their activity levels which then leads to decreases in fitness and 
ultimately physical function11. This hypothesis is discussed in more detail elsewhere11. The 
ability of skeletal muscle mitochondrial to produce ATP, from oxygen delivered via the 
cardiorespiratory system, is one of two major components comprising aerobic capacity (V02 
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peak). It has been shown that that mitochondrial function, measured by 31P magnetic resonance 
spectroscopy (MRS), and oxidative capacity of the quadriceps are highly related to aerobic 
capacity in older adults314,379. Additionally, decreased aerobic capacity is one of the hallmark 
symptoms exhibited by patients with mitochondrial disorders311,344 and has been shown to 
decrease with age independent of activity level and decreases in skeletal muscle mass231. Thus, 
mitochondrial dysfunction may contribute to higher levels of fatigability via lower aerobic 
capacity due partly to decreases in mitochondrial energy production. Longitudinal studies are 
needed to establish causality. 
Adjusting for physical activity completely attenuated the relationship between 
mitochondrial function and fatigability. However, this was expected, as both mitochondrial 
function and fatigability levels are closely associated with physical activity236,247. Mitochondrial 
dysfunction may be a contributor, as well as a consequence of age-related declines in physical 
activity. For example, mitochondrial dysfunction may lead to an increase in fatigability, which 
may in turn lead to a decrease in activity levels due to increased exercise intolerance. Evidence 
exists that skeletal muscle mitochondrial dysfunction activate apoptotic pathways; activation of 
these pathways may lead to nuerodegeneration and could contribute to declines in muscle mass 
with age240,248. These changes may also result in a decrease in physical activity level. Increased 
physical activity leads to an increase in mitochondrial function and energy production, even in 
aged skeletal muscle304,30. Similarly, decreasing fatigability may result in a prolonged increase in 
physical activity levels due to an increased tolerance to more activity. Longitudinal and 
intervention studies are needed to better understand how changes to mitochondrial function and 
physical activity impact each other throughout the lifespan. Interventions aimed at improving 
fatigability via improving mitochondrial function, such as specially tailored exercise programs or 
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other treatments, such as lipid replacement and antioxidant therapy, which has been shown to 
improve mitochondrial function and fatigue levels in those with CFS387 or similar treatments to 
used utilized by patients with mitochondrial myopathies311, may be affective at preventing or 
reversing increased fatigability in older adults. 
No association was observed between mitochondrial efficiency, a marker of the 
conversion of oxygen to ATP at the mitochondrial level, and fatigability. This suggests that 
inefficiency in ATP production at the mitochondrial level, possibly caused by a mitochondrial 
inner membrane impairment or electron leak in the electron transport chain, is not contributing to 
higher fatigability. Additionally, mitochondrial efficiency was not associated with VO2 peak, so 
it was unlikely to affect fatigability via our main hypothesized pathway. Thus, impairments in 
absolute mitochondrial energy production, rather than proportion of maximal mitochondrial 
energy production reached, seem to be associated with fatigability in older adults. However, 
Coen et al showed that lower mitochondrial efficiency was related to slower usual walking speed 
in the SEA cohort, independent of VO2 peak314. Additionally, lower mitochondrial efficiency 
would impair absolute energy production. Perhaps no relationship was observed due to this study 
including a small number (n=30) of higher functioning older adults. The effect of mitochondrial 
efficiency on fatigability warrants further study is a larger population of older adults with a wide 
range of physical function and fatigability levels. 
This study has numerous strengths. Mitochondrial function was measured in vivo, which 
reflects actual mitochondrial energy production in the living skeletal muscle as opposed to 
energy production measured in isolated mitochondria obtained from muscle biopsy.  Muscle 
volume was measured via the gold standard method of MRI and we were able to calculate a 
measure of oxidative capacity of the quadriceps (ATPmax*Quad Volume). Fatigability was 
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measured following a standardized performance test, eliminating any contextual and recall biases 
associated with simply asking participants how fatigued they feel after engaging in certain 
activities. Physical activity was measured objectively using a valid and reliable multisensory 
device. This study also has several limitations. Although fatigability was assessed following a 
standardized performance test, a certain degree of subjectivity and perception remained, as 
participants still had to rate their perceived exertion, as opposed to observing a deterioration in 
performance, such as slowing down due to fatigue. This population of older adults were both 
quite healthy and high functioning, thus it remains unclear whether or not mitochondrial function 
contributes to fatigability in lower functioning, more frail older adults. Finally, this study 
included a small sample (n=30) of older adults. 
In conclusion, this research provides novel evidence showing that mitochondrial 
dysfunction may be implicated in the etiologic pathway of age-related fatigability. Fatigue is a 
common complaint among older adults and has been shown to be related to functional decline8-
10. Increased levels of fatigability may cause older adults to decrease their activity levels, which 
will in turn lead to decreased fitness and ultimately functional impairments and disability. 
Understanding its etiology is vital for preventing its onset. This research suggests that 
mitochondrial dysfunction may lead to higher levels of fatigability by contributing to lower 
aerobic capacity. Physical inactivity may this initiate the process. However, improving 
mitochondrial function may improve fatigability, which may then increase physical activity due 
to an increased exercise tolerance. The causal role of mitochondrial dysfunction and lower 
aerobic capacity in age-related fatigability needs to be studied longitudinally and in a larger 
population of older adults with a variety of physical function.  
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5.0  SUMMARY AND CONCLUSIONS AND FUTURE RESEARCH 
The overall objective of this dissertation was to examine novel aspects of the disablement 
pathway related to skeletal muscle and to investigate their relationships with physical function 
and fatigability in older adults. Specifically, two aspects of skeletal muscle aging were studied, 
skeletal muscle adiposity and skeletal muscle mitochondrial function. First, I found that 
decreases to specific fat depots present in skeletal muscle and VAT following a PA+WL or 
PA+SA intervention were related to improvements in function. Second, I found that 
mitochondrial function is associated with walking performance. This relationship was complex 
in lower functioning older adults. Finally, I found that mitochondrial function is associated with 
higher fatigability levels. This work contributes to the knowledge base by filling important gaps 
regarding the effects of skeletal muscle adiposity and mitochondrial function on physical 
performance in older adults and has also generated new important questions.  
The work regarding decreases in the fat depots of IMAT, HU and VAT provides 
empirical evidence concerning the possible mechanisms by which intentional weight-loss, in 
combination with physical activity, improves physical function in older adults. To our 
knowledge this is the first study showing a direct relationship between decreases in IMAT, VAT 
and HU, following a PA+WL or PA+SA intervention, and improvements in physical function. 
Previous research has shown that weight loss in combination with physical activity improves 
function to a greater degree than either weight loss or physical activity alone. These findings 
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extend this work by showing specific mechanisms related to body composition remodeling for 
why intentional weight loss in combination with physical activity improves function. This study 
is consistent with and expands upon previous cross-sectional work showing that IMAT, VAT 
and HU are associated with worse muscle or physical performance and adverse health conditions 
that may negatively affect muscle or physical performance52,161,347,348,363. Additionally, this work 
is also consistent with and expands upon previous research showing intentional weight loss in 
adults 50-60 years of age results in a preferential loss of IMAT and VAT compared to SUBQ 
fat177. This study extends this research in two important ways. First, by showing a preferential 
loss of IMAT and VAT following intentional weight-loss and physical activity in adults aged 60 
and older; and secondly, by showing these decreases are directly associated with improvements 
in function. The direct relationship between decreases in skeletal muscle fat depots, VAT and 
improved function detected by this work unveils important information regarding the 
mechanisms by which intentional weight-loss and PA improve function in older adults. To 
advance this work, future research should examine the specific mechanisms by which decreasing 
these fat depots improve function. This will be discussed in more detail in the next section. 
The study examining the relationship between walking performance and mitochondrial 
function in older adults contributes to the field of muscle aging in a few important ways. This is 
one of two studies to have examined the relationship between walking performance and 
mitochondrial function in older adults. It is the first to illustrate the heterogeneity of age-related 
disability in regard to skeletal muscle energetics, as mitochondrial energy production was a 
limiting factor only in those higher function older adults and older adults able to walk 400m 
without discomfort and not in lower functioning older adults. This work has also led to new 
hypotheses and research questions which will be discussed below.  
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First, to summarize the results of this study, contrary to our hypotheses, oxidative 
capacity of mitochondria present in the quadriceps (ATPmax) was not associated with time to 
walk 400m in either the low functioning LIFE population or the combined SEA and LIFE 
population. This was in stark contrast to the work of Coen et al.314, who showed a significant 
relationship between ATPmax and gait-speed during the 400m walk in the higher functioning 
SEA cohort. The only other study to examine this relationship also showed a positive 
relationship between ATPmax and a modified get-up and go test312. Since identical protocols, 
MR magnets, technicians and MR spectroscopy analysts were used for the LIFE and SEA 
studies, we hypothesized that confounding characteristics were present in the LIFE cohort. 
Discomfort following the walk was identified as a possible confounding factor. This is 
biologically plausible, as discomfort during the walk could lead to slowing for reasons unrelated 
to oxidative capacity of skeletal muscle mitochondrial function. In LIFE participants without 
discomfort, ATPmax was not significantly associated with walk-time; however, interestingly, the 
direction of the relationship between ATPmax and time to walk 400m was reversed in these 
individuals (higher ATPmax associated with faster walk-times) compared to the entire LIFE 
population and those experiencing discomfort. In the SEA and LIFE combined population 
without discomfort, higher levels of ATPmax were significantly related to shorter walk-times.  
This research poses several new questions, as research regarding the effects of skeletal 
muscle mitochondrial function on physical performance in older adults is really in its infancy. 
These questions include: is skeletal muscle mitochondrial function a limiting factor in higher but 
not lower functioning older adults? If so, why? Does an interaction exist between mitochondrial 
function and gait-efficiency? The results of this study beg this question, for two reasons. First, 
those in the LIFE study, despite being lower functioning and more sedentary, had similar 
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ATPmax values compared to the higher functioning more active SEA participants. Secondly, a 
drastically different relationship between ATPmax and walking performance was observed 
between the two cohorts. We were able to explore this hypothesis to some degree by examining 
those who were experiencing discomfort at the end of the walk, and possibly walking less 
efficiently due to this discomfort separately. Another important question generated as a result of 
this research is the role of muscle mass. It is possible that those in the LIFE cohort, despite 
having similar oxidative capacity of skeletal muscle mitochondria, may have lower oxidative 
capacity of the whole quadriceps muscle due to lower muscle mass. However the LIFE 
participants had larger overall body sizes (BMI); therefore, they are likely to possess higher 
levels of leans mass. Finally, do those lower functioning individuals have too many other adverse 
health conditions unrelated to oxidative capacity of skeletal muscle, such as musculoskeletal or 
joint pain, that limit walking speed? This could very well be the case and larger studies are 
needed to answer these questions. The specific design of a future study aimed to examine these 
questions is discussed in more detail in the following section. 
The study examining the relationship between walking performance and mitochondrial 
function also illustrates the importance of selecting methods for measuring physical function in 
older adults. In general, performance based measures of function are superior to self-report, as 
they are objective measures of function and eliminate recall and perception biases. However, 
choosing the most appropriate objective measures of function in epidemiologic research is 
crucial and can have a large impact on the results and conclusions of research studies. For 
example, a usual paced 400m walk test was employed in the SEA and LIFE study. Perhaps this 
was not the best test to evaluate the physical performance of older adults with a wide-range of 
function, because the lower functioning older adults were likely working closer to their 
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maximum capacitates, where as the higher functioning older adults would not have been. We 
were unable to evaluate this directly; as a higher or maximal level test was not employed. 
Additionally, the SPPB is often used to measure physical function in older adults; however this 
test may not be appropriate if the primary predictor is more related to aerobic function, like 
mitochondrial function, as the SPPB is a more anaerobic test. Similarly, gait-speed is often 
measured over a short distance, e.g. 3 or 4 meters, perhaps gait-speed should be measured over a 
longer distance, e.g. 20m, or a longer walking test, such as the 6 minute walking test or 400m 
walk should be used if the primary predictor is more closely related to aerobic function, such as 
mitochondrial function or fatigability. Future research enrolling older adults with a wide range of 
functional abilities should employ multiple performance based tests, such as a fast and usual 
paced 400m walk. Conducting both a usual and fast paced 400m walk would allow for better 
differentiation, in terms of physical ability, specifically in higher functioning participants. 
The research described in the third paper was aimed at determining if oxidative capacity 
of mitochondria present in the quadriceps (ATPmax) and oxidative capacity of the quadriceps 
(ATPmax*muscle volume), measured by 31P MRS, is related to higher levels of fatigability, 
following a standardized physical performance test. This study showed that both functional 
oxidative capacity of mitochondria in the quadriceps (ATPmax) and oxidative capacity of the 
quadriceps (ATPmax*muscle volume) were significantly lower in older adults with higher levels 
of fatigability. To our knowledge, this is the first study to examine the relationship between in 
skeletal muscle mitochondrial energetics and fatigability in older adults.  The findings are 
consistent with studies showing that patients with mitochondrial disorders have significantly 
higher levels of exercise intolerance311,344. Another important finding shown by this research was 
the fact that those with high and low fatigability consumed nearly identical amounts of oxygen 
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on average during the steady state treadmill test. This suggests that the energy cost of walking, 
per kilogram of body weight, was similar throughout the test in both those with low and high 
fatigability. However, those with high fatigability were working significantly closer to their 
maximum aerobic capacities. The ability of skeletal muscle mitochondrial to produce ATP, from 
oxygen delivered via the cardiorespiratory system, is one of two major components comprising 
aerobic capacity (VO2 peak). Mitochondrial function, measured by 31P magnetic resonance 
spectroscopy (MRS), and oxidative capacity of the quadriceps are highly related to aerobic 
capacity in older adults314,379. Additionally, decreased aerobic capacity is one of the hallmark 
symptoms exhibited by patients with mitochondrial disorders311,344 and has been shown to 
decrease with age independent of activity level and decreases in skeletal muscle mass231. Thus, 
mitochondrial dysfunction may contribute to higher levels of fatigability via lower aerobic 
capacity due partly to decreases in mitochondrial energy production. In other words, VO2 peak 
may be a mediator in the relationship between mitochondrial function and fatigability. This is 
depicted schematically in Figure 9. The data presented in this study suggest this, as including 
VO2 peak in a model predicting fatigability with ATPmax largely attenuates this relationship. 
The results of this study can also be taken into the account with the previous study which 
examined the relationship between mitochondrial function and walking performance. Lower 
mitochondrial function may contribute to lower gait-speed due not only due the direct effect of 
lower availability of energy to skeletal muscles, but also by contributing to lower levels of 
aerobic capacity and higher levels of fatigability. A vicious cycle may exist - lower physical 
activity leading to lower VO2 peak and mitochondrial function247, then mitochondrial 
dysfunction exacerbating the declines in VO2 peak311, which leads to increased fatigability, 
which then leads to a further decrease in physical activity levels330, all of which may contribute 
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to slower walking speeds (Figure 9). Slower walking speed is associated with increased risk for 
disability25, institutionalization40 and death41, so understanding the potential mechanisms and 
etiology of age-related slowing and why some decline more than others is vital for its prevention.  
Additionally, the findings from the study examining mitochondrial function and 
fatigability can be discussed in the context of the first study examining skeletal muscle adiposity. 
This study showed that physical activity seems to target IMAT and that decreases in IMAT were 
directly associated with improvements in physical function. Thus, mitochondrial dysfunction, by 
contributing to lower levels of peak aerobic capacity, resulting in increased fatigability which 
may then cause one to decrease their activity levels, may result in an increase in IMAT. Cross-
sectional research has shown that those with higher levels of fatigability perform less physical 
activity330, but longitudinal and intervention studies are needed to determine if lowering 
fatigability increases physical activity levels in older adults. The effect of lower PA on IMAT 
has also been illustrated by a study showing that 4-weeks of single leg immobilization results in 
a significant gain in IMAT in both the calf and thigh, despite a statistically significant decrease 
in total body mass363. 
Few intervention studies have actually measured changes to fatigability in older adults. 
However, there have been some agents that show promise in lowering fatigue such as  L-
carnatine332,333, lipid replacement antioxidant therapy (specifically a dietary supplement called 
NTFactor®)334 and Yoga335. Moderate physical activity consisting of over-ground walking and 
lower extremity resistance training was ineffective at lowering fatigue; however this study did 
not measure fatigability12. Future intervention studies examining the effective of pharmaceutical 
agents, such as antioxidants and physical activity trials should measure fatigability as opposed to 
global fatigue. Intervention trials are needed to establish effective ways to improve fatigability 
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because lowering may result in a prolonged increase in activity levels due to an increase in 
exercise tolerance. The beneficial effects of increasing physical activity are abundant, well 
documented and include improvements in body composition, mitochondrial function, muscle 
performance and ultimately physical function in older adults48,175,194,301,304.  
 In conclusion, the research presented in this dissertation contributes to the field of 
preventing age-related physical disability by providing evidence implicating novel potential 
underlying causes and mechanisms of age-related declines in physical performance, namely 
skeletal muscle adiposity and skeletal muscle mitochondrial function. Sarcopenia, the loss of 
muscle mass with age, was thought to be the primary neuromuscular cause of decreasing 
mobility and physical function with age; however, longitudinal evidence suggests that decreasing 
muscle mass only modestly predicts declines in muscle performance and mobility in older 
adults83,124,369. Understanding the etiology of age-related declines in physical function and 
mobility is important, as lower function and slower gait-speed are related to increased health care 
costs, institutionalization and an increased risk for mortality6,22,25,41,44. The neuromuscular system 
is a critical component for maintaining function into old-age. This research contributes to the 
field by first, showing for the first time that decreases in skeletal muscle fat depots are directly 
associated with improvements in physical function. Secondly, this work shows that 
mitochondrial function may contribute to declines in physical performance in higher functioning 
older adults and functionally limited older adults able to walk 400m without discomfort. Finally, 
for the first time, mitochondrial dysfunction was found to contribute to increased levels of 
fatigability.  
The findings presented in this dissertation mainly pertain to higher functioning older 
adults, as those in the WELL study, despite being overweight to moderately obese, and the SEA 
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study, were high functioning. Additionally, ATPmax seemed to only be a potential limiting 
factor in the lower functioning LIFE participants able to walk without discomfort. These findings 
are still important and may be potential subclinical markers of early declining function. That is, 
those with higher levels of skeletal muscle adipose tissue and lower levels of mitochondrial 
function, although still functioning at a relatively high level, may be at greater risk for future 
functional decline compared to those with lower levels of IMAT and HU and higher 
mitochondrial function. Therefore, these may be new therapeutic targets to treat and prevent 
declining physical function in older adults who have yet to manifest functional limitations, or 
who have begun to decline physically, but can still walk longer distances without discomfort. 
Preventing declines in function in those who are still higher functioning may have large public 
health implications, as preserving function in those who are still high functioning will prevent 
the adverse effects that declining function precipitates, including lower quality of life, higher 
health care cost and risk for future disability and institutionalization. 
Finally, the most effective ways to prevent disability in older adults are unknown and it is 
likely, due to the heterogeneity of age-related disability, that different interventions will be more 
effective in certain subsets of older adults compared to others. For example, the work presented 
in this dissertation highlights this, as the second paper showed that mitochondrial function may 
be a limiting factor in high but not lowering functioning older adults. Therefore not all older 
adults will benefit from interventions, such as antioxidant therapy, specifically designed at 
promoting mitochondrial function. Similarly, weight-loss, resistance, power and endurance 
training may be more effective in certain subsets of older adults compared to others. Research 
examining the most effective dose and type of training in specific subsets of older adults is 
needed. However, it does seem clear that avoiding obesity and doing physical activity will 
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benefit most older adults, as the benefits of avoiding obesity and doing physical activity are 
widespread48,194,199,350.  
5.1.1 Directions for Future Research 
Opportunities for future research regarding skeletal muscle adiposity and mitochondrial function 
are evident as a result of this work. The biological mechanisms by which decreasing specific fat 
depots may improve physical performance remain unclear. VAT is strongly associated with 
insulin resistance independent of overall adiposity and with higher levels of proinflammatory 
cytokines52,347,348, which can negatively affect muscle performance. Therefore, decreases in VAT 
may result in improvements in metabolic and inflammatory states, which may then positively 
affect muscle and physical performance. Similarly, higher levels of IMAT and HU have been 
shown to be related to insulin resistance and the metabolic syndrome52,146,161,351; therefore, 
decreasing IMAT and HU levels may result in a more optimal metabolic state, resulting in 
improved physical performance. However, fitness level has been shown to be an important 
mediator in the relationship between mitochondrial function, insulin resistance and HU content. 
Specifically, those with the highest levels of fitness also have the highest levels of HU content, 
as it is a readily available and high energy fuel source; however, in more sedentary individuals, 
high HU content has been shown to be related to insulin resistance. Furthermore, following 
participation in a progressive exercise intervention consisting of mostly walking and stationary 
cycling, older adults showed an increase in intramyocellular fat content measured via muscle 
biopsy and a decrease in insulin resistance388. Therefore, fitness level and changes to fitness 
would be important to measure in future studies. A few recent trials conducted in younger adult 
men (age 30-65) and women (age 20–41) have shown that decreases in VAT are associated with 
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improvements in insulin resistance364 and decreases in inflammatory markers365. These studies 
did not examine how these changes affected muscle or physical performance. To our knowledge, 
the relationship between decreases in the fat depots present in skeletal muscle, IMAT and HU, 
and metabolic and inflammatory markers has not been examined. Further intervention trials are 
needed examining the specific relationships between decreases in IMAT, HU and VAT with 
changes in inflammatory and metabolic markers and how they impact physical function in older 
adults. 
Although it is an observational study, the Health ABC study would be an ideal setting to 
examine how these fat depots may affect skeletal muscle and physical performance, as CT 
images were obtained at multiple time points in a subset of participants. However, future 
intervention studies, or even completed ones with stored biospecimens, should examine changes 
in inflammatory and metabolic markers and how these changes impact physical function. 
Research is also needed regarding specific modes (e.g. aerobic vs. strength training) and doses of 
physical activity, in combination with weight-loss, to elucidate the most effective methods for 
optimizing body composition and thus improving function in adults. Again, it is likely that 
certain subsets of older adults, e.g. high and low functioning, obese and not obese, arthritic and 
not arthritic etc..., will benefit differently from specific interventions. For example, those who 
are obese would likely benefit from weight-loss to a greater degree than those who are normal 
weight. Similarly, those who are arthritic may benefit more from power training, which 
emphasizes speed at low levels of resistance, which is easier on joints than traditional resistance 
training, compared to those who are not arthritic or experiencing joint pain. Future interventions 
should examine subgroups of older adults to determine the best methods for improving function, 
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as age-related declines in function can be precipitated by a wide-variety of adverse health 
conditions.  
Further research regarding the etiology of fat depots present in skeletal muscle is also 
needed and mitochondrial dysfunction may be in the etiology pathway. Particularly, if 
mitochondria are unable to metabolize fuel, e.g. fat via beta oxidation, efficiently this may result 
in an accumulation of adipose tissue both in and surrounding skeletal muscle. Although 
longitudinal research is needed to establishing causal relationships, a logical next step would be 
to design a cross-sectional study aimed to examine the relationships between IMAT and 
intramyocellular lipid content (IMCL), mitochondrial function and insulin resistance, or fasting 
glucose levels in those with diabetes. Although CT was used to indirectly measure IMCL content 
by using muscle density in HU as a surrogate, it would be ideal to measure IMCL content by H1 
MRS, as this non-invasive technique can directly distinguish between and quantify intra and 
extracellular adipose tissue. Physical activity and fitness would be important to measure in such 
a study, due to the previously mentioned mediating effects of fitness level on the relationships 
between IMCL content, mitochondrial function and insulin resistance. In mostly sedentary 
individuals, IMCL content would be more likely to be related to lower mitochondrial function 
and higher levels of insulin resistance. Conversely, in more active individuals, higher IMCL 
levels would be more likely to be related to higher mitochondrial function and lower insulin 
resistance. Finally, higher IMAT levels would be more likely to be related to lower 
mitochondrial function and higher insulin resistance regardless of activity level as IMAT is not a 
fuel source. Additionally, higher IMAT levels have been shown to be correlated (unadjusted) 
with lower mitochondrial function in a study consisting of both older (75.7±1.0 years) and 
younger (27.2±1.0) adults162. However, the results of this study could have been an affect of age, 
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decreased physical activity or another confounding factor and not higher IMAT per se. The 
proposed study would provide important information regarding the relationship between IMCL 
and IMAT content, mitochondrial function and insulin resistance and could provide preliminary 
data to propose a longitudinal study to establish causal relationships.   
 Further illustrating the importance of metabolic health to muscle aging is the finding in 
the Health ABC study that older adults with type 2 diabetes, especially those undiagnosed, 
experienced significantly greater decreases in muscle mass and strength compared to non 
diabetic older adults389,390. Future work should also examine changes in muscle mass and 
performance in those with impaired fasting glucose. The biological mechanisms for why older 
adult diabetics experienced significantly greater decreases in muscle mass and strength compared 
to non diabetic older adults, but the authors suggested it may have to do with impairments to 
protein synthesis.  Mitochondrial dysfunction, as mentioned above, may also be a partial driver 
this process, as a vicious cycle precipitated by mitochondrial dysfunction has been 
suggested241,391. Specifically, mtDNA mutations, leading to mitochondrial dysfunction and 
apoptosis of muscle fibers, which in turn causes further ROS production and exposure acerbating 
mitochondrial dysfunction, may be causal to the process of sarcopenia and insulin 
resistance241,290. A longitudinal study, similar to the cross-sectional study mentioned above 
would be needed to establish empirical evidence supporting this vicious cycle hypothesis. 
The study of skeletal muscle energetics and physical performance into old age is really in 
its formative years. It is important to determine how changes in mitochondrial function 
(decreases in energy production), regardless of the underlying mechanisms, impacts physical 
function in older age needs. However, the underlying causes of mitochondrial function are 
important, especially when it comes to designing treatments and interventions to improve 
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mitochondrial function. Ultimately though, from a public health stand point, how mitochondrial 
dysfunction affects the physical abilities of older adults, differs by physical ability and the best 
methods to prevent or reverse mitochondrial dysfunction are of interest. Specifically, a larger 
study similar to the one conducted in the SEA and LIFE cohorts is needed because the SEA and 
LIFE combined study was not powered to examine subgroups, for example those experiencing or 
not experiencing discomfort following the 400m walk. Instead of being cross-sectional, a 
prospective cohort design should be employed in order to collect data at multiple time points, 
which would allow for the assessment of longitudinal relationships, temporality and causal 
associations. There would be two primary hypotheses of the aforementioned study. First, that 
mitochondrial function will be associated with walking performance in those individuals who are 
higher functioning or just beginning to decline, but lack adverse health conditions affecting their 
ability to walk normally and without pain or discomfort. Secondly, that longitudinal decline in 
mitochondrial function will be more closely associated with functional decline in those who are 
higher functioning at baseline. Secondary hypotheses would include: more mtDNA damage will 
be associated with lower mitochondrial function, higher levels of oxidative stress would be 
associated with more mtDNA damage and that lower mitochondrial function will contribute to 
declining VO2 peak.  
The population should include older ages with both a wide age range (e.g. 50 and older) 
and functional capacities in order to increase both the variability and range of ATPmax. The 
primary outcomes would be lower extremity function measured by time to complete both a fast 
and usual paced 400m walk. Incorporating both a fast and usual paced 400m walk would greatly 
eliminate any floor or ceiling effect. A portable oxygen consumption device should be utilized 
during each of the walking tests, if possible. A secondary outcome would be fitness measured by 
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a VO2 max test conducted on a cycle. Utilizing a cycle as opposed to treadmill test would allow 
participants with joint and musculoskeletal pain to complete it. Fatigability, measured using the 
method described in the third paper, would be another secondary outcome. Oxygen consumption 
should also be measured during the 5-minute treadmill bout used to determine fatigability.  
The primary predictors would be mitochondrial function, ideally from both in vivo and in 
vitro measures. Employing both in vivo and in vitro measures would allow for the quantification 
and study of a variety of mitochondrial function parameters including energy production, 
enzyme activity, protein content, mtDNA content and ROS production. Ideally, mtDNA 
sequencing would be conducted in order to measure point mutations and deletions. This would 
allow investigators to examine the role of mtDNA damage in mitochondrial dysfunction and 
whether or not this damage is due to ROS production. Other measures should include a walking 
test performed on a gait-mat or similar device able to measure specific gait-characteristics, 
muscle mass and muscle adiposity by CT or MRI and a measure of both muscle strength and 
power. These additional measures would allow investigators to answer some of the question 
posed above concerning the effects of skeletal muscle energetic on walking performance in 
subgroups of older adults with normal vs. abnormal gait and high vs. low muscle mass. A 
proposed longitudinal study similar to the one described above would be invaluable, as it would 
provide empirical evidence regarding the causal role of mitochondrial dysfunction in sarcopenia, 
insulin resistance, skeletal muscle adiposity and declining function. The role of accumulated 
damage to mtDNA and whether or not this is caused primarily by ROS exposure would also be 
able to be determined. 
It is also important to determine if improving mitochondrial function is related to 
improvements in function. Both resistance and endurance training improve mitochondrial 
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function (Table 4), however; one or the other may be more effective, or possibly a combination 
of both would be most beneficial and if so, perhaps the order of training matters. Perhaps initial 
resistance training is necessary to promote mitochondrial biogenesis and turnover and should be 
followed up with an aerobic exercise regimen to train mitochondria to produce energy more 
efficiently and rapidly. Epidemiologists, exercise physiologists, and basic science researchers 
need to collaborate to design studies that can uncover information regarding both the 
mechanisms and impacts of age-related mitochondrial function and how to reverse, prevent or 
delay its onset. Specifically, a randomized controlled trial could be implemented examine the 
effects four different interventions on mitochondrial and physical function. These four 
interventions would include a group that conducts resistance training for a period of time (e.g. 6 
weeks) followed by 6-weeks of aerobic training, another that conducts the aerobic training first 
followed by a period of only resistance training and finally, the two remaining groups would 
conduct either only aerobic or resistance training for the entire duration of 12-weeks. Power 
training, which emphasizes speed at low levels of resistance, could also be utilized in older 
adults with joint or other pain issues preventing their participation in a traditional resistance 
training regimen. The outcomes of such a proposed study would be mitochondrial function, 
muscle performance, aerobic capacity (VO2 peak) and physical function measured using the 
400m walk test. 
Longitudinal studies are also needed to examine the possible causal role of mitochondrial 
function in increased levels of age-related fatigability. Fatigue is a common complaint among 
older adults and has been shown to be related to functional decline independent of disease status. 
Thus, it is important to study this relationship in longitudinally and in a larger population of 
older adults. Interventions aimed at improving fatigability via improving mitochondrial function, 
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such as specially tailored exercise programs or lipid replacement and antioxidant therapy, which 
has been shown to improve mitochondrial function and fatigue levels in those with CFS387 or 
similar treatments to those utilized by patients with mitochondrial myopathies311, may be 
effective at preventing or reversing increased fatigability in older adults. Theoretically, lowering 
fatigability may result in an increase in physical activity levels due an individual being able to 
tolerate both more frequent and intense activities. Thus, improving fatigability may result in the 
prevention of functional decline or improved function by promoting physical activity levels. 
5.2 PUBLIC HEALTH IMPACT OF THIS WORK 
In the United States, the absolute and relative number of older adults (age ≥65 years) is starting 
to rise rapidly as the baby boomers (born 1946-1964) begin to turn 65. By 2030, one in every 
five Americans (72 million) will be aged 65 and older1.  Additionally, the United States Census 
Bureau estimates that the number of US citizens age 85 and older will increase 3-fold from 5.7 
million in 2008, to 19 million by 20501. The risk for functional limitations and physical disability 
increases with age and is one of the main reasons for why the aging of the US population is a 
large public health issue2-4. In addition to increasing incidence, the prevalence of physical 
disability in older adults is also quite high. According to NHANES, 20% of those aged 60 and 
older have ADL disability, 23% have IADL disability, 30% have mobility disability and 48% 
experience functional limitations.  Physical disability is also quite expensive, as physically 
disability attributable to sarcopenia alone, in the United States in 2000, was estimated to cost 
between $11.8 billion and $26.2 billion6. Furthermore, community-dwelling older adults who are 
functional disabled or transition to being functionally disabled spend $10,000 more on healthcare 
188 
over a 2-year span compared to those who remain functionally independent5. Therefore, research 
designed to study the etiology and risk factors of age-related physical disability is vital and could 
have large public health ramifications.  
Obesity in older adults is also a large public health concern, as obesity has been shown to 
exacerbate physical disability in older adults163,164.  Furthermore, in 2010, men and woman age 
60 and older possessed the highest prevalence rates of obesity compared to any other age group, 
with rates of 42.3% and 36.6% respectively349. The first paper presented in this dissertation 
provides novel evidence concerning mechanisms, specifically decreased in skeletal muscle and 
visceral adiposity, by which weight-loss and weight-loss plus physical activity improves physical 
function in older adults. This research could prove to be very useful to clinicians and public 
health professionals. For physicians, this work provides further evidence that weight-loss in older 
adults is safe, and that targeting specific fat depots through lower extremity exercises and caloric 
restriction may be particular effective in improving physical function. More research is needed to 
determine subsets of participants that would benefit from having a detailed body composition 
exam and the cost/benefit of such exams. For public health professionals and researchers, this 
work provides information that can be used to design more effective interventions.  
The next two papers presented in this dissertation focused on the role of skeletal muscle 
mitochondrial energetics and its effect on walking performance and fatigability in older adults. 
This research is really in its infancy, as epidemiologic studies are just now beginning to explore 
the effects of mitochondrial dysfunction at the whole-body (i.e. walking performance) and 
population levels. The role of the neuromuscular system in inducing age-related declines in 
physical function is still poorly understood.  This research provides novel evidence that deficits 
in mitochondrial energy production may play a role in age-related declines in function and 
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increased fatigability levels. As previously stated, the prevalence and cost of physical disability 
in older adults is quite high. Thus, determining novel underlying causes of functional decline, 
such as mitochondrial dysfunction, is important to effectively prevent and treat physical 
disability in older adults. As mentioned previously, more research is needed to indentify subsets 
of older adults in which mitochondrial dysfunction may be particularly important and to 
determine the best methods to improve mitochondrial function in older adults.  
The prevalence of fatigue in older adults has been shown to be as high as 68%. Fatigue 
has also been shown to be an independent risk factor for functional decline and disability in older 
adults. Therefore fatigue in older populations is a significant public health issue. Furthermore, a 
majority of fatigue can be attributed to underlying diseases; however a large portion cannot 
(~30%)9. The third paper presented in this dissertation provides novel evidence implicating 
mitochondrial dysfunction as a possible underlying cause of increase fatigability levels. 
Determining non-disease related causes of increase fatigability levels in older adult in order to 
better understand its etiology and prevent or treat its onset is important.  
Treating or preventing fatigue in older adults may have large public health ramifications 
for two reasons. First, as previously stated, the prevalence of fatigue in older populations has 
been shown to be quite high. Secondly, decreasing fatigue or fatigability (exercise tolerance), 
may be very effective in increasing an individual’s level of physical activity. That is, if one can 
tolerate more activity, it is logical to think that one may be more inclined to do more activity. 
Thus, improving fatigability may result in a lasting, long-term increase in physical activity, 
which would promote mitochondrial function and optimize body composition. Cross-sectional 
research indicates that older adults wither higher levels of fatigability are less physically active, 
however longitudinal and interventions studies are needed to establish causality and to determine 
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if decreasing fatigability results in increased levels of physical activity. Finally, individuals who 
are fatigued may benefit from a light physical activity program, consisting mainly of walking 
and supplemented with lower extremity resistance or power training. In a fatigued population of 
older adults, it would be important to begin with very low levels of exercise, and then 
progressively increase the intensity and duration of activity over the course of the trail. Starting 
with low levels of activity would aid in not overburdening participants, resulting in poor 
adherence and dropouts. 
In conclusion, this research provides novel evidence regarding specific aspects of muscle 
aging, including skeletal muscle adiposity and mitochondrial dysfunction. Neuromuscular 
performance is an important component to maintain in order to preserve physical function into 
old age. In order to determine the most effective ways to prevent physical disability, 
understanding its etiology is vital. This research is important as the number of older adults is 
rising rapidly and the prevalence of physical disability in older adults is quite high and is related 
to high health care costs, lower quality of life and increase risk for mortality. The findings 
presented in this dissertation mainly pertain to higher functioning older adults. Preventing 
functional decline in higher function older adults would have a large public health impact, as it 
would keep these older adults functionally intact into older ages, avoiding the risks and 
complications that coincide with functional limitations, including further functional decline, 
higher health care costs, institutionalization and death. Mitochondrial function and skeletal 
muscle adiposity may be new therapeutic targets to treat and prevent declining physical function 
in older adults who have yet to manifest overt functional limitations, or who have begun to 
decline physically, but are still early in the disablement pathway.  
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APPENDIX: SUPPLEMENTAL TABLE 
Table 22. Comparison between those in SEA and LIFE with Discomfort at the end of 400m Walk 
SEA (n=5) 
Mean (SD) or N (%) 
LIFE (n=13) 
Mean (SD) or N (%) 
Age, yrs 78.8 (7.2) 75.4 (5.6) 
Sex , female 3 (60.0)* 13 (100.0)* 
Race, white 5 (100.0)* 5 (38.5)* 
BMI, kg/m2 25.8 (3.1) 30.5 (6.1) 
SPPB, 0-12 11.0 (1.7)* 7.7 (1.8)* 
5 Chair-Stand Time, s 11.9 (5.5)** 18.4 (7.5)** 
Gait Speed, m/s 1.3 (0.2)* 0.79 (0.18)* 
Time to Walk 400m, s 344.6 (73.7)* 520.4 (133.6)* 
ATPmax, mM ATP/s 0.44 (0.16, 0.30 - 0.70)** 0.52 (0.14, 0.36 - 0.90)** 
Smoking Status, 
Current/Former 2 (40.0) 2 (15.4) 
Alcohol Intake, 6+ 
drinks/week 0 (0.0) 1 (7.7) 
How often Felt Tired, 
some or more 3 (60.0) 10 (76.9) 
Diabetes 0 (0.0) 2 (15.4) 
History of PAD 0 (0) 0 (0) 
History of CHF 1 (20.0) 1 (7.7) 
History of MI 0 (0.0) 1 (7.7) 
History of COPD 0 (0.0) 1 (7.7) 
History of Arthritis 3 (60.0) 1 (7.7)* 
History of Cancer 3 (60.0)* 1 (7.7)* 
Health Rating, Poor/V 
Poor/Fair 4 (80.0) 1 (7.7) 
Minutes/Day Sedentary 
Activity, 
armband/actigraph 
750.2 (126.3) 610.3 (84.8) 
Minutes/Day Light 
Activity, 
armband/actigraph 
228.2 (110.2) 229.3 (64.1) 
Minutes/Day Mod 
Activity,  42.3 (27.2)* 1.2 (1.2)* 
Minutes/Day All PA Mod 42.7 (27.5)* 1.2 (1.2)* 
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and above 
Minutes/Day All Activity 270.9 (118.3) 230.5 (64.6) 
*between group difference at p<0.05
** between group difference p=0.06 
Table 22 Continued 
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